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ABSTRACT 
 
 
The objective of this work was to design, develop and evaluate erlotinib-loaded 
core-shell type lipid albumin hybrid nanoparticles (CSLAHNPs) for targeted drug 
delivery to non-small cell lung cancer (NSCLC). Erlotinib (ETB) is a highly selective, 
potent and reversible inhibitor of epidermal growth factor receptor tyrosine kinase 
(EGFR) which is overexpressed (50-90%) in NSCLC. ETB is marketed as film coated 
tablets for oral delivery. However, poor survival rate along with life-threatening adverse 
effects were reported from oral administration. Nanoparticulate delivery system of ETB 
might be advantageous to target the tumor cells, thereby increasing therapeutic efficacy 
and reducing off-targeting toxicities of ETB to healthy cells. In this work, a unique 
nanoparticulate carrier termed as CSLAHNPs was used for targeted delivery of ETB. The 
CSLAHNPs system was composed of albumin core and phospholipid bilayer shell. For 
active targeting to EGFR positive NSCLC, anti-EGFR half-antibodes (hAbs) were 
conjugate to EGFR expressing NSCLC. Overall hypothesis was to improve the efficacy 
of ETB in EGFR positive NSCLC using the targeted hAb-ETB- CSLAHNPs and 
untargeted ETB-CSLAHNPs. Blank CSLAHNPs were prepared by two-step method 
using bovine serum albumin and lipid mixture composed of 60:30:10 molar ratio of 
dipalmitoyl-phosphatidylcholine (DPPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]  (DSPE-PEG2000) 
respectively. ETB was loaded into CSLAHNPs by incubation method. Murine anti-EGFR 
monoclonal antibody (mAb) was reduced to hAb using tris(2-carboxyethyl)phosphine 
and conjugated to maleimide terminated ETB- CSLAHNPs via maleimide-thiol 
conjugation reaction. CSLAHNPs were further characterized for physicochemical 
properties including mean size, polydispersity index, zeta potential, drug loading 
efficiency, in vitro drug release, and in vitro serum stability. The optimized ETB-
CSLAHNPs and hAb-ETB-CSLAHNPs were evaluated for their in vitro biological 
properties including cellular association cellular uptake, endolysosomal trafficking, cell 
viability, colony formation assay and western blots in two human lung adenocarcinoma 
cells; A549 ( having wild-type EGFR) and HCC827 (having an acquired mutation in 
EGFR) cells. The mean size of hAb-ETB-CSLAHNPs (targeted) and ETB-CSLAHNPs 
(untargeted) was between 190-210 nm, suitable for intravenous delivery. The zeta 
potential, drug loading, and drug entrapment efficiency were about -13 mV, 2 % w/w, 
and 31% w/w respectively. CSLAHNPs exhibited sustained drug release profiles over 72-
96 h in PBS pH 7.4. Fluorescent lipid tagged hAb-ETB- CSLAHNPs showed enhanced 
uptake and accumulated in the cells. Significant reduction in % cell viability was 
observed for targeted hAb-ETB- CSLAHNPs compared to control groups in HCC827 
cells after 72 h. The analysis of IC50 demonstrated that both targeted hAb-ETB- 
CSLAHNPs and untargeted ETB-CSLAHNPs could be more effective than ETB alone in 
both EGFR- positive NSCLC cells. Short-term stability data at refrigerator condition 
demonstrated that the lyophilized form of CSLAHNPs containing 16-fold sucrose 
(lyoprotectant) significantly improved the physical and chemical stability compared to 
liquid dispersion for 60 days of storage. Overall, the results indicated that hAb-ETB- 
CSLAHNPs and ETB-CSLAHNPs would be promising ETB delivery systems for EGFR-
overexpressing NSCLC.  
 vi 
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 INTRODUCTION* CHAPTER 1.   
 
 
Non-Small Cell Lung Cancer and Treatment Options 
 
Lung cancer is a major health problem and the leading cause of cancer related 
mortality for both men and women worldwide (1). Every year about 1.59 million men 
and women die of this deadly disease around the world with around 169,000 deaths in the 
US alone (2, 3). Human lung cancer is divided into two major types based on the 
histopathological appearance: small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC). NSCLC represents 85 to 90 % of all lung cancer cases, the rest being 
SCLC (4). The most common histological types of NSCLC include squamous cell, 
bronchoalveolar, and adenocarcinoma. Only 15 % of the cases are detected with cancer in 
the primary site while 22 % cases have lymph nodes metastasis and 55 % have distant 
metastasis at the time of diagnosis (5). There are various stages of the NSCLC; occult 
(hidden), stage 0 (carcinoma in situ), I (A and B), II (A and B), III (A and B), and IV. 
 
There are different types of the treatments available for NSCLC; some treatments 
are standard or conventional, while some are investigational treatments being used in 
clinical trials. The treatment options include surgery, radiation therapy, chemotherapy, 
targeted therapy, laser therapy, photodynamic therapy, cryosurgery, electrocautery, 
chemoprevention, and new combinations therapy (6). NSCLC is treated with local 
resection and radiation therapy followed by chemotherapy. In approximately 85% cases, 
lung cancer patients are diagnosed with advanced inoperable stage of the disease (7), and 
the main treatment option is the chemotherapy.  
 
 
Chemotherapy and Molecularly Targeted Therapy for NSCLC 
 
In traditional or conventional chemotherapy, cytotoxic anticancer drugs are 
administered orally or intravenously. Depending on the stages of the disease, chemo 
drugs are used as neoadjuvant therapy (before surgery), adjuvant therapy (after surgery) 
or as main treatment (advanced stages). The traditional chemo drugs most often used in 
NSCLC include cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, vinorelbin, 
irinotecan, etoposide, vinblastine, and premetrexed (8). In first line treatment of NSCLC 
at advanced stages, mono or combination chemotherapy is followed with a 4-6 dosing 
cycles of platinum based agent (cisplatin/carboplatin) alone or in combination with 
docetaxel, paclitaxel or gemcitabine. If platinum based therapy fails, second line therapy 
                                                 
 
 
 
*Adapted with permission Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, 
Thoma LA, and Wood GC. Core-shell-type lipid-polymer hybrid nanoparticles as a drug 
delivery platform. Nanomed Nanotechnol Biol Med. 2013;9(4):474-491. Elsevier, 
Copyright 2013. 
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is used as the standard treatment option. Molecularly targeted therapy has become a 
routine option for the second line treatment for NSCLC. It includes 4-6 dosing cycles 
with one of the cytotoxic agents (vinrelbine, premetrexed), or molecularly targeted agents 
(gefitinib, erlotinib, or bevacizumab).  
 
Of all the second line treatments available, erlotinib (brand name Tarceva®; OSI 
Pharmaceuticals Inc., Melville, NY and Genentech, Inc. South San Francisco, CA) is the 
most widely prescribed drug. Erlotinib (ETB) belongs to epidermal growth factor 
receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs (5). In 2004, US FDA 
approved ETB for the treatment of locally advanced or metastatic NSCLC after failure of 
at least one chemotherapy regimen. Chemically, ETB is N-(3-ethynylphenyl)-6,7-bis(2-
methoxyethoxy)quinazolin-4-amine (Figure 1-1). The drug is available as ETB 
hydrochloride film coated tablets in 25 mg, 100 mg and 150 mg strengths (9). It has oral 
bioavailability of ~ 60%, median elimination half-life of ~ 36 h, apparent volume of 
distribution 232 L, and plasma protein binding of ~ 95%. It is metabolized primarily by 
CYP3A4 in liver. In a randomized, placebo-controlled, double-blind phase III trial 
(BR.21), ETB showed higher overall survival (6.7 months vs 4.7 months), higher 
response rate (8.9% vs <1%) (10), higher median duration response (7.9 months vs 3.7 
months) and higher progression free survival (2.2 months vs 1.8 months) compared to 
placebo (10). Comparison between ISEL phase III trial for gefitinib (Iressa®, 
Astrazeneca) and BR.21 trail demonstrated the survival benefit for all enrolled subjects 
with ETB compared to gefitinib which showed survival benefit for patients with 
adenocarcinoma or never smokers (11). In two phase III trials (OPTIMAL and 
EURTAC), significant progression free survival benefits were observed in patients with 
advanced EGFR-mutation positive NSCLC compared to standard chemotherapy (12, 13). 
With chemotherapy, 5-year survival at advanced stages (III and IV) of NSCLC remains 
only about 15 % and 1% respectively (14). One of the main reasons for the poor survival 
rates among NSCLC patients is the limited efficacy of traditional chemotherapy along 
with severe adverse side effects of the high doses of toxic anticancer drugs.  
 
 
Erlotinib and Its Mechanism of Action  
 
The schematic representation of the mechanism of action of ETB is shown in 
Figure 1-2. Epidermal growth factor receptor (EGFR) belongs to the bigger HER family 
of receptors. There are four subtypes of HER family receptors; HER1 (EGFR or erbB1), 
HER2 (EGFR2 or erbB2), HER3 (EGFR3 or erbB3), and HER4 (EGFR4 or erbB4). 
EGFR is a 170 kDa transmembrane glycoprotein receptor with an amino terminal 
extracellular domain (binds to ligands), a single hydrophobic transmembrane-anchoring 
region, a tyrosine kinase (TK) region and a carboxyl-terminal cytoplasmic region with 
tyrosine kinase activity (15). After binding with appropriate ligands (e.g. EGF), inactive 
monomers form active homo or heterodimers, results in the autophosphorylation of TK 
domain of EGFR. This process activates a complex network of downstream signaling 
pathways including MAPK, PI3k/PKB, PKC, RAS-RAF-MAPK p44/42. EGFR signaling  
involves cell maintenance, cell proliferation, survival, angiogenesis, and metastasis. 
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Figure 1-1. Chemical structure of erlotinib 
 
Chemical name of erlotinib is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) 
quinazolin-4-amine.  
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Figure 1-2. Schematic diagram of the mechanism of action of erlotinib 
 
EGFR (also known as HER1) have tyrosine kinase (TK) domains in the cytoplasmic 
portion of the receptor. Binding of ligands (EGF) to the extracellular domain of EGFR 
induces either homodimerization or heterodimerization of the receptors. Dimerization 
results in phosphorylation of TK domain leading to autophosphorylation, followed by 
intracellular signaling cascades, such as the RAS–RAF–MEK–ERK and PI3K–AKT 
pathways, that induce cellular proliferation, angiogenesis, and metastases. The binding of 
erlotinib to the ATP-binding site of TK domain results in blockage of the catalytic 
activity of the kinase, thereby inhibiting downstream signaling pathways responsible for 
cellular proliferation.  
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EGFR-TK has been identified as the effective molecular target and overexpressed 
(50-90%) in several cancer types including NSCLC (16). ETB is a highly selective 
inhibitor of HER1/EGFR-TK. The drug binds with the ATP-binding site of the tyrosine 
kinase domain of EGFR, which blocks the catalytic activity of the kinase, thereby 
inhibiting downstream signaling of the pathways responsible for cell proliferation, 
survival, metastasis, and angiogenesis (17). 
 
 
Drawbacks of Erlotinib Therapy 
 
ETB is administered as 25 mg to 150 mg oral tablet once daily. The oral route is 
most preferred and easy way of administering drugs for systemic therapy of NSCLC. 
However, a number of adverse effects or toxicities were reported. Severe skin rash and 
diarrhea were observed to be the major dose- limiting toxicities from traditional oral 
delivery of ETB (10, 18). Diarrhea occurred in 55% of the patients with severe diarrhea 
in 6% of the patients (10). Rash was reported in 75% of the patients (19). Other immune 
mediated life-threatening toxicities include drug-induced hepatitis, Stevens-Johnson 
Syndrome(20), toxic epidermal necrolysis (21), gastrointestinal perforations (22), ocular 
lesions (23), interstitial lung disease (24), liver and kidney problems, bleeding and 
clotting problems. 
 
Additionally, administration of oral ETB tablets is not convenient to cancer 
patients with gastrointestinal disorders or abnormalities. Approximately 40% of the 
cancer patients undergoing standard dose chemotherapy develop mucositis which causes 
structural and functional changes to the gastrointestinal tract (25). The pathological 
condition of gastrointestinal mucositis resulted in malabsorption of drugs and other 
nutrients (26). Evidently, intravenous administration of erlotinib was investigated to 
overcome the patient non-compliance of oral tablet. The phase I dose escalation study 
reported that a high dose of intravenous ETB formulation was well-tolerated with minor 
adverse events as compared to oral tablet (27).  
 
Another major concern with ETB therapy is the development of drug resistance 
by the NSCLC tumors. ETB has been used as the first line therapy in patients with EGFR 
mutations consisting of either exon 19 deletions or L858R point mutation in exon 21(28, 
29). However, most advanced NSCLC tumors develop resistance after 6 – 12 months of 
drug therapy (30). The main mechanisms of resistance identified include secondary 
resistance EGFR T90M mutations (31), oncogene kinase switch, and MET amplification 
(32). 
 
 
Barriers to Drug Delivery in Solid Tumors 
 
In order to reach the target tumor cells, intravenously administered therapeutic 
drug delivery systems must penetrate across blood vessel walls of the tumor and the 
tissue matrix or interstitium. The complexity of in vivo system was evidenced by the 
presence of multiple biological barriers that pose significant challenges in drug delivery 
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to solid tumors (33-39). The emergence of nanoparticles (NPs) based drug delivery 
systems showed potential advantages of efficient drug delivery to solid tumors in 
experimental therapeutics (40-42). However, their full clinical success still remains 
elusive with little to moderate improvement in clinical benefit (43). Only a small fraction 
of the drug reaches the tumor site, imposing significant risk for the development of drug 
resistance. After intravenous injection, NPs face the first barrier which is the 
mononuclear phagocytic system (MPS) or reticuloendothelial system (RES). MPS/RES is 
part of the immune system consisting of phagocytes cells such as monocytes and 
macrophages located in reticular connective tissues of liver, kidney, and spleen (44). The 
serum complement proteins such as C3, C4, and C5 form the corona around unprotected 
NPs, triggering the process of opsonization, followed by phagocytosis by circulating as 
well as residual macrophages (45). Opsonization process is influenced by 
physicochemical properties of the NPs such as size, shape, surface charge, and surface 
chemistry (46). One of the common ways to circumvent the MPS barrier is PEGylation 
that is coating of NPs by hydrophilic polyethylene glycol (PEG) or PEG-containing 
copolymers (47, 48). The bushy or mushroom structure of PEG chains repel the 
absorption of opsonin proteins on NPs via steric repulsion forces, thereby blocking the 
opsonization process (49). The second barrier is the vascular endothelial layer, a semi-
permeable layer of cells which lines the inner walls of the blood vessels. The presence of 
proteoglycan layer (also known as glycocalix) which covers the endothelial layer, serves 
to control the permeability of solutes and macromolecules across blood vessels. The 
passage of molecules across healthy endothelial layer occurs by trans or paracellular 
pathways with size limit of 5-6 nm. However, the tumor endothelial layer is 
discontinuous with “gaps” in the lining which helps to extravasate NPs via the process 
known as enhanced permeability and retention (EPR) effect (50). However, significant 
differences were observed in tumor vascular morphology including pore cutoff size, 
organization, and blood flow rate not only among various tumor types but also within 
same tumor type. The heterogeneities of tumor vasculature have resulted in limited EPR 
effect of NPs (34, 51, 52). The third barrier is the tumor microenvironment. The solid 
tumor is characterized by an avascular necrotic core region, a hypoxic region, a 
vascularized circumference, and an acidic front (53). The extracellular matrix (ECM) or 
the tumor interstitium consists of collagen, elastin, proteoglycans, and hyaluronic acid 
(54). ECM provides resistance to the diffusion of NPs through the interstitium. Interstitial 
fluid pressure is higher in the center of the tumor and lower in periphery (52). The 
extravasation of NPs occurs mainly by diffusion and convection based on the 
concentration gradient or interstitial fluid pressure (54). Therefore, NPs has to overcome 
the outward fluid convection to diffuse into the tumor. Finally, NPs have to cross cellular 
barriers. The internalization of NPs into the tumor cells depends on interaction of NPs 
with cell membrane. The physicochemical properties of NPs including size, surface 
charge, hydrophobicity, presence of targeting ligands can influence their entry into the 
cells. Once internalized, NPs has to reach its intracellular target through endosomal 
vesicles and organellar barriers. Finally, overexpression of drug efflux transporter, P-
glycoprotein (P-gp) may decrease the intracellular concentrations of drug inside the 
tumor. It has been demonstrated that NPs can overcome the P-gp-mediated efflux pump 
mechanism (55). 
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A lot of progress has also been made in the field of nanoparticulate drug delivery 
in order to overcome each of these barriers and a number of novel approaches have been 
brought to the forefront (34, 52, 56). Targeting tumor microenvironment was 
demonstrated to enhance drug distribution to tumors. Besides passive targeting by EPR 
effect, active targeting can improve chemotherapy retention in tumors. The potential of 
active targeting mediated drug therapy was demonstrated by FDA approval of 
transtuzumab emtansine (T-DM1, Genentech), an antibody-drug conjugate in the 
treatment of HER2 positive breast cancer (57). Normalization of the tumor 
microenvironment is another strategy to improve drug delivery in solid tumors. Vascular, 
stress and matrix normalization of the tumor microenvironment have demonstrated to 
enhance tumor localization and intratumoral distribution of chemothapeutics. Vascular 
normalization using antiangiogenic therapy was shown to alleviate hypoxia and improve 
antitumor efficacy of NPs (58, 59). In stress normalization, targeting stromal cells and 
matrix molecules (collagen, hyaluronen) reduces stress by decompressing vessels and 
improves perfusion and drug delivery (60). Matrix normalization by degrading or 
modifying ECM can improve the delivery of nanomedicines to solid tumors (61). 
 
 
Hybrid Nanoparticles for Erlotinib Delivery to Solid Tumors 
 
Drug delivery system (DDS) plays an important role by influencing the 
pharmacokinetic profile of the drug, rate and duration of drug release, site of drug action, 
and finally the pharmacological effects and adverse effects (62). An effective DDS 
ensures that therapeutically active drug is available at the site of action at right 
concentration and time (63, 64). Therefore, an optimal DDS for ETB should improve the 
therapeutic efficacy of ETB by overcoming the barriers to drug delivery and also 
minimize toxicity, and lower the total dose required for the therapy. Nanoscaled targeted 
DDS meets most of the required attributes for the improved therapy of malignant diseases 
such as cancer. Rationally designed DDS with optimal physicochemical characteristics 
can reach to the tumor site passively through the leaky vasculature surrounding the tumor 
by enhanced permeation and retention (EPR) effect. Targeting ligand conjugated to the 
surface of nanoparticles (NPs) can achieve active targeting by binding to the specific 
receptors overexpressed by tumors. Surface modified NPs with flexible hydrophilic 
polymers have the ability to evade the RES system and prolong blood circulation time. 
NPs can carry high payload of anticancer drug (s), proteins, genes, and targeting ligands. 
NPs protect the entrapped drug from enzymatic inactivation. By reducing the free drug in 
circulation, the systemic toxicities could be minimized. There are various types of 
nanoscaled DDS which are approved or being investigated in clinical trials or in research 
and development phases. This includes liposomes, polymeric NPs, albumin NPs, 
nanocapsules, micelles, solid lipid NPs, dendrimers, PEGylated proteins, viral NPs, 
polymer-drug conjugates, antibody-drug conjugates, carbon nanotubes, and inorganic 
NPs (42).  
 
The focus of nanoparticle design over the years has evolved toward more complex 
nanoscopic core-shell architecture using a single delivery system to combine multiple 
functionalities within nanoparticles. Core-shell-type lipid-polymer hybrid nanoparticles 
 8 
 
(CSLPHNPs), which combine the mechanical advantages of biodegradable polymeric 
nanoparticles and biomimetic advantages of liposomes, have emerged as a robust and 
promising delivery platform (65-70). In CSLPHNPs, a biodegradable polymeric core is 
surrounded by a shell composed of layer(s) of phospholipids. The hybrid architecture can 
provide advantages such as controllable particle size, surface functionality, high drug 
loading, entrapment of multiple therapeutic agents, tunable drug release profile, and good 
serum stability (65). The multifunctional ETB-loaded CSLAHNPs conjugated with anti-
EGFR half-antibody might be advantageous in selectively targeting EGFR overexpressed 
on NSCLC tumor and delivering ETB to increase therapeutic efficacy and reduce off-
targeting toxicities of ETB after intravenous administration. The following section 
describes a comprehensive review on hybrid nanoparticles. 
 
 
Review of Hybrid Nanoparticles Literature 
 
 
Introduction 
 
Nanoparticles (NPs) have attracted much attention because of their ability to 
deliver drugs to the therapeutic targets at relevant times and doses. Of all the common 
nanoparticulate systems, liposomes and biodegradable polymeric NPs (PNPs) have 
emerged as the two dominant classes of drug nanocarriers. This is evidenced by 
increasing numbers of clinical trials, research reports, and approved drug products (71-
73). Both classes have advantages and limitations in terms of their physicochemical and 
biological properties. Historically, lipids have been used for several decades in various 
drug delivery systems including liposomes (71), solid lipid NPs (74), nanostructured lipid 
carriers (75), and lipid-drug conjugates (76). Most liposomes are biocompatible, 
biodegradable, non-toxic or mildly toxic, flexible, and non-immunogenic for systemic 
and non-systemic administration if their component lipids are from natural sources (77). 
However, there are several limitations of liposomal drug products from the viewpoint of 
physical and chemical stability, batch-to-batch reproducibility, sterilization, drug 
entrapment, and manufacturing scale-up (73, 77-79). Generally, PNPs are advantageous 
in terms of smaller particle size, tissue penetrating ability, a greater variety of preparation 
methods, availability of various polymers, improved stability in biological fluids, 
versatile drug loading and release profiles (72, 80). The limitations of PNPs include use 
of toxic organic solvents in the production process (81), poor drug encapsulation for 
hydrophilic drugs, drug leakage before reaching target tissues, polymer cytotoxicity, 
polymer degradation, and scale-up issues (80). 
 
Novel, integrated systems known as “lipid-polymer hybrid nanoparticles” 
(LPHNPs) have been introduced in an effort to mitigate some limitations associated with 
liposomes and PNPs (69, 82). Briefly, the biomimetic characteristics of lipids and 
architectural advantage of polymer core are combined to yield a theoretically superior 
delivery system. LPHNs are solid, sub-micron particles composed of at least two 
components; one being the polymer and the other being the lipid. Various bioactive 
molecules such as drugs, genes, proteins, and targeting ligands can be entrapped, 
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adsorbed, or covalently attached in the hybrid system. The common choices of 
biodegradable polymers include polylactic-co-glycolic acid (PLGA), polycaprolactone 
(PCL), dextran, or albumin due to their biocompatibility, biodegradability, non-toxicity 
and previous use in approved products (83, 84). Lipids used are often zwitterionic, 
cationic, anionic and neutral phospholipids such as lecithin, 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) (85-91). Various classes of LPHNPs are summarized in 
Table 1-1 and are classified depending on the arrangement of lipid and polymer in the 
hybrid system. Due to their perceived advantages over other existing hybrid systems, 
significant effort has been directed towards the understanding of CSLPHNPs (92-101). 
The primary objective of this review article is to discuss CSLPHNPs which are composed 
of polymeric core and lipid shell. Discussions on other types of LPHNs will be limited as 
it is not within the scope of this communication. 
 
 
Core-shell type lipid/polymer hybrid nanoparticles 
 
CSLPHNPs continue to gain recognition in drug, gene, protein, and vaccine 
delivery (102-105). Based upon the CSLPHNPs concept, a new nanoparticulate drug 
delivery system, known as “Supra molecular bio-vectorTM” (SMBVTM), was introduced 
in the early 1990s by Biovector Therapeutics (106). SMBVTM is an artificial analog of 
virus composed of a modified polysaccharide hydrogel core covered with phospholipids 
acting as a shell. Because of its size ( ~ 60 nm) and architecture mimicking the structure 
of viruses (107), SMBVTM has been investigated for various purposes such as delivery of  
anticancer agents (108), nasal vaccines (107), and antisense oligonucleotides (109). 
Originally, core-shell type hybrid microparticles and NPs were synthesized with a lipid 
shell and a core that was made from inorganic materials such as silica (110), magnetic 
iron oxide (111), or organic materials such as polysaccharides (112), polystyrene (113), 
polyelectrolyte capsule (114), or polymer microgels (115). Comprehensive reviews by 
Troutier and Ladaviere (116) and Richter et al (117) are available on lipid membrane 
systems supported by various organic and inorganic colloidal solid cores and are not 
highlighted in this review. Instead, the main focus here is placed on polymeric cores 
(preferably biodegradable) which can be utilized in drug delivery systems. 
 
CSLPHNPs systems can be described as the polymeric core coated with single or 
multiple layers of lipids that constitute the shell. Based on the concept of core-shell 
architecture, “lipoparticles” were first synthesized for various biotechnological and 
biomedical applications such as immunological kits and biosensors for amplifying 
biomolecular recognition (87, 89). The special features of lipoparticles are imparted by 
their method of preparation and use of the types of lipid materials. They are generally 
prepared by mixing liposomes and PNPs to form lipid-polymer complexes where a lipid 
bilayer or lipid multilayers cover the surface of the polymeric core. The space between 
polymeric core and lipid layer is occupied with water or aqueous buffer (Figure 1-3). 
Cationic or zwitterionic phospholipids have been used to construct the shell of the 
lipoparticles to promote electrostatic interactions with oppositely charged polymers.   
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Table 1-1. Various types of lipid polymer hybrid nanoparticles 
 
Type Description Synonyms Reference 
Polymer core-
lipid shell 
Colloidal 
supramolecular 
assemblies consisting of 
polymer particles coated 
with lipid layers 
Lipoparticles 
Lipid polymer particle 
assemblies 
Lipid-coated NPs 
Nanocell 
Polymer-supported 
lipid shells 
(118), 
(90),(119), 
(89),(87, 
88),(120), 
(121), (122), 
(123) 
Polymer caged 
liposomes 
These systems are 
composed of polymers, 
anchored or grafted at 
the surfaces of  
the liposomes to provide 
stability  
Not applicable (78, 79) 
Monolithic 
HLPNPs 
Lipid molecules are 
dispersed in a polymeric 
matrix 
Mixed lipid polymer 
particles 
(84) 
Core-shell 
type hollow 
lipid-polymer-
lipid NPs 
Hollow inner core 
surrounded by 
concentric lipid layer, 
followed by polymeric 
layer, again followed by 
lipid layer along with 
lipid-PEG. 
Not applicable (124) 
Erythrocyte 
membrane-
camouflaged 
polymeric NPs 
Sub 100 nm polymeric 
particles are  coated with 
RBC membrane derived 
vesicles to mimic 
complex surface 
chemistry of erythrocyte 
membrane 
Biomimetic NPs (125) 
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Figure 1-3. Schematic diagrams of CSLPHNPs with its structural components  
 
CSLPHNPs with lipid bilayer (left) and monolayer (right). 
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In a recent report, Zhang et al (69) have designed a novel CSLPHNPs system that 
were composed of three functional building blocks each having distinct attributes that 
influences the whole hybrid delivery system. The first building block was polymeric core 
that was composed of a biodegradable hydrophobic polymer (e.g., PLGA) and acted as 
the carrier for poorly water soluble drugs. This core imparts controlled drug release from 
the system. The second component was the shell or the outer corona of the hybrid 
particles that was composed of hydrophilic substrates, most commonly lipid-PEG 
conjugates. This layer allows the particles to evade uptake by the immune system and 
imparts long-circulating characteristics. The shell can also be manipulated to facilitate the 
attachment of targeting ligands. Finally, the third component was composed of a lipid 
monolayer at the interface of core and shell. This layer helps to reduce drug diffusion 
from the core and water penetration into the core thereby increasing drug encapsulation 
and altering drug release rates. 
 
 
Advantages of CSLPHNPs 
 
The solid polymeric core of CSLPHNPs acts as a cytoskeleton that provides 
mechanical stability, controlled morphology, biodegradability, narrow size distribution, 
and high available specific surface area (126-128). The lipid shell enveloping the 
polymeric core is biodegradable, biocompatible and exhibits biomimetic behavior similar 
to cell membranes. The shell has the ability to interact with a wide variety of molecules, 
either within the membrane or on the surface of the membranes (129). Improved 
encapsulation of hydrophobic and hydrophilic drugs with therapeutically effective drug 
entrapment efficiency and drug loading have been reported in CSLPHNPs for a number 
of drugs compared to liposomes or PNPs (96, 99, 102). Amphiphilic character of lipids 
facilitates the adsorption of hydrophilic compounds on the hydrophilic bilayer surface 
and insertion of hydrophobic molecules into the hydrophobic lamellar region (129-132). 
This feature allows CSLPHNPs to entrap and deliver multiple hydrophilic and 
hydrophobic therapeutic agents simultaneously into the single delivery platform (99, 
133).Optimization of the core and shell properties can result in tunable and sustained 
drug release profiles (134). CSLPHNPs exhibit storage and serum stability over 
prolonged periods (104, 134). Besides passive targeting of CSLPHNPs based on particle 
size, they can be conjugated with appropriate targeting ligands such as aptamers (134), 
folic acid (97, 135), transferrin (136), anticarcinoembryonic antigen half-antibody (94), 
single-chain tumor necrosis factor (121) to deliver NPs at the target tissues for treating 
cancers. Smaller than 100-nm particles (similar to virus-like architecture) are promising 
for intracellular drug targeting and vaccine adjuvants (137). 
 
 
Methods of preparation of CSLPHNPs 
 
Methods used to prepare CSLPHNPs broadly fall into two categories; the two-
step method and the single-step method. 
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Two-step method. In this approach, the polymeric core and lipid shell are 
prepared separately using two independent processes; then the two components are 
combined by direct hydration, sonication or extrusion to obtain the desired lipid shell–
polymer core structure (Figure 1-4). Several investigators have prepared lipid polymer 
particle assemblies or lipoparticles to obtain solid supported lipid bilayers which act as a 
model for artificial cell membrane and also for drug delivery applications (87, 89, 104, 
119, 120, 133, 135, 138). In the two-step process, cationic lipid vesicles and anionic 
PNPs are drawn together by electrostatic interactions.(90).  
 
The fusion of the PNPs and lipid vesicles can be accomplished by employing 
different mixing protocols (116). In such processes, the dry lipid film can be hydrated  
with the PNPs dispersion. Another alternative is to introduce the PNPs into pre-formed 
lipid vesicles. Such a process is usually followed by low energy mixing processes such as 
vortexing the resulting mixture. This mixture is heated at a temperature above phase 
transition temperature (Tm) of the lipid (89). This facilitates reorganization of the lipid 
onto the particle surface. The non-adsorbed lipids, micelles and free PNPs are separated 
by centrifugation to obtain a final CSLPHNPs dispersion. 
 
There are several factors that affect final particle size of lipoparticles. Examples 
of relevant factors are methods applied to produce lipid vesicles (direct hydration, 
sonication or extrusion), mixing protocol of lipid vesicles/PNPs, type of polymers/lipids, 
pH and ionic strength of buffers used, surface charge of lipid vesicles, vesicle to particle 
ratio and temperature of incubation (89, 116). In general, addition of water or an aqueous 
buffered solution to dry lipid film forms large multilamellar vesicles. However use of 
additional steps such as sonication or extrusion leads to formation of small unilamellar 
vesicles with smaller particle sizes and a lower polydispersity index10. Troutier et al 
reported that particle of approximately 100 nm were obtained using membrane extrusion 
compared to 250 nm using hydration or 500 nm using sonication approach (89). 
Simultaneous loading of two drugs, doxorubicin and combretastatin, into “nanocells” 
using the two step approach has been reported (133). In this study, doxorubicin-PLGA 
conjugated PNPs were prepared using an emulsion-solvent evaporation technique. Then, 
combretastatin loaded lipid vesicles were prepared using phosphatidylcholine, 
cholesterol, and PEG-DSPE. Finally, hybrid dual drug loaded “nanocells” were obtained 
by extruding the mixture of PNPs and lipid vesicles. The size of the particles ranged from 
180-200 nm. The authors reported that combretastatin released from the CSLPHNPs at a 
faster rate compared to doxorubicin. The differential drug release was attributed to 
localization differences inside “nanocells”. The authors postulated that combretastatin 
was entrapped at/in the shell, whereas doxorubicin was located in the core.  
 
In the two-step process, the particle size and drug loading of the core can be 
precisely controlled to produce final lipid-polymer hybrid nanoparticles of appropriate 
size, drug loading and release characteristics (89, 133). In addition, the theoretical 
amount of the lipid required to uniformly coat the core with uniform bilayer of 
phospholipids can be calculated based on the properties of the core and phospholipids 
(139, 140). However, it should be cautioned that the two-step method may reduce drug 
encapsulation efficiency for water soluble drugs due to the incubation step since drug  
 14 
 
 
 
 
Figure 1-4. Schematic representation of the steps involved in lipoparticle 
synthesis by two-step method 
 
(a) Polymeric nanoparticle cores (PNPs) are prepared separately. (b) Lipid shells 
(liposomes) are prepared separately. (c) Both polymeric cores and lipid shells are mixed 
and incubated. (d) Finally, lipoparticles are obtained. 
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molecules may leak out from the core before a lipid coat is formed on the core surfaces 
(141). Some limitations of this method are the technical complexity and less efficient 
processes of preparing both polymeric core and liposome vesicles separately.  
 
 
Single-step method. In an approach to circumvent the problems of time 
consuming preparation steps, a relatively simple approach which combines the dual steps 
of the two-step method into a single step has been evaluated. Here a nanoprecipitation 
process is synchronized with a simultaneous self-assembly process (Figure 1-5).One of 
the critical factors influencing successful preparation of CSLPHNPs using this method, is  
the amount of lipid for uniform lipid coating of polymeric core particles. Variations of 
the single-step method have been reported in the literature. These include modified 
solvent extraction/evaporation and nanoprecipitation methods. 
 
Modified solvent extraction/evaporation method is a modification of the 
emulsion-solvent evaporation method first reported by Gurny et al (142). The method has 
been used to prepare CSLPHNPs loaded with docetaxel (86, 97) and paclitaxel (98). 
Briefly, the polymer and drug are dissolved in a water-immiscible organic solvent such as 
dichloromethane, chloroform, or ethyl acetate. Lipid is then dispersed in water by bath 
sonication, mechanical stirring, or sometimes with heat. The organic solution is mixed 
into aqueous phase and the resulting dispersion is sonicated using a probe sonicator in an 
ice bath. The dispersed phase is broken into tiny nanodroplets, which are solidified into 
nanospheres coated with lipid layer. The organic solvent is usually removed by 
evaporation in a rotary evaporator under reduced pressure or stirred overnight. The 
particle suspension is purified by centrifugation followed by washing. The washed 
particles are freeze-dried to obtain a dry powder. Liu et al (97) used this method to 
prepare folic acid-conjugated docetaxel-loaded CSLPHNPs having the particle size of 
approximately 200-300 nm and drug encapsulation efficiency of 60-66 %. They observed 
a decrease in mean particle size of CSLPHNPs with increasing concentrations of lipid. 
This phenomenon was attributed to the presence of DLPC lipid that acts as an emulsifier 
thereby lowering the surface tension of the lipid monolayer, resulting in lower surface 
free energy and smaller CSLPHNPs. A typical approach to entrap hydrophilic small and 
macromolecules in microparticles/NPs is to use a multiple emulsion/solvent evaporation 
method. A similar approach used to prepare hollow core-shell type lipid-polymer-lipid 
hybrid NPs. This method used a modified double emulsion/solvent evaporation for 
encapsulation and delivery of nucleic acids (124). The hollow aqueous core acted as the 
reservoir for hydrophilic small interfering RNA (siRNA). Briefly, in the first step, 
primary water-in-oil (w/o) type emulsion was formed by dispersing the aqueous siRNA 
into an organic solvent containing a polymer and a cationic phospholipid by sonication. 
Here the phospholipid layer helps to stabilize the aqueous droplets and increase the 
loading of siRNA by polycomplexation. A secondary oil-in-water (o/w) type emulsion 
was prepared by adding the primary emulsion into aqueous dispersion of another 
phospholipid (lecithin) and DSPE-PEG. Finally, the organic solvent was evaporated to 
prepare multilayered CSLPHNPs. Not only macromolecules but also water soluble 
hydrophilic small molecular weight drugs such as antibiotics have been encapsulated  
within CSLPHNPs via the double-emulsion solvent evaporation method (141). 
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Figure 1-5. Schematic representation of the single-step method involving 
nanoprecipitation and self-assembly processes  
 
(a) Drug, polymer dissolved in organic solvent forming organic phase. (b) The organic 
phase is added dropwise into aqueous phase containing phospholipids. (c) The resulting 
dispersion is sonicated or homogenized to obtain CSLPHNPs. 
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In the modified nanoprecipitation method, polymer(s) and hydrophobic drug(s) 
are dissolved in a water-miscible organic solvent (e.g., acetonitrile or acetone).The 
organic solution is then added, drop by drop, to the aqueous dispersion containing lipid  
The mixture is vortexed and subsequently homogenized or ultrasonicated to reduce the 
particle size to nanometer range. Valencia et al reported a similar method based on rapid 
mixing of lipid and polymer solutions using a continuous flow microfluidic device that 
used hydrodynamic flow focusing in combination with passive mixing structures to 
prepare CSLPHNPs in a single step (143). Their study indicates that in order to ensure 
proper dispersion of lipid and lipid-PEG conjugate, it is necessary to heat the aqueous 
dispersion (generally ~ 65°C) before adding the organic solution. To uniformly coat the 
polymeric core with a lipid shell and to evaporate the organic solvent, the dispersion was 
stirred for several hours with a magnetic or mechanical stirrer. CSLPHNPs formed were 
purified by ultracentrifugation, centrifugal ultrafiltration or dialysis.  
 
The critical factors to be optimized for particle size, polydispersity, and surface 
charge include the type of the lipid, ratio of lipid/polymer, phase-volume ratio of organic 
to aqueous phase and viscosity of the polymer (69, 93, 143). Docetaxel loaded 
CSLPHNPs were prepared by this method to produce particles of mean size of 66 nm and 
encapsulation efficiency of approximately 60 % (134). 
 
Recently, a fast and simple method of producing CSLPHNPs using sonication 
was reported by Fang et al (93). They prepared CSLPHNPs of uniform and controllable 
size (~ 65 nm) and low polydispersity index (~ 0.08) by using bath sonication for 5 min 
compared to a few hours for other fabrication approaches. The size and polydispersity of 
the particles was effectively controlled by optimizing the ratios of lipid-PEG/polymer and 
lipid/lipid-PEG/polymer.  
 
 
Drug loading and entrapment efficiency of CSLPHNPs  
 
Many small molecular weight chemotherapeutic drugs, proteins and nucleotides 
have been encapsulated or entrapped in CSLPHNPs. One reason for poor drug loading 
(DL) and entrapment efficiency (EE) in CSLPHNPs is the presence of excess lipids could 
form vesicles by entrapment or adsorption of drug via hydrophobic interactions and/or 
hydrogen bonding (144). Additionally during purification, these vesicles are washed 
away, leading to drug loss. Therefore, the amount of the lipid required to uniformly coat 
the core nanoparticles has to be optimized using empirical and/or experimental 
techniques. There are various techniques for drug loading into CSLPHNPs. The drug can 
be loaded into both the polymeric core as well as in the lipid shell, thereby increasing the 
total drug payload. Moreover, two different drugs can also be loaded into the core and the 
shell (145). The most commonly used strategy is to incorporate the drug during core 
production or lipid film formation. Another option is to adsorb or absorb the drug with 
the cores and lipid vesicles separately before combining to form CSLPHNPs. However, 
the DL is generally expected to be better in the incorporation approach than the 
adsorption approach (146). The adsorption method has been used to load DNA into 
lipoparticles composed of PLA core/DPPC-DPTAP lipid shell (103). The 
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macromolecules or proteins shows greatest loading efficiency near its isoelectric point 
when it has minimum solubility and maximum adsorption (147). For small molecules, the 
use of ionic interactions between the drug and polymer can be an effective way to 
increase the drug loading (96). Examples of the factors which may influence the DL and 
EE are aqueous solubility of the drug, affinity and miscibility of the drug in both polymer 
and lipid phases (96), amount of lipid (144), drug-lipid charge interactions (141), aqueous 
phase pH (148), and methods of preparation. Often it is required to carry out in-depth 
physicochemical characterization during preformulation studies to optimize LC and EE 
(149). For instance, Li et al have analyzed the combined solubility parameters and 
partition coefficients for screening the best lipid and polymer for the highest LC and the 
maximum binding capacity to the cationic drug verapamil (149). Based on the approach, 
they have reported drug EE greater than 90% and DL between 5 to 36.1 % (96). The 
amount of the lipid is also a decisive factor for EE of lipophilic drugs in CSLPHNPs. Liu 
et al reported the decrease in EE from 42 % to 15 % when the lipid component was 
lowered from 0.1 % to 0.01 % for paclitaxel particles (144). Drug lipid charge 
interactions may be important for encapsulation of drugs. Cheow et al reported successful 
encapsulation of zwitterionic levofloxacin and ofloxacin when PLGA polymer and 
phosphatidyl choline (PC) lipid were used, whereas formation and loading of cationic 
ciprofloxacin into the CSLPHNPs was unsuccessful (141). When PC was replaced with 
non-ionic polyvinyl alcohol, ciprofloxacin loaded CSLPHNPs were successfully 
produced. The results suggested the possibility of unfavorable ionic interactions between 
the anionic PC and cationic ciprofloxacin for the failed formulation. The method of 
preparation also affects the DL and EE. The method used during core PNPs preparation, 
such as solvent displacement method leads to poor DL and EE for hydrophilic 
compounds (150). Another problem of the two-step method is that encapsulated drugs 
leak out before the lipid coat is formed (141). 
 
 
Surface modifications of CSLPHNPs 
 
In addition to the incorporation of drug, the outer surface of the CSLPHNPs can 
be functionalized to make long circulating particles along with the capability of active 
targeting. PEGs have become a standard for creating long-circulating NPs, thereby 
reducing plasma protein adsorption, macrophage uptake and particle aggregation, while 
increasing circulation time (151). For long circulating CSLPHNPs, outer surface is 
coated with hydrophilic polymeric chains of PEGs anchored in the bilayer with DSPE. 
The functional coating of PEG stabilizes the particles in storage due to steric hindrance 
by its long polymer chains (93). Another surface modification relates to the acidic 
environment of tumors. A pH-sensitive PEG coating shed its coating under the acidic 
condition, fused with cell membrane and entered into tumor cells (92). A red blood cell 
approach to particle surface functionalization was made by coating biodegradable PNPs 
with natural erythrocyte membranes. The membrane included both membrane lipids and 
associated proteins (125). The erythrocyte membrane which covered the polymeric core 
mimicked the natural endogenous erythrocyte, thus escaping from the recognition by the 
reticulo-endothelial system and producing a prolonged circulation time. Erythrocytes 
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have different surface antigens (blood groups) and patients should be cross-matched 
before injecting these “erythrocyte membrane camouflaged NPs”. 
 
Surfaces of CSLPHNPs can also be modified with folic acid, monoclonal 
antibodies or therapeutic cytokines for targeting to tumors located in the various parts of 
the body. In general, antibodies or other targeting ligands are attached to the surface of 
liposomes and NPs using various covalent and non-covalent coupling techniques, as 
reviewed by Nobs et al (152). For example, anti-carcinoembryonic antigen (CEA) half- 
antibody was conjugated to the LPHNPs surface by a maleimide-thiol coupling reaction 
(94). CSLPHNPs containing attached folic acid on the surface can be prepared by using 
pre-synthesized DSPE-PEG5k-Folic acid (97). Alternatively, CSLPHNPs can display a 
cell death ligand such as tumor necrosis factor α (TNF α) on the outer surface which 
mimics the bioactivity of membrane bound TNF α. In one study, the dual attachment of 
TNF α in both the core and the shell showed strong and specific binding to TNF receptor-
expressing cells (121).  
 
 
Physicochemical characteristics of CSLPHNPs 
 
Several physicochemical and biological techniques for the characterizing 
CSLPHNPs are summarized in Table 1-2. Also included are discussions on mechanism 
of hybrid particle formation, structure and stability of CSLPHNPs. 
 
 
Interaction and mechanism of hybrid particle formation. The interactions 
between lipids and polymer particles to form hybrid particles have not been well defined. 
Generally, different mechanisms of lipid-polymer hybrid particle formation can be 
distinguished based on the method of preparation. In the single-step method, polymer 
particle formation involves the precipitation of polymer from an organic solution and the 
diffusion of the organic solvent in an aqueous medium (93). Then, the lipid molecules 
self-assemble spontaneously by hydrophobic interactions on the polymeric particle 
surface to form a monolayer. In cases when the lipid-PEG component is incorporated, the 
lipid moiety of the lipid-PEG conjugate is inserted into the lipid monolayer, and the polar 
PEG moiety faces outward into the external media to form the stabilizing shell for the 
hybrid particles. 
 
The possible mechanism of hybrid particle formation in the two-step method can 
be understood from a study by Carmona-Riberio and de Moraes Lessa (113). Their study 
involved phospholipid adsorption by polystyrene particles. According to the authors, the 
process occurs in two steps. First, the phospholipid forms a bilayer in aqueous solution 
and attaches to the polystyrene particle surface by adsorption to form homodispersed and 
stable phospholipid vesicle-covered particles. Second, after bilayer attachment, 
hydrophobic attractions between the polystyrene surface and hydrocarbon chain of the 
phospholipid bilayer collapses the bilayer structure and leaves a monolayer covering the 
polymer particle. In the process, the lipid and polymer contact is favored by electrostatic 
interactions, hydrophobic attractions, or van der Waals forces. In addition, the input of  
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Table 1-2. Summary of the techniques used for physicochemical and biological 
characterization of lipid-polymer hybrid nanoparticles 
 
Parameter/property Method of characterization 
Particle size distribution Photon correlation spectroscopy (94, 102, 134, 141, 153) 
Surface charge Zeta potential by PCS (102, 134, 153) 
Morphology TEM (86, 89, 102, 134), SEM (94, 141, 154), AFM (155), 
CLSM (89, 123), fluorescence microscopy (89, 134) 
Lipid shell thickness SAXS (87), TEM (87) 
Interface chemical 
composition 
XPS (89, 98) 
Lipid shell fluidity FRAP (123), fluorescent probes (106) 
Lipid shell transition NMR (87, 88, 96), FTIR (96), DSC (96), PXRD (96) 
Drug loading and 
entrapment 
HPLC (98), dialysis (86, 134), centrifugation (141), 
membrane filtration (102) 
Drug release Dialysis followed by HPLC(86, 134)/UV-visible 
spectrophotometry(96, 141), sample and separate method 
(98, 102) 
In vitro cellular uptake Fluorescence microscopy (94, 97, 134) 
Cell viability and 
cytotoxicity 
MTT cell viability assay (86, 98), MTS cell proliferation 
assay (134), tryptan blue staining (102), clonogenic assay 
(102), ATPLite 1-step luminescence ATP detection 
assay(94) 
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external energy such as heating, sonication or agitation helps to rearrange lipids onto the 
polymer particles. Surface charges also play a major role in forming the lipid layer onto 
polymer particles. Stable particles are formed by electrostatic interactions between a  
negatively charged polymer and a cationic lipid. Moreover, affinity of the phospholipid 
for the polymer particle depends on the hydrophilicity of the polystyrene surface. Surface 
hydration of the polystyrene particles can shield the attractive forces and decreases 
affinity for the lipid monolayer coverage.  
 
 
Structure of CSLPHNPs. The morphology, two dimensional fluidity, lipid shell 
permeability, and distribution of lipids in polymeric particles have been assessed using  
confocal laser scanning microscopy and cryo-transmission electron microscopy (Cryo-
TEM) (123). Often, samples in TEM are stained with uranyl acetate, osmium tetraoxide, 
or phosphotungstic acid for better imaging contrast to differentiate the core-shell 
structure. Zhang and co-workers deciphered the structure of the PLGA-lecithin-DSPE-
PEG LPHNs by TEM using negative staining of the low electron dense lipid layer (69). 
Information about the structure of the hybrid particles are obtained by using conventional 
fluorescence microscopy and confocal laser scanning microscopy (CLSM). For example, 
the co-existence of a polymer core and lipid layer has been confirmed after overlay of the 
fluorescent images of nitro-2-1,1-benzoxadiazol-4-yl phosphatidyl choline (NBD-PC) at 
365 nm for the polymeric core and at 534 nm for the lipid layer (89). As indicated 
previously, lipid composition and its concentration play a significant role in the formation 
of various nanostructures of hybrid particles. Thus, the presence of excess lipid during 
preparation leads to the formation of multilamellar lipid coatings on the particle or may 
form free liposomal vesicles. Bershteyn et al (123) reported two distinct structures when 
an excess concentration of lipid (DOPC) and lipid-PEG conjugate (DOPC-PEG) were 
used to prepare lipid/PLGA hybrid NPs. In the first case when excess DOPC was used, it 
formed an onion-like structure with multilamellar stacks of lipid packed together around 
the polymer core. When 10% mole of DOPC was replaced by DOPC-PEG, lipid 
“flowers” were formed with “petals” extruding from the polymer core. 
 
 
Stability. Evaluation and optimization of physical or colloidal as well as chemical 
stability are required for any nanoparticle based drug delivery system to prepare a stable 
product with an acceptable shelf-life. The phospholipids that constitute the shell of the 
CSLPHNPs may act as surfactants to stabilize the hybrid NPs (156-158). Often times, the 
phospholipids alone are not enough to stabilize the system. For instance, the electrostatic 
repulsion between colloidal particles failed to stabilize a hybrid nanoparticle based 
system prepared from poly(lactic acid) core and lipid mixtures composed of 
DPPC/DPTAP when incubated in high ionic salt concentration such as 10 mM aqueous 
salt solution (159). 
 
Four major factors that affect the colloidal stability of lipoparticles have been 
identified. These include pH and ionic strength of the aqueous medium, temperature, 
curvature of radius of lipoparticles, and vesicle-to-particle ratio (87). These factors are 
discussed below. 
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Lipoparticles usually become unstable with an increase in ionic strength of the 
continuous phase. For lipoparticles composed of a poly-lactic acid (PLA) core and 
DPPC/DPTAP lipid shell, a significant increase in particle aggregation was seen when 
the ionic strength of the aqueous phase increased from 1 mM to150 mM of NaCl 
solution. This phenomenon can be explained as ion screening of electrostatic charges on 
the particle surface(160).The adsorption of lipid onto polymer particle is affected by 
incubation temperature. When incubation occurs at temperature (T) below glass transition 
temperature (Tg), the entire vesicle adheres onto particles without rupturing. However, 
when T is greater than Tg, lipid reorganization onto the polymer particle is accelerated. 
Sicchierolli and Carmona-Riberio (161) studied the adsorption of DPPC lipid on the 
surface of polystyrene microspheres at two different temperatures (25°C and 65°C) for 1 
h. High adsorption of DPPC at room temperature suggested entire vesicle adhesion on 
latex particles. But at a temperature above Tg for the lipid, monolayer coverage on 
polystyrene particles was observed because of a change in the physical state of the lipid 
into a liquid-crystalline state. Spontaneous or intrinsic curvature of the lipid monolayer 
assemblies arises from the geometric packing of the lipid molecules by intermolecular 
interactions (162). Generally, small vesicles having a higher curvature radius tend to coat 
the smaller polymer particles (163). For spherically shaped monolayers, intrinsic 
curvature (R) of the lipid monolayer membrane can be derived from the Equation 1-1: 
 
 ? ?? ? ???? ?? ? ????? ? ?? ? ???? ??? ? ??????  (Eq. 1-1) 
 
Where V is the volume of the entire lipid molecule, l is the length, and A is the 
area of the lipid head group at the lipid-water interface.  
 
The proportion of lipid vesicles with regard to polymeric particles is an important 
parameter affecting overall size and stability of lipoparticles. Vesicle to particle ratio 
(Av/Ap) can be expressed by the Equation 1-2: 
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(Eq. 1-2) 
 
Where Ap can be determined from the particle number and mean diameter. Based 
on the study by Troutier et al (90), it can be hypothesized that the stability of the 
lipoparticles depends on the value of Av/Ap. For instance, a high Av/Ap value suggests 
electrostatic stabilization of the lipoparticles; while a low Av/Ap value suggests 
aggregation will occur. The aggregation behavior at low Av/Ap values can be attributed 
to the formation of bridges between lipid and polymer and incomplete coating that 
exposes the anionic zone of the polymer. 
 
One approach to improve the colloidal stability of CSLPHNPs is by steric 
repulsions between particles after incorporating a lipid- PEG conjugate into the 
formulation (164, 165). It has been reported by Thevenot et al that lipoparticle 
stabilization was improved drastically from 1 mM to at least up to 150 mM sodium 
chloride solution for a period of 1 year at 4oC when 10 mol % lipid-PEG conjugate was 
added into the formulation (159). In the process of stabilization by lipid-PEG conjugate, 
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two important aspects were identified; PEG degree of polymerization (n) and molar 
percentage of lipid-PEG conjugate, which affected the final stability of lipoparticles. The 
stability of lipoparticles towards ionic strength revealed that longer the PEG degree of 
polymerization (i.e. chain length), the greater the stability in polar salt solution. The 
decreasing order of lipoparticle colloidal stability was reported as a function of PEG 
degree of polymerization: PEG113> PEG45> PEG16. The molar percentage of lipid-PEG 
conjugate also affected the amount of lipid adsorbed onto particles, thereby affecting the 
surface coverage by PEG. The amount of lipid-PEG adsorbed decreased when n 
increased. Due to the steric hindrance by long PEG chains, lipid-PEG45 conjugate 
adsorption was 3 mol % compared to initial amount of 10 mol %. 
 
Another approach to improve the colloidal stability of CSLPHNPs is to 
incorporate suitable amounts of additional surfactants along with the phospholipids (141). 
For example, addition of 10 % of D-α-tocopherol polyethylene glycol 1000 succinate, 
TPGS (an amphiphilic biocompatible, biodegradable surfactant ) along with PC confers 
stability of CSLPHNPs in phosphate buffered saline (141). Reasonably, the projection of 
the long and bulky PEG chain of the TPGS enhances stability as compared to small 
choline head group of PC (166). Finally, lyophilization may be used to further enhance 
the colloidal stability of CSLPHNPs in storage (167). 
 
Unlike the physical stability issue that is a common concern for CSLPHNPs 
dispersions, the chemical stability is drug specific depending on the presence of 
susceptible functional groups and also the aqueous solubility of the compound. For 
example, drug molecules containing esters and amides are susceptible to hydrolytic 
degradation, while oxidative degradation is common for amine compounds (168). For 
poorly water soluble drug molecules, the possibility of chemical reactions in CSLPHNPs 
is not as substantial as that in solution-based formulations. Considering the inactive 
ingredients of CSLPHNPs, the phospholipids may degrade by hydrolysis and oxidation 
reactions during their storage in aqueous dispersions (169). The common strategy to 
enhance the chemical stability of CSLPHNPs is to transform the nanoparticles dispersion 
into dry solid dosage form using lyophilization technique with suitable cryoprotectants 
(167, 170). 
 
 
Immunocompatibility of CSLPHNPs 
 
Drug delivery systems including CSLPHNPs should be biocompatible, 
hemocompatible and immunocompatible thus avoiding undesirable interactions with the 
immune system (171). The recognition of therapeutic nanoparticles as foreign entities 
may result in multilevel immunological responses (e.g. cytokine release, interferon 
response and lymphocyte activation) leading to severe toxicity and/or lack of therapeutic 
benefit (172). 
 
Since a CSHLPNs system is composed of polymeric core nanoparticles and lipid 
shell, the immunocompatibility properties of the individual components should be 
considered. There is ample evidence showing the immunogenic properties of polymeric 
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nanoparticles composed of synthetic polyesters and polyanhydrides (173, 174). Although, 
the phospholipid bilayers are made up of natural phospholipids found in body, it has been 
reported that therapeutic liposomes containing paclitaxel, or docetaxel activate the 
complement system resulted in adverse immune phenomenon C activation-related 
pseudoallergy (175, 176). Complement activation can be enhanced by the 
physicochemical properties of liposomes including size (177, 178), charge (179), 
aggregation (180), polyamino coating (181), presence of endotoxin contaminants (182), 
drugs like doxorubicin (180), and PEGylation (183). Liposomes are vulnerable to 
immune recognition since the vesicles mimic the size and shape of some pathogenic 
microbes, ectosomes, nanobacteria, and viruses. Additionally, lack of self-discriminating 
molecules (e.g. C control proteins) on the phospholipid bilayers makes them susceptible 
to immune attack (171, 184-186). Currently there is scarcity of immunocompatibility 
studies on the CSLPHNPs and detailed investigations are warranted. The pioneering 
work on the immunological characteristics of CSLPHNPs including complement system 
activation, plasma/serum protein binding and coagulation cascade activation was reported 
by Salvadore-Morales et al (153). Among the three surface functional groups of 
CSHLPNs tested, the methoxy group induced lowest level of complement activation 
compared to the amine and carboxyl groups. They showed that the surface chemistry of 
the CSLPHNPs also changed human plasma and serum protein adsorption profiles. The 
findings of the complement activation and coagulation assay of their study provided 
evidence for good biocompatibility of CSLPHNPs. 
 
Based on the immunocompatibility issues of polymeric core NPs and liposomes, 
it is necessary to evaluate the immunocompatibility properties of the CSLPHNPs. Several 
in vitro and in vivo techniques such as complement activation assay, platelet count and 
function test, plasma coagulation, and protein binding studies are available (171, 187). 
Assessment of the complement activation proteins (e.g. SC5b-9, Bb, C4d) using enzyme-
linked immunosorbent assay is one of the most useful in vitro predictors of the 
immunological reactions (188). 
 
The immunocompatibility of a complex drug delivery system such as CSLPHNPs 
is often challenging to predict based on their physicochemical properties due to the 
composition of formulations that differs both in nature and percentage of lipids and 
polymer. Moreover, the immunological response not only depends on the biomaterials 
but also on the host innate immune reactivity. Therefore, detailed investigations 
accounting for both delivery system and patient related factors should be performed to 
assess the immunocompatibility. 
 
 
Applications of CSLPHNPs 
 
Various applications of the CSLPHNPs are summarized in Table 1-3. Among 
their versatile applications, some major areas with significant clinical implications were 
discussed. These major application areas include vaccine adjuvants, cancer targeting and. 
gene delivery. In cancer targeting, the most widely investigated disease areas include 
breast cancer, prostate cancer and pancreatic cancer.  
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Table 1-3. Summary of the application of CSLPHNPs in drug delivery 
 
Encapsulant Polymer Lipid Particle 
size 
EE/DL Application Reference 
siRNA and Gemcitabine mPEG-PLGA Lecithin,cholesterol, 
DSPE-PEG2000 
122-142 nm EE 42 % Pancreatic 
cancer 
(190) 
Curcumin and RGD  mPEG-PLGA Lecithin, cholesterol, 
RGD-PEG-Chol 
216 nm EE 96 % 
DL 5 % 
Brain 
targeting for 
glioma 
(70) 
Mitomycin C PLA SPC 200-300 nm EE 37 % 
DL 10 % 
Cancer (191) 
Lysozyme PCL PC, glyceryl 
tripalmitate 
90-470 nm EE 45-90% Protein 
delivery 
(192) 
siRNA PLGA DOTAP 213-286 nm EE 30 % Gene 
delivery 
(193) 
Doxorubicin and  
GG918  
HPESO Tristearin/ stearic acid 150-270 nm EE 70–90 % MDR breast 
cancer 
(99) 
Doxorubicin HPESO Stearic acid 290 nm EE 76 % MDR breast 
cancer 
(100) 
Doxorubicin PLGA DPPC 195 nm DL 1 % MDR breast 
cancer 
(138) 
Paclitaxel PLGA Lecithin 83-95 nm NR Pancreatic 
cancer 
(94) 
Verapamil HCl Dextran  Decanoic acid 342 nm EE 90-99 % NR (96) 
Paclitaxel PLGA DLPC 200-300 nm EE 43-56 % Cancer (98) 
Paclitaxel PLGA OQLCS 184-194 nm EE 84-88 % Cancer (135) 
Docetaxel, indium 
111 and yttrium 90  
PLGA Docetaxel, indium 
111 and yttrium 90  
65 nm EE 60 % Prostate 
cancer 
(134) 
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Table 1-3. Continued 
 
Encapsulant Polymer Lipid Particle size EE/DL Application Reference 
AChE PMOXA-
PDMS-
PMOXA  
EPC/DPPC 75 nm NR Protein 
delivery 
(91) 
Docetaxel PLGA Soy lecithin 60-70 nm NR Cancer (86) 
Docetaxel PLGA Lecithin/DSPE-PEG 70-80 nm EE 60 % Cancer (69) 
Plasmid DNA PEI Triolein/EPC/ 
DSPE-PEG 
128 nm NR Gene 
delivery 
(95) 
Plasmid DNA PLGA DOTAP/DC-Chol 100-400 nm NR Gene 
delivery 
(154) 
Plasmid DNA PLA DPPC/DPTAP 325-340 nm NR Gene 
delivery 
(103) 
mRNA PBAE DOPC/DOTAP 230-300 nm NR mRNA based 
vaccine 
(194) 
siRNA PLGA EPC/lecithin/DSPE-
PEG 
225 nm NR Tumor 
suppression 
(124) 
7α-APTADD PLGA Egg PC/DOPE/ 
TPGS 
170 nm EE 78-82 % Breast cancer (136) 
Fluoroquinolone 
antibiotics 
PLGA Phosphatidyl choline 260-420 nm EE 37 % Lung biofilm 
infection 
(141) 
5-Fluorouracil PGA/ Dextran Cetyl alcohol 
/Tripalmitin 
600-1100 nm EE 4-25 % Lung cancer (130-132) 
FITC-BSA Protamine 
sulfate 
Cholesterol/ 
DSPC/DHA 
130-200 nm EE 19-60 % 
DL 5-18 % 
Protein 
delivery 
(104) 
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Vaccine adjuvants. NPs are promising adjuvant delivery systems for enhancing 
and directing the adaptive immune response of vaccine antigens (189). Biodegradable 
polymeric microparticles and NPs composed of PLGA have been investigated as 
potential vaccine delivery systems due to their ability to control the release of antigens 
and co-delivering immunostimulatory molecules along with antigens in the same particle  
(195). However, low antigen EE and denaturation of the antigen during 
nanoencapsulation have limited their development (196, 197). Antigens adsorbed or 
covalently coupled onto the surface of pre-synthesized CSLPHNPs could be viable 
strategies for vaccine delivery (105, 198). “Synthetic pathogens”, which are surface-
modified biodegradable CSLPHNPs, can be used to imitate structural features of  
pathogens for designing vaccine adjuvants (137). In this context, polymeric core 
nanoparticles (e.g. PLGA) are advantageous since they activate inflammasome in  
antigen-presenting cells and enhance innate/adaptive immune responses (199). In 
addition, lipid bilayers displaying protein antigens and molecular “danger signals” (such  
as pathogen-associated molecular patterns) create pathogen-mimicking antigens and 
related motifs to boost the immune response (105). The surface display of antigen onto 
lipid-based NPs has been shown to induce robust antibody responses by mimicking the 
structure and surface chemistry of microbial pathogens (200). For example, high IgG 
titers (> 106) were observed with sustained levels over 100 days after immunization with 
nanograms of ovalbumin antigen conjugated onto the surface of CSHLPNPs along with 
monophosphoryl lipid A or α-galactosylceramide as molecular “danger signals” (105). 
Moreover, the strategy allows the conjugation reaction to proceed under mild aqueous 
conditions thus avoiding harsh processing during encapsulation (178). Additionally, the 
immune response can be altered by the presence of heterogeneous surface functional 
groups. It has been reported that the presence of amine terminal group of DSPE-PEG on 
the PLGA-lecithin CSLPHNPs induced highest complement activation and could be 
considered as vaccine adjuvants (153). 
 
 
Cancer targeting. Recent advancements in nanotechnology have fuelled NPs 
development of different sizes, shapes, core physicochemical properties, and surface 
modifications for the potential treatment of cancers. CSLPHNPs are being developed for 
tumor-selective delivery of anticancer agents to increase the cell-kill e?ect while 
protecting the healthy tissue from exposure to a cytotoxic agents, thereby reducing 
systemic toxic e?ects (142). The following section discusses selected studies dealing with 
in vitro evaluation and in vivo evaluation. Most of the literature on CSLPHNPs has 
focused on in vitro cell culture models as the means to proof of concept.  
 
Breast cancer is the most common form of cancer and affected more than 200,000 
females in 2010 in the United States. Multidrug resistance (MDR) is a common cause of 
failure of chemotherapy in breast cancer patients (201). MDR is caused by 
overexpression of membrane drug efflux transporter P-glycoprotein (P-gp), which 
reduces intracellular uptake of anticancer drugs (202). Excellent reviews are available on 
the cause and strategies for overcoming MDR (203, 204). For example, a CSLPHNPs 
system containing doxorubicin was developed and evaluated for cytotoxicity against 
MDR breast cancer cells by Wong et al (99-102). The particle size and EE of the 
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CSLPHNPs were reported to be 50-200 nm and 65-80 %, respectively. Cell-kill and 
cellular uptake were significantly enhanced in CSLPHNPs forms compared to the 
solution formulation. Two possibilities for the mechanism of cytotoxicity of doxorubicin-
loaded CSLPHNPs were proposed: i) free drug was released from CSLPHNPs and acted 
on the cells, and ii) drug-loaded CSLPHNPs entered and released the drug inside cells, 
thereby evading the P-gp efflux pump. In a subsequent publication, the authors proposed 
that the second mechanism was more likely to happen. Drugs in CSLPHNPs entered the 
cells by a combination of diffusion and phagocytosis. Because of the physical association 
of the drug with the anionic polymer, the drug was not easily removed by the P-gp efflux 
pump. Therefore, chronic suppression of the MDR cell proliferation was observed 
because of the continued buildup of drug inside cells (98). 
 
Another potential strategy to overcome MDR of breast cancer cells is to 
simultaneously use a combination of chemotherapeutic drug and P-gp inhibitor 
/chemosensitizer such as verapamil in a single nanoparticle cargo (204). Similar strategy 
using a CSLPHNPs capable of co-delivering doxorubicin and elacrider (chemosensitizer) 
was developed and evaluated by Wong et al (99). The particle size was found to be 187-
272 nm. EE was 71-76 % for doxorubicin and 80-88 % for elacrider. In this study, the 
dual agents co-encapsulated in CSLPHNPs showed greatest uptake and anticancer 
activity in human MDR breast cancer cell line MDA435/LCC6/MDR. 
 
In another study, a CSLPHNPs system having PLGA core and phosphatidyl 
choline shell was designed for loading 7α-APTADD, an investigational aromatase 
inhibitor for treatment of estrogen-responsive breast cancer (136). Transferrin, a natural 
80 kDa glycoprotein, was conjugated to CSLPHN to target SKBR-3 breast cancer cells 
with overexpressed transferrin receptors. EE and mean diameter were measured to be 37 
% and 170 nm. Aromatase inhibition activity of the targeted CSLPHNPs was 
significantly higher in SKBR-3 cells compared to non-targeted CSLPHNPs.  
 
Prostate cancer is the second leading cause of cancer mortality in men over the 
age of 40 in the United States (205). Prostate-specific membrane antigen (PSMA) is a 
type II membrane integral glycoprotein overexpressed in prostate cancer cells and has 
been identified as a biochemical marker (206). Several PNPs and liposomal targeted 
delivery systems were developed for prostate cancer (207-209). A new CSLPHNPs 
system composed of a PLGA core and lecithin/DMPE-DTPA lipid shell was developed 
for prostate cancer by co-delivering chemotherapeutic drug docetaxel (Dtxl) and the 
therapeutic radionuclide yttrium 90 (90Y) (134). The CSLPHNPs were termed as 
“chemorad NPs”. They were prepared by the single-step nanoprecipitation method to 
produce mean particle size of 65 nm. Oligonucleotide aptamer A10, which has high 
affinity and selectivity to PSMA positive prostate cancer cells, was attached to the outer 
surface of the CSLPHNPs via coupling reaction with DSPE-PEG to produce targeted 
particles (Apt-Dtxl-90Y-NPs). An increase in uptake of chemorad NPs was observed in 
the LNCaP prostate cancer cell lines. “Chemorad NPs” were able to kill 80 % of the 
LNCaP cells (PSMA-positive) compared to the PC3 cell line (PSMA-negative) and 
untargeted control groups. The experimental findings of this study suggested the potential 
of chemorad NPs to improve chemoradiotherapy in prostate cancer patients. 
 29 
 
Pancreatic cancer, especially adenocarcinoma of the exocrine pancreas, is the 
fourth leading cause of cancer death in the United States (210). However, the current 
chemotherapeutic regimen showed little or modest improvement in patient survival 
because of poor vascularization and inadequate perfusion of the tumor (211). Liposomal 
paclitaxel and gemcitabine (212), cisplatin and gemcitabine (213), curcumin-
encapsulated PLGA NPs (214), and EGFR-targeted gemcitabine-loaded PLGA NPs (215) 
showed promising efficacy in refractory pancreatic cancer in animal studies and clinical 
trials. Anti-carcinoembryonic antigen (CEA) half- antibody was conjugated to paclitaxel-
loaded CSLPHNPs, which were investigated for targeting ability against BxPC-3 (CEA-
positive) and XPA-3 (CEA-negative) pancreatic cancer cells (94). Antibody conjugated 
CSLPHNPs with particle size of 95 nm were prepared by nanoprecipitation via self-
assembly of PLGA, lecithin, and DSPE-PEG. Monoclonal antibody was attached to 
CSLPHNPs through a maleimide-thiol coupling reaction. Targeting specificity, as well as 
enhanced cellular cytotoxicity of paclitaxel-loaded CSLPHNPs was observed in CEA 
positive cells compared to their non-targeted counterparts. This can be explained by 
occurrence of the receptor mediated endocytosis process which facilitated particle 
internalization into cells. Thus, the delivery platform showed therapeutic potential of 
CSLPHNPs in the targeting of pancreatic cancer. 
 
There are few available studies reported in the literature based on in vivo 
evaluation of drug loaded CSLPHNPs in animal cancer models (101, 131-133, 135). To 
best of my knowledge, the pioneering research involving in vivo evaluation of dual drug 
loaded CSLPHNPs, known as “nanocell”, was reported in 2005 by Sengupta et al (133). 
The delivery system comprised of chemotherapeutic agent doxorubicin conjugated to 
PLGA forming polymeric core (nucleus, similar to a cell) and the antiangiogenic agent 
combretastatin entrapped within the lipid shell. Tumors were induced by implanting 
GFP-positive BL6/F10 melanoma cells or lewis lung carcinoma cells in male c57/BL6 
mice. Intravenous administration of different combinations of CSLPHNPs containing 
doxorubicin and/ combretastatin showed that CSLPHNPs containing dual agents 
exhibited distinctly greater reduction in tumor volume with increasing percent survival in 
Kaplan-Meier survival graphs compared to CSLPHNPs with other combinations. The 
study proved that the dual agent loaded-CSLPHNPs treatment induced inhibition of 
tumor growth in a dose-dependent manner with more susceptibility towards melanoma 
than lung carcinoma. In addition, white blood cell count assay indicated that the delivery 
system resulted in least systemic toxicity compared with other combinations. 
 
Another study dealt with the in vivo evaluation of the doxorubicin-loaded 
CSLPHNPs in the solid tumor model induced by injecting EMT6 mouse mammary 
cancer cells intramuscularly into the hind legs of BALB/c mice (101). The cationic 
anticancer agent doxorubicin was complexed with anionic polymer HPESO to form a 
core, which was then covered by the lipid mixture of stearic acid and tristearin. The mean 
time for the tumor to reach the cutoff size was significantly prolonged by 7 days. The 
tumor growth delay value was 100% in mice after receiving 0.2 mg of doxorubicin in the 
form of CSLPHNPs compared to blank CSLPHNPs injected into the tumor. The normal 
tissue toxicity of the particles was minimal after a single dose of intratumoral injection, 
suggesting the usefulness of the delivery system for local treatment of breast cancer. 
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Gene delivery. Delivery of nucleic acids represents a challenge and great 
opportunities to treat chronic diseases, genetic disorders, and cancers (216). Cationic 
liposomes and biodegradable PNPs have been investigated as gene delivery carriers 
(217). Polymer-based non-viral carriers have received significant attention because of the 
death of a patient in a clinical trial of viral-based gene therapy (218). Among various 
non-viral based approaches, particularly polymer and lipid-based non-viral carriers have 
several advantages: low immunogenicity, low toxicity, absence of viral recombination, 
low production cost, and the possibility of repeated administration (219). 
 
Cytotoxicity, stability in serum, duration of gene expression, and particle size of 
the non-viral based carriers still remain major limitations of lipid and polymer-based 
systems. Recently, CSLPHNPs have emerged as an alternative, biodegradable, stable, 
and long-lived nanoparticle vector delivery system. Plasmid DNA encoding luciferase 
reporter gene was entrapped in CSLPHNPs composed of PLGA and cationic lipids 
DOTAP/DC-cholesterol (154). The CSLPHNPs (100-400 nm) were able to transfect the 
luciferase gene in adherent 293 human prostate cancer cells 500-600 times more 
efficiently than did unbound DNA after 48 h. Another CSLPHN was reported by Li et al 
(95) for efficient non-viral gene delivery with higher transfection efficiency and lower 
toxicity compared to commercial LipofectamineTM2000. In another study, CSLPHNPs 
with a mean particle size of 128 nm were prepared by emulsion evaporation technique 
using different combinations of triolein, polyethylenimine (PEI), egg yolk 
phosphatidylcholine (EPC), and PEG-DSPE. Plasmid DNA was complexed with NPs by 
adsorption. A green fluorescent protein intensity study revealed that the transfection 
efficiencies of CSLPHNPs/DNA complexes were 37 % and 34 % for HEK293 and 
MDA-MB-231 cells, respectively. Transfection efficiency was significantly higher than 
that of commercial LipofectamineTM 2000. Additionally, the proton-sponge effect 
destabilized the endosomal membrane and enhanced transfection. PEG helped as a 
protective layer and reduced the degradation of plasmid DNA by lysosomal enzymes 
after entering the lysosome. 
 
For siRNA delivery, cationic nanoscale complexes such as lipoplexes or 
polyplexes were used successfully to deliver siRNA (220). But some of these systems 
have disadvantages such as toxicity, induction of inflammatory responses and instability 
in serum. Shi and coworkers (124) designed a relatively neutral surface charged hybrid 
nanostructure capable of protecting siRNA and lipoplexes from physiological 
environments. This delivery system was termed “differentially charged hollow core/shell 
lipid-polymer-lipid hybrid nanoparticles” which were composed of four functional 
building blocks; a positively charged inner hollow core made up of cationic lipid, a 
hydrophobic PLGA layer, with a neutral lipid layer having outer PEG chains. 
Combination of a modified double emulsion solvent evaporation method and a self-
assemble method yielded an average particle size of around 225 nm and neutral surface 
charge. The hybrid system was capable of releasing siRNA in a sustained manner, 
enhanced in vivo gene silencing and inhibited luciferase gene expression in murine 
xenograft tumors. This strategy has opened another potential avenue for successful gene 
delivery for the treatment of multidrug resistant cancers. 
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Summary, future prospects and challenges of CSLPHNPs 
 
CSLPHNPs are the alternative platform for drug delivery.  These particles design 
uses an integrative approach by combining two classes of nanocarriers, namely polymeric 
NPs and liposomes. These particles have several beneficial features for treating various 
diseases, particularly cancers. Often treatment of a single type of cancer requires 
administering multiple drugs, and, in this aspect, CSLPHNPs are promising because they 
have to the potential to deliver multiple drugs simultaneously from a single platform. 
Specifically, incorporating two drugs into the core and lipid layer can offer a viable 
approach to treat MDR and life-threatening diseases. Apart from small molecular weight 
drugs, delivery of diagnostic agents such as quantum dots, macromolecules such as 
proteins, and genes, offers other exciting strategies with CSLPHNPs. Because their 
structural similarity to the viral architecture, CSLPHNPs offer potential as vaccine 
adjuvants. Furthermore, recent advancements in the CSLPHNPs delivery system such as 
coating PNPs with natural erythrocyte membrane, entrapping quantum dots inside these 
hybrid particles and concurrent administration of chemotherapy/radiotherapy, have 
shown potential for theranostic applications in the treatment of malignancies and other 
diseases. 
 
The design and development of CSHLPNPs as drug delivery platforms have been 
concentrated in the architecture and in vitro efficacy. The complexities of these systems 
afford new challenges in translating the in vitro efficacies into tangible therapeutic 
options.  More focused research is warranted, especially in key areas of development 
including stability, scale-up, optimization of targeting ligand density, in vivo fate, 
toxicity, and pharmacokinetic profiles. 
 
Stability of new drug product is an essential prerequisite. Therefore, the long-term 
physical and chemical stability of these hybrid nanoparticles in various environmental 
stress conditions need to be systematically evaluated to have a shelf life assigned to the 
marketed product. The critical parameters that should be evaluated include, but are not 
limited to, particle size distribution, drug entrapment, retention of entrapped drug in the 
system, physical robustness of the system, and effect of stressed environments on any of 
the aforementioned parameters (221). As with any colloidal system, stability can be a 
challenge in the liquid state. Thus, if instability is observed in aqueous states, other 
strategies could be evaluated including lyophilization or other stabilization techniques to 
address instability issues (170). 
 
Active targeting has been considered to be a significant shift in the paradigm of 
therapeutic efficacy of nanoparticulate drug delivery systems (41). Although, these 
systems show potential in early in vitro or “proof-of-concept” studies, a number of 
factors that can impact its efficacy need to be addressed. One such factor is the 
optimization of the targeting ligand on the hybrid NPs surface. The selection of the 
targeting ligands should additionally be evaluated because some of these targeting agents 
possess pharmacological activity (222). Understanding of the targeting ligand is crucial to 
address therapeutic outcomes and also address confounding outcomes due to 
polypharmacological inconsistencies. 
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The pharmacokinetic and pharmacodynamics (PK/PD) effects of these systems 
should be critically evaluated. Traditional PK evaluations are dependent of the 
availability of the free drug in the biological system to postulate its PD or metabolic fate. 
When drugs encapsulated in CSLPHNPs are administered, the PK/PD profile may be 
altered when compared to only the free drug due to altered release of the drug from these 
systems. Therefore, the appreciation of this phenomenon is essential in understanding the 
final therapeutic outcomes of these systems. A recent review by Li and Huang 
specifically addresses this aspect of the PK/PD fate of NPs and should be a valuable 
resource for the readers (46). 
 
A primary requirement for any product entering the pharmaceutical market is the 
availability of large scale production methods which need to be cost-effective and meet 
the regulatory requirements. Current bench scale processes employed for the developing 
CSLPHNPs systems are labor intensive and are not amenable to direct scale-up. 
Moreover, most of these delivery systems are intended for parenteral administration and 
thus directly impact its aseptic production. Although, significant advances in aseptic 
processing have been utilized for the manufacturing of CSLPHNPs systems, it often 
comes with a high price-tag and can be cost-prohibitive.  
 
 
Central Hypothesis and Specific Aims 
 
Lung cancer is the leading cause of cancer related death for both men and women 
worldwide (1). NSCLC represents 85 to 90 % of all lung cancer cases. Lung cancer 
patients are diagnosed at an advanced inoperable stage of the disease with the main 
treatment option being chemotherapy with cytotoxic drugs. However, the 5-year survival 
rate at advanced stages (III and IV) of NSCLC remains only about 15 % and 1 % 
respectively (4). One of the main reasons for the poor survival rates among patients with 
advanced stages of NSCLC is the limited efficacy of traditional chemotherapy along with 
severe adverse effects of the high doses of cytotoxic anticancer drugs. Besides cytotoxic 
chemotherapies, a number of molecularly targeted agents were developed exploiting two 
major cancer cell pathways: EGFR and VEGFR (the vascular endothelial growth factor 
receptor). EGFR has been identified as the effective molecular target and overexpressed 
(50-90 %) in several cancer types including NSCLC (5). In 2004, US FDA approved the 
drug, erlotinib (ETB) for the treatment of locally advanced or metastatic NSCLC after 
failure of at least one chemotherapy regimen. ETB is a highly selective inhibitor of 
HER1/EGFR-TK. The drug binds with the ATP binding site of the tyrosine kinase 
domain of EGFR, which blocks the catalytic activity of the kinase, thereby inhibiting 
downstream signaling of the pathways responsible for cell proliferation, cell survival, 
angiogenesis, and metastasis (6). However, limited therapeutic efficacy along with 
several toxicities was reported from the traditional oral delivery of ETB (7, 8). 
Additionally, administration of oral ETB tablets is not convenient to cancer patients with 
gastrointestinal disorders/abnormalities (27). Another major concern with ETB therapy is 
the development of drug resistance by P-glycoprotein mediated efflux pump or other  
pathways in NSCLC tumors (30). 
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The low survival rate in NSCLC patients demands the development of novel and 
efficacious therapeutic approaches for the treatment of NSCLC. Nanoparticulate carriers 
are attractive for cancer therapy due to their ability to enhance accumulation of anticancer 
agents at the tumor site, resulting in increased tumor cell kill efficacy, reduction in dose 
and dose-related adverse effects to healthy cells (41). There has been some investigations 
on the ETB loaded NPs reported in the literature. ETB loaded polymeric NPs in mice has 
shown improved efficacy and reduced toxicities associated with the drug (223). Another 
study revealed polymeric NPs improved antitumor efficacy of ETB in A549 human lung 
adenocarcinoma cells (224). Formulation of reverse micelles containing ETB showed 
improved in vitro efficacy of ETB in pancreatic cancer cells (225). Huang and coworkers 
examined the inhibition of HER1/EGFR-TK signaling using an anti-EGFR monoclonal 
antibody (mAb) and tyrosine kinase inhibitor, which target extracellular and intracellular 
domains of the receptor (14). This approach suggests potential new strategy to maximize 
effective target inhibition, which may improve the therapeutic efficacy for the treatment 
of NSCLC. Recently, our group has published a review on core–shell-type lipid–polymer 
hybrid nanoparticles as drug delivery platform (65). This unique platform combines the 
mechanical advantages of biodegradable polymeric nanoparticles and biomimetic 
advantages of liposomes into a single, integrated platform. The system provides 
advantages such as controllable particle size, surface functionality, high drug loading, 
potential for entrapment of multiple therapeutic agents, tunable drug release profile, and 
good serum stability (65). For the proposed study, core-shell type lipid-albumin hybrid 
nanoparticles (CSLAHNPs) were utilized as a novel and unique nanoparticulate carrier 
for the delivery of ETB in NSCLC. The schematic diagram of the proposed delivery 
system was shown in Figure 1-6. The core was composed of albumin which is a natural 
protein present in blood. The shell were composed of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) which is a major lung surfactant phospholipid. Both albumin and 
phospholipid are biocompatible and biodegradable. Finally, anti-EGFR monoclonal half-
antibody (hAb) were conjugated to the CSLAHNPs. 
 
The central hypothesis of my project is that permeability and uptake of anti-EGFR 
half-antibody (hAb) conjugated erlotinib (ETB)-loaded CSLAHNPs (targeted) and 
erlotinib (ETB)-loaded CSLAHNPs in NSCLC tumor cells is expected to improve the 
therapeutic efficacy of ETB while reducing off-toxicities of the drug in the treatment of 
EGFR positive NSCLC compared to free ETB in solution (Figure 1-7). Therefore, in 
order to test the hypothesis, the following specific aims were proposed: 
 
 
Aim 1. To design, develop, characterize and optimize CSLAHNPs  
 
The purpose of this specific aim was to prepare and characterize blank 
CSLAHNPs without encapsulation of drug ETB to understand the CSLAHNPs delivery 
platform. Formulation and process parameters that influence physicochemical properties 
including mean size, polydispersity index (PDI), zeta potential, morphology, and related 
critical quality attributes CSLAHNPs were identified and optimized to guide subsequent 
design, preparation and optimization of ETB-loaded CSLAHNPs.   
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Figure 1-6. Schematic representations of albumin nanoparticles (A), liposomes 
(B), and CSLAHNPs (C) 
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Figure 1-7. Schematic representation of the central hypothesis 
 
Targeted anti-EGFR half-antibody conjugated ETB-loaded CSLAHNPs bind to the 
extracellular domain of EGFR overexpressed on human NSCLC cells. After receptor 
binding and internalization, the drug is released in the cytoplasm and binds with 
intracellular tyrosine kinase domain of EGFR and prevents subsequent downstream 
signaling pathways. 
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Aim 2. To develop, characterize and optimize erlotinib loaded CSLAHNPs 
 
The purpose of this specific aim was to prepare and characterize erlotinib loaded 
CSLAHNPs (ETB-CSLAHNPs). Various strategies were used for drug loading in 
CSLAHNPs. Formulation and process parameters that influence mean size, PDI, zeta 
potential, drug loading, drug entrapment efficiency, morphology, drug release, storage 
and serum stability CSLAHNPs were identified and optimized.  
 
 
Aim 3. To develop, characterize and optimize targeted erlotinib-loaded CSLAHNPs 
 
Anti-EGFR monoclonal antibody (mAb) was selectively reduced to half-antibody 
(hAb) fragments  and conjugated to ETB-CSLAHNPs via maleimide-thiol conjugation 
for the preparation of targeted anti-EGFR hAb conjugated erlotinib-loaded CSLAHNPs 
(hAb-ETB-CSLAHNPs). The hAb-ETB-CSLAHNPs were characterized for mean size, 
PDI, zeta potential, drug loading, drug entrapment efficiency, morphology, drug release, 
storage and serum stability CSLAHNPs. 
 
 
Aim 4. To evaluate cellular uptake, and efficacy of CSLAHNPs in human NSCLC 
cells  
 
The cellular uptake, efficacy, mechanism of uptake, intracellular trafficking, and 
up/downregulation of p-EGFR after the treatment of the targeted and  
untargeted ETB-CSLAHNPs were evaluated in human lung cancer cells (A549 and 
HCC827). 
 
 
Aim 5. To lyophilize and develop stable CSLAHNPs 
 
The purpose of this specific aim was to improve the shelf-life of the CSLAHNPs 
via lyophilization process. The untargeted and targeted liquid formulations were 
subjected to lyophilization process to preserve CSLAHNPs as dry powder. The stability 
of liquid dispersion and lyophilized dry powder were evaluated after stored at different 
storage conditions for various lengths of time.  
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 PREPARATION, CHARACTERIZATION, AND CHAPTER 2.   
OPTIMIZATION OF CORE SHELL TYPE LIPID ALBUMIN HYBRID 
NANOPARTICLES 
 
 
Introduction 
 
Protein based colloidal drug delivery systems prepared from plasma proteins have 
attracted much attention because they offer several advantages: biodegradability, 
biocompatibility, non-antigenic, easy to prepare, controlled particle size distribution, 
various possibilities for surface modification, greater stability, relatively easy to scale up 
and binding ability for a number of hydrophilic and lipophilic drug molecules (226, 227). 
Among various plasma proteins, albumin has been widely used in versatile drug delivery 
systems including microparticles, nanoparticles (NPs), and micelles for various drugs and 
diagnostic agents (226, 228). Three different types of albumins can be used in drug 
delivery purposes: ovalbumin (229), bovine serum albumin (230), and human serum 
albumin (231). Significant amount of drug can be loaded into albumin matrix due to the 
presence of drug binding sites (232). Additionally, presence of high quantity of charged 
amino acids allow electrostatic attraction and loading of charged drug molecules and 
oligonucleotides into albumin matrix (233-236). A significant advantage of albumin NPs 
includes its accumulation to the tumor and inflamed site. This is due to the passive 
targeting or enhanced permeation and retention (EPR) effect and its active targeting 
ability mediated by binding with endothelial gp60 receptors overexpressed on these 
tissues (237, 238). Marketed products include albumin NP bound paclitaxel 
(AbraxaneTM) which was approved by the US Food and Drug Administration in 2006 for 
the treatment of metastatic breast cancer (237, 239, 240). For diagnostic applications, two 
albumin NPs based products (Nanocoll® and Albures®) were approved for the detection 
of cancer and rheumatoid arthritis respectively (228). Among different types of albumin, 
bovine serum albumin (BSA) has been widely used to prepare drug delivery systems 
including NPs because of its defined primary structure, non-antigenicity (241), stability, 
abundance, low cost, ease of purification, and ligand binding properties (226). It is a 
globular protein with molecular weight of ~ 66 kDa and isoelectric point (pI) of 4.7 in 
water at 25oC (230, 242). It has a single polypeptide chain consisting of about 583 amino 
acids residues, 17 intrachain disulfide bridges, and 1 sulfhydryl group (243). BSA based 
albumin NPs (ANPs) are produced by desolvation or coacervation (244-248), 
emulsification (249, 250), thermal gelation (251, 252), nanospray drying (253), nab-
technology (254), disulfide bond reduction (255, 256), and self-assembly methods (257). 
Desolvation is the most widely used method for the preparation of ANPs. Detailed 
investigations on the formulation and process variables of the desolvation method were 
reported in the literature (244-246, 258).  
 
NPs can broadly be classified as simple NPs and composite or core-shell NPs 
based on the number of materials used and the structural features (259). Simple NPs as 
the name implies are composed of a single material whereas composite NPs are made up 
of two or more materials. The focus of nanoparticle design over the years has evolved 
towards more complex nanoscopic core-shell architecture to combine multiple 
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functionalities (116, 260, 261). Core-shell NPs can broadly be described as NPs 
comprising of a core (inner material) and shell (outer layer material) (259). A wide range 
of combinations of inner and outer materials were used such as organic/organic, 
organic/inorganic, inorganic/organic, and inorganic/inorganic (259). Significant 
advancement in nanotechnology has enabled to produce not only core-shell NPs with 
spherical or symmetric shapes but also other non-spherical shapes (259). 
 
Core-shell type lipid-polymer hybrid nanoparticles (CSLPHNPs), which combine 
the mechanical advantages of biodegradable polymeric NPs and biomimetic advantages 
of liposomes, have emerged as a robust and promising delivery platform (65, 82, 262). In 
CSLPHNPs, a biodegradable polymeric core is surrounded by a shell composed of 
layer(s) of phospholipids. Various bioactive molecules such as drugs, genes, proteins, and 
targeting ligands can be entrapped, adsorbed, or covalently attached in the hybrid system. 
The common choices of biodegradable polymers include polylactic-co-glycolic acid 
(PLGA), polycaprolactone (PCL), dextran  due to their biocompatibility, 
biodegradability, non-toxicity and previous use in approved products (83, 84). Lipids 
used are often zwitterionic, cationic, anionic and neutral phospholipids. The examples 
include lecithin, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-
3-trimethylammonium-propane (DPTAP), 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). The hybrid 
architecture can provide advantages such as controllable particle size, surface 
functionality, high drug loading, entrapment of multiple therapeutic agents, tunable drug 
release profile, and good serum stability (134). Besides passive targeting of CSLPHNPs 
based on particle size, they can be conjugated with appropriate targeting ligands such as 
aptamers (134), folic acid (97, 135), transferrin (136), antibody (94), and single-chain 
tumor necrosis factor (121) to deliver NPs at the target tissues for treating cancers. 
 
In this project, a unique drug delivery system known as core-shell type lipid 
albumin hybrid nanoparticles (CSLAHNPs) was proposed. The delivery system was 
comprised of albumin core surrounded by phospholipid layer for the delivery of ETB, a 
small-molecule EGFR tyrosine kinase inhibitor for the therapy of NSCLC (previously 
described in Chapter 1. Core-shell type hybrid NPs comprising of albumin core is a 
unique strategy which has not been reported in the literature till date. BSA was selected 
as the biodegradable polymer to: i) form the core of the CSLPHNPs, ii) to support the 
phospholipid layer, and iii) to bind the hydrophobic drug molecules. The shell of 
CSLAHNPs was composed of DPPC, cholesterol, and DSPE-PEG2000 with a molar 
ratio of 60:30:10 respectively. DPPC is the major lung surfactant phospholipid having a 
polar head group and two non-polar hydrocarbon tails of palmitic acid (263). 
Incorporation of DSPE-PEG2000 has become a preferred strategy to reduce NPs uptake 
by RES organs and to increase NPs circulation time (264). All the components (BSA, 
DPPC and DSPE-PEG2000) have been approved by the Food and Drug Administration 
(FDA) for medical applications. CSLAHNPs were expected to be biocompatible, 
biodegradable, and potentially safe as a drug carrier for clinical use. 
 
Particle size and surface characteristics are the two important physicochemical 
properties of any nanoparticle based delivery system for intravenous administration. 
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These properties mainly affect their transport across biological membranes, body 
distribution, and cellular uptake (265-267). The functional or physiologic pore size of the 
renal glomerular capillary was found to be 4.5-5 nm in diameter (268). Hepatobiliary 
clearance eliminates viruses and other small particles of size 10-20 nm (269). In addition 
to size, surface characteristics of NPs influence opsonization process by which proteins 
are adsorbed on the particle surface and leads to elimination of the particles from 
systemic circulation (264). The mean diameter of blood capillaries or microvessels which 
connect arterioles and venules was found to be around 5-10 μm (270). Uncoated bare 
NPs of size in the range 2-300 nm are taken up by the liver sinusoidal endothelial cells 
while greater than 2-300 nm sized particles are taken up by the Kupffer cells. Therefore, 
prolonged circulation of NPs in the blood is desired because it would increase the 
probability of extravasation of NPs into the target tissues. For intravenously injected NPs, 
a size range of 100-300 nm with a hydrophilic particle surface is expected to be optimum 
for drug delivery applications. Majority of the marketed therapeutic and diagnostic NP-
based products falls into the size range of 100-300nm. Apart from size, the size 
distribution of NPs is another important parameter. It is measured by a parameter called 
polydispersity index (PDI). Conceptually, PDI is the measure of the width of particle size 
distribution and expressed by a dimensionless number between 0 to 1 (271). If PDI value 
is lesser than 0.1, it is considered monodispered size distribution (272). For the present 
study, PDI below 0.2 was considered acceptable. Another important NP property is the 
surface charge which is measured by zeta potential. The electrostatic potential at the 
electrical double layer surrounding the NPs in solution is known as zeta potential. NPs 
with zeta potential close to ± 10 mV is considered neutral whereas zeta potential greater 
than ± 30 mV indicates strong electropositvity or electronegativity (273). NPs with near 
neutral zeta potential or mildly charged surfaces tend to aggregate faster, which may 
enhance clearance by the RES. Stronger the surface charge, better is the colloidal stability 
of NPs and hence a longer shelf life on storage as well (274). Cationic NPs was found to 
interact more with the negatively charged cell membranes thereby enhancing toxicity to 
healthy tissues whereas anionic NPs was found to be non-toxic (275). NPs with negative 
zeta potential with a magnitude lesser than -30 mV are desirable for in vivo stability and 
also for colloidal stability on storage. Therefore, optimization of formulation and process 
parameters which control the particle size and surface characteristics would be a rational 
approach to improve the efficacy of NPs in biological system. Therefore, the objective of 
this study was to identify and optimize formulation and process parameters, and to 
develop a prototype formulation to prepare blank CSLAHNPs which could be utilized 
subsequently for drug loading and antibody conjugation. 
 
 
Experimental Section 
 
 
Materials 
 
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000, 
purity 95-99%) was obtained from Sigma-Aldrich (St. Louis, MO). The lipids used in this 
work were all of research grade. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
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and 1,2-distearoyl-sn-glycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000) 
[DSPE-PEG2000] were purchased from Avanti Polar Lipids (Alabaster, AL). 
Cholesterol, ferric chloride hexahydrate, and ammonium thiocynate were purchased from 
Sigma (St. Louis, MO). High performance liquid chromatography (HPLC) grade water, 
ethanol, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade 
chloroform and 1N sodium hydroxide solution were purchased from Acros Organics 
(Morris Plains, NJ). All other chemicals and reagents were of analytical grade and used 
without further purification or characterization.  
 
 
Preparation of CSLAHNPs 
 
CSLAHNPs were prepared using a two-step method which combined desolvation 
method (245) and lipid film hydration method (133, 159). The schematic representation 
of the two-step method was shown in Figure 2-1. 
 
In the first step, albumin nanoparticles (ANPs) were prepared by the desolvation 
(also known as pH-coacervation) method widely reported (244, 258, 276-278). Briefly, 
BSA was dissolved in 10 mM sodium chloride solution and pH was adjusted to 6- 9 with 
1N sodium hydroxide solution. Ethanol was added dropwise at 0.5-2 mL/min into the 
aqueous phase (water/ethanol volume ratio 1:2 ) until turbidity appeared. The coacervates 
formed were hardened for 12 h after adding glutaraldehyde solution and the resulting 
albumin nanoparticles were purified by centrifugation at 12000 rpm for 30 min, washed 3 
times and reconstituted in 1x PBS.  
 
In the second step, lipids (DPPC, cholesterol, DSPE-PEG2000; molar ratio 
60:30:10) dissolved in methanol: ethanol (50:50 v/v) was evaporated in vacuum 
evaporator in a round-bottom flask. The dry lipid film was hydrated with ANPs 
dispersion (1x PBS) for 15-30 min at 45-50oC. After hydration, two separate methods 
were utilized for CSLAHNPs preparation; sonication and extrusion. The dispersion was 
sonicated in water bath for 10 min. In parallel, another batch was hydrated with ANPs 
dispersion (1x PBS) for 15-30 min at 45-50oC and extruded through a stack of 
polycarbonate membranes (0.8 μm/0.4 μm/ 0.2 μm) using mini-extruder. The free 
vesicles and micelles were removed by ultracentrifugation at 10000-14000 rpm for 20-30 
min, followed by washing thrice. The unbound free drug and other small molecular 
weight species were removed by gel filtration column (sepharose CL 4B) by spinning the 
sample at 400 g for 5 min with 1x PBS as the elution buffer. The final product was 
reconstituted in 1x PBS. 
 
 
Optimization of ANPs 
 
A number of formulation and process variables were selected to produce optimum 
core ANPs with size (100-250 nm), PDI lesser than 0.2 and zeta potential lesser than -30 
mV. These variables included the pH of albumin solution (6-9), albumin concentration  
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Figure 2-1. Schematic representation of the two-step method for the preparation 
of blank CSLAHNPs 
 
In the step I, blank core ANPs were prepared by adding ethanol dropwise, followed by 
hardening with gluteraldehyde. In step II, mixture of lipids (DPPC, cholesterol, DSPE-
PEG2000 at a molar ratio of 60:30:10) were dissolved in ethanol:methanol (50:50 v/v), 
followed by evaporation of organic solvents to form a dry lipid film. Finally, the film was 
hydrated with ANPs to from blank CSLAHNPs.  
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(5-40 mg/mL), rate of addition of ethanol (0.5-2 mL/min), concentration of the cross-
linker gluteraldehyde (0.188-0.97 % w/w), and water-to-ethanol volume ratio (1:1-1:4). 
 
 
Optimization of CSLAHNPs 
 
Since preparation of CSLAHNPs required incubation of ANPs at or above the 
transition temperature of lipids, the thermal stability of ANPs was determined. Briefly, 
ANPs were incubated at 45-50oC for 30 min, followed by determination of the 
physicochemical properties (size, PDI, and zeta potential). The best method to prepare 
CSLAHNPs was selected; either sonication or extrusion. The most important factor that 
influenced the physicochemical properties of CSLAHNPs was total lipid-to-albumin ratio 
(WLipid/WANPs). An empirical calculation was performed to predict the WLipid/WANPs based 
on the assumptions; the spherical ANPs, 100 % DPPC in the bilayer, 5 nm lipid bilayer 
thickness. In parallel, different WLipid/WANPs ratios were selected (0, 5, 10, 15, 20, and 30 
%) to prepare blank CSLAHNPs. 
 
 
Characterization of ANPs and CSLAHNPs 
 
The mean hydrodynamic size (Z-average) of ANPs and CSLAHNPs was 
determined by dynamic light scattering (also known as photon correlation spectroscopy) 
principle using Zetasizer Nano ZS90 (Malvern Instruments, Westborough, MA) equipped 
with 50 mW diode laser as a source of light operating at 532/633 nm. Particle scattered 
photons were detected at an angle of 90°. The samples were suitably diluted with HPLC 
grade water for the determination of Z-avg. Three independent measurements were 
performed for each sample. Zeta potential was determined by electrophoretic light 
scattering (also known as laser doppler micro-electrophoresis) technique in the Zetasizer 
Nano ZS (Malvern Instruments, Westborough, MA). Samples were suitably diluted in 
HPLC grade water or 1x PBS, filled into the disposable capillary cell (DTS1070), and 
analyzed in triplicate.  
 
The phospholipid (DPPC) that were coated onto ANPs at various WLipid/WANPs % 
were quantified by colorimetric assay previously published (279). Briefly, a 2 mL portion 
of 0.1 N ammonium ferrithiocynate solution was added to 1 mL of DPPC in chloroform 
at various concentrations (0-80 μg/mL). The mixture was vortexed for 2 min, chloroform 
layer collected, and optical density was read at 464 nm. A calibration curve of DPPC was 
prepared by plotting optical density versus concentrations of DPPC. To determine DPPC 
content in CSLAHNPs, an aliquot was added to chloroform, agitated for 2-5 min and 
optical density of the chloroform layer was measured after addition of 2 mL of 
ammonium ferrithiocynate solution. 
 
Morphology of the ANPs and CSLAHNPs was characterized by transmission 
electron microscopy using a negative staining technique. Sequential two droplet method 
was used for staining samples with 1% w/v sodium silicotungstate on 400-mesh formvar 
support film on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA) and 
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dried. The TEM images were acquired using JEOL 2000EX transmission electron 
microscope (JEOL USA, Inc., Peabody, MA) equipped with high resolution digital 
camera. 
 
 
Results and Discussion 
 
In the two-step, ANPs (core) were prepared by desolvation (coacervation) method 
in the first step (245). In the second step, the lipid film was hydrated with the ANPs 
dispersion at or above the transition temperature of phospholipids, followed by sonication 
to obtain CSLAHNPs (87, 88, 133). In the desolvation method, ANPs were prepared by 
dropwise addition of a desolvating agent (ethanol or acetone) into aqueous albumin 
solution (adjusted to a particular pH) until the solution became turbid. The turbidity was 
caused addition of desolvating agent which leads to conformational change in protein 
structure by reducing the aqueous solubility of albumin which was phase separated to 
form NPs. At this point, NPs were hardened by addition of gluteraldehyde which 
crosslinked between ɛ-amino groups of lysine and arginine residues (280, 281). The 
hydrophilic surface of the ANPs favors formation of phospholipid bilayer with the 
hydrophilic polar head groups facing towards the hydrophilic albumin core. The process 
was governed by the ratio of lipids and ANPs (also expressed as WLipid/WANPs). In 
addition, the input of external thermal and vibrational energy by heat, sonication and 
agitation increased the mobility and rearrangement of lipids onto the ANPs to form 
CSLAHNPs.  
 
A number of formulation and process variables were studied during the 
preparation ANPs by the desolvation method. As mentioned in the introduction, the 
desired physicochemical properties of blank CSLAHNPs include hydrodynamic mean 
size around 100-250 nm, PDI < 0.2, and zeta potential < -30 mV. The pH of the albumin 
solution prior to ethanol addition significantly influenced mean size of the final ANPs 
(Figure 2-2). The mean size drastically decreased from greater than 1μm at pH 6 to 485 
nm at pH 7. At pH 8, the mean size further reduced to around 183 nm. However, further 
increase in pH to 9 increased size to about 294 nm. The isoelectric point (pI) of the BSA 
was reported to be 4.7 to 5.4 (242, 282). When pH was closer to the pI of BSA, ANPs 
became unstable as indicated by mean size of greater than 1 μm. When pH was increased 
further, carboxyl groups on BSA were ionized to a higher extent. The higher charge 
density in the ANPs increased the electrostatic repulsion and decreased the particle size at 
elevated pH (245). The high electronegative charge density was evident from the 
increased negative zeta potential of ANPs from -15 mV at pH 6 to around -50 mV at pH 
9. Similar findings were reported for the optimization of ANPs by the desolvation method 
(245). Next, the effect of initial albumin concentration on the mean size and 
polydispersity index (PDI) was studied at pH 8 (Figure 2-3). No significant difference in 
mean size was observed for 5 mg/mL and 20 mg/mL albumin concentrations while size 
increased at 40mg/mL albumin concentration. At a high albumin concentration, ANPs 
were close to one another which enhanced coalescence and increase in size. Another 
possible explanation is the increased viscosity of the solution at higher albumin 
concentration, which caused increased droplet size after ethanol addition and ultimately  
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Figure 2-2. Influence of the pH on the mean size and zeta potential of ANPs 
 
The smallest mean size was obtained at pH 8. Values were presented as mean ±SD (n=3); 
albumin concentration: 20 mg/mL; ethanol addition rate: 1 mL/min; water/ethanol (v/v): 
1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and zeta potential were 
measured in pure HPLC grade water. 
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Figure 2-3. Influence of albumin concentration on the mean size and 
polydispersity index of ANPs 
 
The smallest mean size was obtained at albumin concentration of 20 mg/mL. Values were 
presented as mean ±SD (n=3); albumin solution pH: 8; ethanol addition rate: 1 mL/min; 
water/ethanol (v/v): 1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and 
PDI were measured in pure HPLC grade water. 
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leads to increased mean size. of ANPs. Addition of a chemical cross-linker such as 
gluteraldehyde provides better stability, shape, insolubility at high temperatures, and 
reduced swelling. In order to study the effect of crosslinking degree on the size and PDI 
of ANPs, different gluteraldehyde-to-albumin ratios (% w/w) were used during 
preparation of ANPs (Figure 2-4). The gluteraldehyde-to-albumin ratios of 0.188 %, 0.47  
%, and 0.94 % w/w corresponded to the 40, 100, and 200 % of the calculated amount 
necessary for quantitative cross-linking of 59 episilon amino groups of the lysine in the 
albumin molecule (230). It was observed that 0.47 % w/w of gluteraldehyde-to-albumin 
ratio produced smallest mean size of ANPs. The effect of rate of ethanol addition on 
mean size revealed a higher size at low rate (0.5 mL/min) while reduced size was 
obtained from higher flow rates of 1 mL/min and 2 mL/min (Figure 2-5). Finally the 
volume ratio of water-to-ethanol showed smallest mean size of ANPs at 1:2 while size 
increased at 1:3 and 1:4 ratios (Figure 2-6).  
 
The thermal stability of the ANPs was performed at 45-50oC since this is above 
the phase transition temperature of the major lipid component (Tm[DPPC] 41.4oC) present 
in the lipid bilayer (283). Thermal stability data showed no significant change in mean 
size, PDI, and zeta potential before and after incubation (data not shown). DSC data also 
confirmed the thermal stability of serum albumin at 45-50oC (284). No significant 
difference in the physicochemical properties of CSLAHNPs was observed for 
CSLAHNPs prepared by sonication or extrusion. Sonication was chosen as the preferred 
method compared to extrusion for the preparation of CSLAHNPs. This is because a 
significant amount of CSLAHNPs were lost during extrusion method. Unlike liposomes 
which could deform and pass through the pores of the polycarbonate membrane, the rigid 
structure of CSLAHNPs possibly clogged the membrane pores and resulted in poor yield. 
The proportion of total lipids with regard to core ANPs (expressed by lipid-to-ANPs 
weight ratio or WLipid/WANPs) was an important parameter influencing the overall size and 
stability of CSLAHNPs. At high concentrations of phospholipids, free multilamellar 
vesicles formed to a greater extent. As a result, the mean size and PDI of CSLAHNPs 
increased. Furthermore, the purification of final CSLPHNPs was difficult at a very high 
phospholipid concentration. At low or suboptimal lipid concentrations, there would be 
insufficient coating on the polymeric core particles, resulting in instability. The number 
of phospholipid molecules per unilamellar liposome was calculated based on assumptions 
of spherical geometry of liposomes, 5 nm lipid bilayer thickness, and 0.71nm2 surface 
area of phospholipid head group (139). Based on the similar assumptions, the 
WDPPC/WANPs ratio was calculated to be ~10 % based on the theoretical assumptions of 5 
nm DPPC lipid bilayer around spherical 190nm ANPs (core) taking into account the 
DPPC molecular surface area of the head group (0.628 nm2) (285) and density of BSA 
(1.32 gm/cc). The effect of WLipid/WANPs  on the mean size and zeta potential of 
CSLAHNPs was studied experimentally to validate the calculated value. When 
WLipid/WANPs was increased to 5, 10, 15, 20, 30 %, the mean particle size also increased 
gradually from 190 nm to around 300 nm (Figure 2-7). This can be explained by the 
formation of multiple lipid layers around the core which increased the mean size of 
CSLAHNPs. At around 15 % WLipid/WANPs (equivalent to ~8 % WDPPC/WANPs), mean size 
was around 200 nm which was 10 nm higher compared to the ANPs. Zeta potential value 
also reduced from -30 mV to about -10mV when WLipid/WANPs increased from 0 to 30 %. 
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Figure 2-4. Influence of gluteraldehyde-to-albumin ratio on the mean size and 
polydispersity index of ANPs 
 
The smallest mean size was obtained at 0.47 % w/w of gluteraldehyde to albumin. Values 
were presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution 
pH: 8; ethanol addition rate: 1 mL/min; water/ethanol (v/v): 1:2; mean size and PDI were 
measured in pure HPLC grade water. 
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Figure 2-5. Influence of ethanol addition rate on the mean size and polydispersity 
index of ANPs 
 
The smallest mean size was obtained at ethanol addition rate of 1 mL/min. Values were 
presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution pH: 
8; water/ethanol (v/v): 1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and 
PDI were measured in pure grade water. 
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Figure 2-6. Influence of water-to-ethanol ratio on the mean size and 
polydispersity index of ANPs 
 
The smallest mean size was obtained at water/ethanol volume ratio 1:2. Values were 
presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution pH: 
8; ethanol addition rate: 1 mL/min; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean 
size and PDI were measured in pure grade water. 
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Figure 2-7. Effect of lipid-to-albumin nanoparticles weight ratio on the mean size 
and zeta potential of CSLAHNPs 
 
The optimum weight ratio of total lipid to the ANPs was found at 15 % to form the lipid 
bilayer around core ANPs. Values were presented as mean ±SD (n=3); mean size and 
PDI were measured in pure grade water. 
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The change in zeta potential was indicative of the formation of lipid shell around the 
ANPs. About 60 mol % of the lipid bilayer was composed on DPPC which is a 
zwitterionic phospholipid with negative charge on the phosphate group and a positive 
charge on the amine (286). The net charge of DPPC molecule is close to zero at pH 7.4. 
Therefore with the increase in lipid concentration, the zeta potential of the CSLAHNPs 
gradually dropped from -30 mV to -10 mV due to the coating of neutral DPPC around 
core ANPs. As shown in Figure 2-7, the WLipid/WANPs of ~ 15 % resulted in CSLAHNPs 
with favorable combination of size (200 ± 4 nm) and zeta potential (-15± 2 mV) for drug 
delivery application. The optimized WLipid/WANPs of 15 % (which was equivalent to 
WDPPC/WANPs of ~8 %) obtained experimentally were also in conformity with the 
calculated WDPPC/WANPs of ~10 %. The concentration of the DPPC adsorbed onto 
CSLAHNPs was quantified using a colorimetric assay. The data suggested that 
WDPPC/WANPs of 4.47 ± 1.12 % w/w were adsorbed out of the initial WDPPC/WANPs of 8 %. 
The difference could be explained by the heterogeneity of ANPs population with various 
mean sizes which required varied amounts of DPPC to coat the core.  
 
To characterize the structure of CSLAHNPs, they were imaged by transmission 
electron microscopy (TEM) with negative staining by sodium silicotungstate. Sodium 
silicotungstate stained the lipid bilayer membrane with high electron density compared to 
ANPs (core). The TEM image of the ANPs (core) was shown in Figure 2-8. The ANPs 
were smooth and spherical in shape with the absence of dark corona at the edges of  
particles. Figure 2-9 showed TEM image of CSLAHNPs with distinct dark corona 
around the periphery of each CSLAHNP. The thickness of the layer was measured   
around 5 nm which confirmed the presence of phospholipid bilayer (shell) around the 
core (287). The CSLAHNPs were smooth and spherical in shape with some degree of  
polydispersity as seen with core ANPs in Figure 2-8. The particle size observed in TEM 
was in good agreement with that obtained by DLS. A slight reduction in size was 
observed in TEM compared to DLS. This is because DLS provides the statistical Z-
average hydrodynamic size based on the diffusion coefficient of particles in the liquid 
phase using the Stokes-Einstein equation whereas TEM provides estimation of the 
projected area diameter of particles in the dried state under high vacuum (288). 
 
 
Summary and Conclusion 
 
Blank CSLAHNPs with albumin core and phospholipid bilayer shell were 
successfully designed, prepared and optimized by the two step method using bovine 
serum albumin, DPPC, cholesterol, and DSPE-PEG2000 as the formulation ingredients. 
All the ingredients used were biodegradable, biocompatible, non-immunogenic or mildly 
immunogenic and approved by FDA for human use. The formulation and process 
variables were identified and optimized in the?preparation of CSLAHNPs by the two-
step method. Various factors influenced the physicochemical properties including mean 
size, polydispersity index, and zeta potential of both ANPs (core) and CSLAHNPs. In the 
two-step method, the a number of variables were identified and optimized for the 
preparation of ANPs (core) by the desolvation method (first step); albumin concentration 
20 mg/mL, pH of the albumin solution at 8, ethanol addition rate 1mL/min, volume ratio  
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Figure 2-8. Transmission electron micrograph of the ANPs (core) 
 
ANPs were spherical and uniform with a low population of smaller particles. 
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Figure 2-9. Transmission electron micrograph of CSLAHNPs 
 
The sample was stained with 1 % sodium silicotungstate. The particles showed smooth 
and spherical shapes with moderate degree of polydisersity. The lipid shell appeared as a 
dark corona around each particle. 
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of water to ethanol 1:2, and gluteraldehyde-to-albumin ratio 0.47 %w/w. In the second 
step, DPPC, cholesterol, and DSPE-PEG2000 were used at a molar ratio of 60:30:10 for 
the preparation of CSLAHNPs by the lipid film hydration method. The critical parameter 
was identified as the weight ratio of lipid-to-ANPs (WLipid/WANPs) during the 
optimization of CSLAHNPs. The experimental WLipid/WANPs was found around 15 % 
w/w (equivalent WDPPC/WANPs ~ 8 % w/w) which was close to the calculated value (̴ 10% 
w/w) based on the theoretical assumptions. TEM images showed smooth and spherical 
particles of both ANPs (core) and CSLAHNPs with some degree of polydispersity. A 
distinct electron dense corona around periphery of the CSLAHNPs was visible which was 
absent in ANPs. 
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 PREPARATION, CHARACTERIZATION, AND CHAPTER 3.   
OPTIMIZATION OF ERLOTINIB LOADED CORE SHELL TYPE LIPID 
ALBUMIN HYBRID NANOPARTICLES 
 
 
Introduction 
 
Lung cancer, particularly non-small cell lung cancer (NSCLC) is the leading 
cause of cancer related mortality in both men and women worldwide (2). Erlotinib 
hydrochloride (ETB), an EFGR tyrosine-kinase inhibitor, promotes cell cycle arrest and 
apoptosis, and leads to the inhibition of angiogenesis and cell invasion (16). ETB was 
approved as the second or third line therapy in patients with locally advanced or 
metastatic NSCLC after failure of at least one chemotherapy regimen (17). ETB is 
available on the market as oral film-coated tablet 25-150 mg, sold under the trade name 
Tarceva®, and showed oral bioavailability of 60 % (289). NSCLC treatment requires 
long-term administration with a minimum of 4-6 cycles and the drug is likely to attack 
both cancerous and normal cells. As a consequence of long term therapy, toxic effects 
were observed including severe skin rash and diarrhea. No injectable formulation of ETB 
is available in the market, although such a form would be useful for patients with 
gastrointestinal abnormalities (27).  
 
The development of an injectable formulation of ETB would be useful for 
administering the drug in patients with NSCLC. Nanoencapsulation of anticancer drugs 
in colloidal nanocarriers offers the advantages of more favorable pharmacokinetics, drug 
protection, the enhancement of therapeutic efficacy, the reduction of potential toxic side 
effects and the increase of patient comfort by avoiding repetitive bolus injections (40, 
290-292). A recent study showed a reduction in sub-acute toxicity in mice after 
intravenous administration of ETB loaded in PLGA NPs (223). Among various 
nanoparticulate drug delivery systems, CSLAHNPs have emerged as a promising drug 
delivery platform effective for anticancer agents, antibiotics, proteins, and genes. The 
system showed advantages of encapsulation of multiple drugs, increased overall drug 
payload, controlled drug release profiles, and improved stability (65). Many small 
molecular weight chemotherapeutic drugs (135, 138), antibiotics (141), proteins (91) and 
nucleotides (103, 194) have been encapsulated or entrapped in CSLPHNPs (70, 277, 293-
300). CSLPHNPs can be loaded with either a single drug or two drugs (133, 145, 301). 
For single drug loaded CSLPHNPs, the drug can be loaded into both the polymeric core 
as well as in the lipid shell, thereby increasing the total drug payload in the system. For 
two drugs, CSLAHNPs can also be co-loaded with one drug in the core and the other one 
in the shell (145). This is a unique feature of CSLPHNPs which can combine multiple 
functionalities in a single delivery platform. There are two commonly used strategies for 
drug loading in CSLPHNPs; incorporation method and ad/absorption method. In the 
incorporation method, drug(s) is/are incorporated during the preparation step i.e. in the 
core and/or in the lipid film. Another option is to adsorb or absorb the drug with the cores 
and lipid vesicles separately before combining to form CSLPHNPs. However, the DL is 
generally expected to be better in the incorporation approach than the adsorption 
approach (146). The adsorption method has been used to load DNA into lipoparticles 
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composed of PLA core/DPPC-DPTAP lipid shell (103). The macromolecules or proteins 
show greatest loading efficiency near its isoelectric point when it has minimum solubility 
and maximum adsorption (147). For small molecules, the use of ionic interactions 
between the drug and polymer can be an effective way to increase the drug loading (96). 
Examples of the factors which may influence the DL and EE are aqueous solubility of the 
drug, affinity and miscibility of the drug in both polymer and lipid phases (96), amount of 
lipid (144), drug-lipid charge interactions (141), aqueous phase pH (148), and methods of 
preparation. Often it is required to carry out in-depth physicochemical characterization 
during preformulation studies to optimize LC and EE (149). For instance, Li et al have 
analyzed the combined solubility parameters and partition coefficients for screening the 
best lipid and polymer for the highest LC and the maximum binding capacity to the 
cationic drug verapamil (149). Based on the approach, they have reported drug EE 
greater than 90 % and DL between 5 to 36.1 % (96). The amount of the lipid is also a 
decisive factor for EE of lipophilic drugs in CSLPHNPs. Liu et al reported the decrease 
in EE from 42 % to 15% when the lipid component was lowered from 0.1 % to 0.01 % 
for paclitaxel particles (144). Drug lipid charge interactions may be important for 
encapsulation of drugs. Cheow et al reported  successful encapsulation of zwitterionic 
levofloxacin and ofloxacin when PLGA polymer and phosphatidyl choline (PC) lipid 
were used, whereas formation and loading of cationic ciprofloxacin into the CSLPHNPs 
was unsuccessful (141). When PC was replaced with non-ionic polyvinyl alcohol, 
ciprofloxacin loaded CSLPHNPs were successfully produced. The results suggested the 
possibility of unfavorable ionic interactions between the anionic PC and cationic 
ciprofloxacin for the failed formulation. The method of preparation also affects the DL 
and EE. The method used during core PNPs preparation, such as solvent displacement 
method leads to poor DL and EE for hydrophilic compounds (150). Another problem of 
the two-step method is that encapsulated drugs leak out before the lipid coat is formed 
(141). 
 
For the present work, bovine serum albumin (BSA) was selected as the core 
material with phospholipids (DPPC, cholesterol, DSPE-PEG2000) as the shell for the 
loading of ETB in CSLAHNPs. Serum proteins including albumin offer several 
advantages; biodegradability, biocompatibility, non-antigenic, easy to prepare, controlled 
particle size distribution, various possibilities for surface modification, greater stability, 
relatively easy to scale up and binding ability for a number of hydrophilic and lipophilic 
drug molecules (226, 227). BSA is a well-known globular protein which has been well-
investigated over the past 40 years (302). The molecule consists of three intrinsic 
fluorophores; tryptophan (trp), tyrosine, and phenylalanine with two trp residues; trp-212 
and trp-134 (243). Trp-212 is located within a hydrophobic binding pocket and Trp-134 
on the surface of a molecule(243). The interaction and binding of drugs with albumin is 
of great importance in various biomedical applications, particularly drug delivery and 
receptor targeting. ETB-loaded CSLAHNPs (ETB-CSLAHNPs) with high drug payload 
would be advantageous in maximizing the therapeutic efficacy of ETB for the therapy of 
NSCLC. The objective of the study was to optimize drug loading strategies in 
CSLAHNPs along with investigation of the formulation and process variables that 
influence physicochemical properties of ETB CSLAHNPs. 
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Experimental Section 
 
 
Materials 
 
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000, 
purity 95-99 %) and glutaraldehyde solution (25 % in water) were obtained from Sigma-
Aldrich (St. Louis, MO). Erlotinib hydrochloride (purity 99 %) was obtained from LC 
Laboratories (Woburn, MA). The lipids used in this work were all of research grade. 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG2000] were purchased 
from Avanti Polar Lipids (Alabaster, AL). Cholesterol, ferric chloride hexahydrate, and 
ammonium thiocynate were purchased from Sigma (St. Louis, MO). High performance 
liquid chromatography (HPLC) grade water, ethanol, and methanol were obtained from 
Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform and 1N sodium hydroxide 
solution were purchased from Acros Organics (Morris Plains, NJ). All other chemicals 
and reagents were of analytical grade and used without further purification or 
characterization.  
 
 
Quantification of erlotinib 
 
A sensitive reversed phase HPLC method was developed and validated to 
quantitate ETB in the CSLAHNPs. HPLC system consisted of a Waters 600 controller, 
Waters 717 plus auto sampler and a Waters 2996 photodiode array detector. Data were 
acquired and processed with Waters Millennium 32 software (version 4.0). 
Chromatographic separation was achieved on a NovaPak® C18 reverse phase column 
(3.9 X 150 mm) from Waters (Milford, MA). The isocratic mobile phase consisting of 
acetonitrile and acidified water pH 2.6 (40:60, v/v) was pumped at a flow rate of 1.0 
mL/min with an injection volume of 20 μL. ETB (retention time, 5.0 min) was monitored 
at 346 nm with a photodiode array detector.  
 
 
Optimization of drug binding to albumin 
 
The drug binding capacity of albumin was determined experimentally. The 
various parameters or variables that affect drug binding with BSA were investigated and 
optimized to obtain ETB-ANPs with highest drug loading capacity. Briefly, albumin 
solution (1 mg/mL) and aliquots of ETB (drug) in DMSO were added and incubated in 
various pH conditions for 0-24 h at both room temperature (RT) and at 37oC. At 
predefined time intervals, the sample was filtered through Amicon® Ultrafiltation device 
(MWCO 30 kDa) after addition of twice the volume of acetonitrile/water (40:60) mixture 
to extract the unbound drug in the filtrate. Drug concentration in the filtrate was 
determined by HPLC method stated above. 
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Preparation of ETB-ANPs 
 
Erlotinib loaded ANPs (ETB-ANPs) were prepared by two different methods: 
incorporation method and absorption method. The method that provided highest drug 
loading efficiency was chosen. 
 
In the incorporation method, albumin was dissolved in water and drug dissolved 
in DMSO as cosolvent. Then, albumin solution and drug solution were incubated together 
at various ratios of drug to albumin: 2, 4, 8, 12 or 24 h at different pH conditions (3.4, 5.4 
or 7.4) and at different temperature conditions (20 oC or 37oC). Drug loaded ANPs were 
prepared by first adjusting the pH of the albumin drug mixture to pH 8-9, followed by 
addition of ethanol dropwise at 1 mL/min until turbidity appeared. The nanosized 
droplets or coacervates formed were hardened for 12 h after adding glutaraldehyde 
solution (0.47 % w/w of BSA) and the resulting ETB-ANPs were purified by 
centrifugation at 12000 rpm for 30 min (159). ETB-ANPs were also washed thrice. 
 
Drug loading in ANPs can be accomplished by ad/absorption method because of 
the presence of drug binding sites in albumin molecules (303, 304). In the ad/absorption 
method, ANPs (core) was first prepared by desolvation method as discussed in the 
previous chapter. Then, ANPs and drug solution in DMSO were incubated together at 
various drug to albumin ratios, 12 or 24 h, at different pH conditions (3.4, 5.4 or 7.4) and 
at different temperature conditions (20 or 37oC). The ETB-ANPs were purified by 
centrifugation at 12000 rpm for 30 min (159).  
 
 
Preparation of ETB-CSLAHNPs  
 
ETB-ANPs that were prepared in the previous step were used in the preparation 
of ETB-CSLAHNPs. About 5 % w/w of additional drug/lipids was incorporated into the 
lipid film. Drug and lipids (DPPC, cholesterol, DSPE-PEG2000; molar ratio 60:30:10) 
were dissolved in a small quantity of methanol/ethanol (50:50 v/v) in a round bottom 
flask and evaporated in vacuum evaporator for 1-2 h to form dry lipid film. The lipid film 
was hydrated with ANPs dispersion in1x PBS) for 15-30 min at 45-50oC. The dispersion 
was sonicated in a bath sonication for 10 min. The optimized lipids to ETB-ANPs ratio of 
15 % w/w was used as described in Chapter 2. 
 
 
Purification of ETB-CSLAHNPs  
 
The free vesicles and micelles were removed by ultracentrifugation cycle at 
10000-14000 rpm for 20-30 min, followed by washing thrice. The unbound free drug and 
other small molecular weight species were removed by gel filtration column (Sepharose 
CL 4B) by spinning the sample at 400 g for 5 min with 1x PBS as the elution buffer. The 
final product was reconstituted in 1x PBS.  
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Characterization of ETB CSLAHNPs  
 
The mean diameter, PDI, and zeta potential of the ETB-CSLAHNPs were 
determined using the methods reported in Chapter 2. Particle surface morphology and 
shape of the ETB-CSLAHNPs were characterized by TEM as mentioned in Chapter 2.  
 
In order to examine the particle surface morphology and shape, scanning electron 
microscopy (SEM) was also used. A concentrated aqueous suspension was spread over a 
slab and dried under vacuum. The sample was shadowed in a cathodic evaporator (also 
known as “sputter coater”) with a gold layer of 20 nm thick in an argon gas environment 
at 45 mA current for 5 seconds. Photographs were taken using a JSM-5200 Scanning 
Electron Microscope (Tokyo, Japan) operated at 10 kV. 
 
Yield of CSLAHNPs was determined by microgravimetry analysis (305). An 
aliquot (50-100 μL) of the CSLAHNPs dispersion was put in an aluminium pan, dried for 
2h at 80oC, and cooled off. Subsequently, the pans were weighed with a microbalance. 
The yield (mg/mL) was calculated from the difference in weight of the empty and 
CSLAHNPs filled pan.  
 
Drug entrapment efficiency (DEE) and drug loading (DL) of ETB-CSLAHNPs 
were quantified by HPLC method as reported earlier in this chapter. For comparison, 
DEE and DL of ETB-ANPs (core) were also quantified by HPLC method. The drug was 
extracted from CSLAHNPs/ANPs using acetonitrile/water (40:60 v/v) as solvent under 
sonication for 30-45 min. After centrifugation, the supernatant was injected in HPLC 
system to determine the quantity of ETB using the method previously reported. DEE and 
DL were calculated by the Equation 3-1 and Equation 3-2 respectively. 
 
 
??????? ?
?????????????????????????????
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 (Eq. 3-1) 
 
 
?????? ?
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?????? ????????????????????????????????
 (Eq. 3-2) 
 
Transmission infrared spectra were recorded on a Fourier transform infrared 
(FTIR) spectrophotometer (Perkin-Elmer Spectrum BX, Perkin-Elmer Inc., Norwalk, CT, 
USA). The FT-IR spectra were obtained by averaging 32 scans at a resolution of 2 cm−1. 
 
Thermal analysis was conducted using DSC 2010 differential scanning 
calorimeter (TA Instruments, New Castle, DE). The temperature and heat flow 
calibrations were performed at a heating rate of 5°C/min from 0 to 200°C with indium as 
a standard substance. Powder samples, 1–5 mg each, were analyzed at the same settings 
under a purge of nitrogen (50 mL/min). Each analysis was performed in triplicate. 
 
Drug release was quantified in 4000 mL of dissolution media (PBS pH 7.4 and 
acetate buffer pH 5.4) using dialysis method previously reported (69). The in-house set 
up for in vitro drug release experiment was shown in Figure 3-1. A 100μL portion of the  
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Figure 3-1. Schematic diagram of the in-house experimental setup for in vitro 
drug release study 
 
The ETB-CSLAHNPs liquid dispersion was equally divided and placed in minidialysis 
tubes (MWCO 3.5 k Da). The tubes were put inside the floater and placed in a beaker 
containing dissolution medium kept on a magnetic stirrer to agitate the medium. The 
beaker and the magnetic stirrer were kept inside an environmental chamber maintained at 
37oC. 
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ETB-CSLAHNPs dispersion in 1x PBS were pipetted out and added into each Slide-A-
Lyzer MINI dialysis microtubes with a molecular weight cutoff of 3500 Da (Pierce, 
Rockford, IL). Minidialysis tubes were kept in a floater which was placed in a beaker 
containing 4000 mL of the dissolution medium (PBS pH 7.4 or acetate buffer pH 5.4) 
under magnetic magnetic stirring at 75 rpm at 37oC. The entire set up was kept inside a 
temperature controlled oven. At predefined time point, dialysis tubes containing samples 
were taken out, extracted in acetonitrile/water (40:60 v/v) with sonication or vortexing 
for 0.5-1 h at room temperature. After centrifugation, the samples were injected in HPLC 
to quantify the amount of drug released in specified time points. Data of the ETB release 
from ETB-CSLAHNPs were analyzed for release kinetics by zero-order, first order, 
Higuchi, Hixon-Crowell, and Korsemeyer-Peppas model (306, 307).  
 
The colloidal stability of CSLPHNPs in serum was performed according to the 
previously published absorbance (93, 125). CSLAHNPs were suspended in 50 % fetal 
bovine serum (FBS) with a final nanoparticle concentration of 1 mg/mL (dispersed in 1x 
PBS). In order to do this, particles were washed in PBS using Amicon® Ultrafilter and 
concentrated to 2 mg/mL. An equal volume of FBS was then added. Samples were 
incubated at 37oC with periodic light shaking. At each time point, an aliquot of NP 
solutions was at predetermined time points (0, 0.5, 1, 2, 3, 4, and 6 h). Due to interference 
of high concentration of plasma proteins at 50 % FBS, absorbance measurements were 
conducted at 560 nm for each time point using a UV-Visible Spectrophotometer. The 
measurements were performed in triplicate at room temperature. 
 
 
Results and Discussion 
 
For the purpose of rational design of ETB-CSLAHNPs, preformulation 
characterization studies were performed. ETB is a quinazolinamine derivative with the 
molecular weight of 429.9, pKa of 5.42 at 25oC with pH dependent solubility profile (9). 
Increased aqueous solubility was observed at a pH of less than 5 due to protonation of the 
secondary amine (9). The pH of maximum solubility occurs at pH 2. Pharmacokinetics 
data showed 95 % binding with plasma proteins in humans (9). Binding of ETB with 
bovine serum albumin (BSA) was studied (308, 309). BSA has three homologues 
domains (I, II, III) with each domain having two sub-domains (A and B) and 17 disulfide 
bonds (310). Human serum albumin (HSA) also has three domains (I, II, III) with each 
having two subdomains and stabilized by 17 disulfide bridges (243). The major drug 
binding sites in BSA and HSA are located in the hydrophobic cavities in subdomains IIA 
and IIIA (311, 312). Because of the structural similarities with HSA, BSA has been 
frequently used as a model protein for drug binding studies (313). The binding of ETB 
with BSA was investigated by Liu et al (308). Using NMR, spectroscopic, 
thermodynamic and molecular modeling methods, they reported that ETB was bound to 
domain II of BSA with high affinity through hydrogen bond and van der Waals forces. 
Rasoulzadeh et al also reported the formation of ETB-BSA complex through 
hydrophobic interaction and the presence of single ETB binding site on BSA (309). 
Therefore, BSA was selected as the core forming material of the CSLAHNPs for the 
loading and delivery of ETB.  
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The ETB binding study was performed to select and optimize the formulation and 
process variables for the subsequent preparation of ETB-ANPs. The unbound ETB was 
quantified by HPLC method using the standard curve which was linear between 0.625 
and 80 μg/mL with a coefficient of determination (r2) value of 0.9999. The effect of pH 
of the incubation medium was studied at room temperature (RT ̴ 20oC) and at 37oC for 4h 
(Figure 3-2). The results exhibited highest ETB binding with BSA at pH 7.4 and pH 5.4 
while binding capacity decreased at acidic pH 3.4. No significant difference was 
observed for RT and 37oC incubation. This observation could be explained by pH-
ionization hypothesis. The isoelectric point (pI) of BSA is ~ 4.7-5.4 at 25oC. ETB has a 
pKa of ~ 5.4. BSA molecules exist as predominantly cationic below its pI. ETB is a 
weakly basic compound and exists as highly ionized (cationic) with protonation of 
secondary amine. Therefore, electrostatic repulsion of ETB and BSA molecules reduced 
their interaction at pH 3.4. At pH 5.4, 50 % of ETB would ionize while remaining 50 % 
would be unionized. Therefore, the hydrophobic interaction and ionic interaction between 
ETB and BSA lead to increased drug binding capacity. At pH 7.4, ETB would be 
maximally unionized and the hydrophobic interaction between drug and BSA was 
predominant. The influence of incubation time on drug binding to albumin was studied at 
RT and 37oC while keeping the pH of the incubation medium at 7.4 (Figure 3-3). Higher 
drug binding was observed at RT compared to 37oC for 1 h to 24 h. Maximum drug was 
bound to albumin at 8 h, pH 7.4 and at RT condition. The effect of drug-to-albumin 
molar ratio on the drug binding capacity was shown in Figure 3-4. Maximum drug 
binding occurred at drug-to-albumin molar ratio of 10:1 after 8h at pH 7.4.  
 
ETB was encapsulated in the CSLAHNPs to develop a prototype formulation for 
drug delivery to NSCLC. The preparation, characterization and optimization of 
CSLAHNPs (without ETB) were described in detail in Chapter 2. ETB-CSLAHNPs were 
also prepared by the two-step method with two different strategies for loading the drug 
(ETB) into CSLAHNPs; incorporation and sorption method. In the incorporation method, 
ETB was added to BSA solution prior to addition of ethanol to form ETB-loaded ANPs. 
In the sorption method, ANPs were first prepared by desolvation method, followed by 
incubation with ETB to form ETB-ANPs. Figure 3-5 showed the drug loading (DL %) 
and mean size of ANPs as a function of incubation time using incorporation method. 
However, DL was poor with no significant difference observed between two incubation 
times (4 h, 8 h, and 12 h) and two temperatures (RT and 37oC). The addition of high 
volume of ethanol might have solubilized ETB during particle formation and significant 
amount of drug was lost in the subsequent purification of ANPs. Sorption method showed 
higher DL in ANPs at 12 h and RT incubation (Figure 3-6). This is because the drug was 
added after the preparation of ANPs and the desolvating agent (ethanol) did not interfere 
with DL of ANPs. In the method, a part of the drug was absorbed while other parts were 
adsorbed on the surface of ANPs, increasing the final DL. Therefore, sorption method 
was selected for the preparation of ETB-ANPs. 
 
After the preparation of ETB-ANPs, additional ETB (5 % w/w ETB/lipid) was 
also incorporated in the lipid bilayer (composed of DPPC, cholesterol, DSPE-PEG2000 
molar ratio 60:30:10) to increase DL and DEE of the final ETB-CSLAHNPs. The 
physicochemical properties of the optimized ETB-ANPs and ETB-CSLAHNPs were 
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Figure 3-2. The influence of pH on the drug binding to albumin in solution at 
room temperature (RT ̴ 20oC) and at 37oC for 4h 
 
The data were presented as mean ± SD (n =3). The highest ETB binding with BSA at pH 
7.4 and pH 5.4 while binding capacity decreased at acidic pH 3.4. No significant 
difference was observed for RT and 37oC incubation. 
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Figure 3-3. The effect of incubation time on drug binding to albumin in solution 
 
The pH of the solution was kept at 7.4. The study was performed at two temperature 
conditions: RT (20oC) and 37oC. The data were presented as mean ± SD (n =3). Higher 
drug binding was observed at RT compared to 37oC for 1 h to 24 h. Maximum drug was 
bound to albumin after 8 h, pH 7.4 and at RT condition. 
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Figure 3-4. The influence of drug-to-albumin molar ratio on drug binding to 
albumin in solution after 8 h. at pH 7.4 
 
The data were presented as mean ± SD (n =3). Maximum drug binding occurred at drug-
to-albumin molar ratio of 10:1 after 8 h at pH 7.4. 
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Figure 3-5. Influence of drug loading and mean size of ETB-ANPs prepared by 
incorporation method as a function of incubation time at RT and 37oC 
 
The data were presented as mean ± SD (n =3). In the incorporation method, DL was poor 
with no significant difference observed among 4, 8, and 12 h at two temperatures (RT 
and 37oC). 
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Figure 3-6. Influence of drug loading and mean size of ETB-ANPs prepared by 
sorption method as a function of incubation time at RT and 37oC 
 
The data were presented as mean ± SD (n =3). Sorption method showed higher DL in 
ANPs at 12 h and RT incubation. 
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shown in Table 3-1. ETB-CSLAHNPs were 194 nm in size with PDI 0.16, zeta potential 
-15.6 mV, yield 83.5 % w/w, DL 2.08 % w/w, and DEE 32.75 % w/w.  
 
TEM photomicrograph of ETB-CSLAHNPs was shown in Figure 3-7. Sodium 
silicotungstate was used for negative staining. ETB-CSLAHNPs were smooth and 
spherical in shape with distinct dark lipid corona around core. Similar observation was 
reported for TEM image of CSLAHNPs in chapter 2. Additionally, SEM image was 
taken for these particles which also showed spherical particles with low to moderate 
degree of polydispersity (Figure 3-8). As mentioned in Chapter 2, a reduction in size was 
observed in both TEM and SEM images compared to DLS. This is because DLS provides 
the statistical Z-average hydrodynamic mean size based on the diffusion coefficient of 
particles in the liquid phase using the Stokes-Einstein equation whereas TEM and SEM 
provide estimation of the projected area diameter of particles in the dried state under high 
vacuum (288).  
 
FT-IR analysis was used to characterize any chemical interaction that occurred in 
the hybrid NPs system among the drug, albumin and lipids. The FT-IR spectra of ETB, 
BSA, DPPC, cholesterol, DSPE-PEG2000, physical mixture of ETB and BSA, ETB-
ANPs and ETB-CSLAHNPs were shown in Figure 3-9. ETB peaks found at 649, 867, 
901, 948, 1029, 1073, 1213, 1242, 1355, 1431, 1484, 1624, and 3401 cm−1.. The FT-IR 
spectra of native ETB illustrated characteristic bands due to different functional groups 
such as 3495, 1637, 1509 and 1024 cm−1, corresponding to OH stretching vibration, NH 
stretching, aromatic C-C stretching and C=O stretching, respectively. The spectra of 
ETB-CSLAHNPs showed the presence of bands similar to the physical mixture of ETB 
and BSA. Therefore, it can be inferred that ETB-CSLAHNPs system showed no 
significant adverse chemical interaction among the constituents.  
 
DSC studies were carried out to determine whether the drug was incorporated in 
the CSLAHNPs as crystalline, amorphous, or bound form. In Figure 3-10, the DSC 
thermograms demonstrated that pure ETB had a sharp endothermic melting peak at 
235oC. Pure BSA powder showed two endothermic peaks: smaller peak at ~150oC and 
bigger peak around 200oC. DPPC melted around 65oC and pure DSPE-PEG2000 showed 
dual endothermic peaks (40oC and 50oC). ETB-CSLAHNPs showed endothermic peaks 
corresponding to BSA and lipids with no peak for ETB. This suggested that the 
encapsulated ETB might exist in the BSA and lipid matrix as either amorphous form or in 
disordered crystalline phase (314).  
 
Figure 3-11 showed the plot of the drug release data expressed as percentage 
drug released from ETB-CSLAHNPs in two dissolution media (PBS pH 7.4 and acetate 
buffer pH 5.2) as a function of time. The encapsulated ETB was released from the 
CSLAHNPs at a sustained rate over 96 h. When PBS pH 7.4 was used as the dissolution 
medium, ETB-CSLAHNPs showed a biphasic release pattern with initial fast release 
medium, ETB-CSLAHNPs showed a biphasic release pattern with initial fast release 
followed by slower release up to 96 h. The initial faster release of around 60 % of the 
encapsulated drug was observed in 24 h, followed by slower release of drug from 
CSLPHNPs up to about 100 % in 96 h. The initial faster drug release could be attributed  
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Table 3-1. Physicochemical properties of the optimized ETB-ANPs and ETB-
CSLAHNPs 
 
Batch Mean 
Size 
(nm) 
PDI Zeta 
potential 
(mV) 
Yield 
(% 
w/w) 
DL 
(% 
w/w) 
DEE 
(% w/w) 
ETB-ANPs 185 ±8 0.13±0.01 -25.1±3.9 71.3±3.5 1.42±0.5 24.95±7.73 
ETB-
CSLAHNPs 
194 ±6 0.16±0.02 -15.6±4.1 83.5±5.9 2.08±0.7 32.75±5.34 
 
Data presented as mean ±standard deviation (n=3). In ETB-CSLAHNPs, lipids were 
composed of DPPC, cholesterol, DSPE-PEG2000 (molar ratio 60:30:10). In ETB-ANPs, 
initial drug-to-albumin molar ratio was kept at 10:1 (6.45% w/w drug/albumin). 
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Figure 3-7. TEM image of ETB-CSLAHNPs 
 
Scale bar represents 100 nm. TEM image revealed spherical and smooth shape of ETB 
(drug) loaded CSLAHNPs with dark corona of lipid bilayer. The image was similar to 
TEM image of the blank CSLAHNPs as shown in Chapter 2. 
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Figure 3-8. SEM image of ETB-CSLAHNPs 
 
Scale bar represents 200 nm. SEM image revealed spherical and smooth shape of ETB 
(drug) loaded CSLAHNPs. 
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Figure 3-9. FTIR spectra of CSLAHNPs and its components 
 
(A) physical mixture of ETB and BSA, (B) ETB, (C) ETB-ANPs, (D) ETB.HCl, (E) 
ETB-ANPs, (F) ETB-CSLAHNPs, (G) BSA, (H) Cholesterol, (I) DPPC, and (J) DSPE-
PEG2000. FTIR revealed no adverse chemical interaction was present in the CSLAHNPs 
containing drug. 
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Figure 3-10. DSC thermograms of CSLAHNPs and its components 
 
(A) ETB. HCl, (B) ETB-CSLAHNPs, (C) BSA, (D) DPPC, (E) DSPE-PEG2000, and (F) 
Cholesterol. DSC results indicated the existence of drug in the CSLAHNPs as amorphous 
or molecularly dispersed solid solution state. 
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Figure 3-11. In vitro drug release profiles of ETB-CSLAHNPs in pH 7.4 and 
acetate buffer pH 5.2 
 
The data were presented as mean ± SD (n=3). Sustained release of drug from 
CSLAHNPs was observed for about 72-96 h. Drug release rate was faster in pH 5.2 
compared to pH 7.4. 
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to the presence of drug at or near the surface of CSLPHNPs. The burst release effect was 
absent probably due to the presence of hydrophobic lipid bilayer around the ANPs which  
acted as the diffusion controlled membrane. The biphasic drug release pattern was 
reported for ANPs and surfactant coated ANPs in the literature (234, 315). BSA was used 
as the core forming biodegradable polymer which was reported to be highly permeable 
for low molecular weight drugs. The predominant mechanism of drug release from BSA 
matrix occurred through diffusion rather than polymer degradation. However, the burst 
release effect was absent due to the presence of hydrophobic lipid bilayer which acted as 
the diffusion controlled membrane. When acetate buffer pH 5.2 was used as the 
dissolution medium, the drug release rate was faster compared to PBS pH 7.4, indicating 
pH sensitive release of ETB-CSLAHNPs (Figure 3-11). After 24 h, ETB-CSLAHNPs 
released about 80 % drug in pH 5.2 while about 60 % drug release was observed at pH 
7.4. After 48 h, drug release was around 100 % at pH 5.2 while only about 66 % drug 
was release at pH 7.4. Significant difference between drug release profiles at two 
different pH media was observed from after 6 h up to 96 h. The pH sensitivity of ETB-
CSLAHNPs might be beneficial for enhanced drug release in the acidic 
microenvironment of tumors and also the acidic endosome/lysosome compartments of 
cells (316-318). Table 3-2 showed the coefficient of determination and release rate 
constants calculated from in vitro drug release data using various drug release kinetic 
models (zero order, first order, Higuchi, Hixon-Crowell, and Korsmeyer-Peppas). From 
the drug release profiles at pH 7.4, Higuchi and 1st order kinetic models fitted best (r2 ̴ 
0.97). This indicated that the drug release from CSLAHNPs occurred through diffusion 
controlled mechanism. Drug release profile at pH 5.2 fitted best with 1st order kinetics 
(r2 ̴ 0.92). Therefore, it can be interpreted from first order release kinetics that the drug 
release rate was dependent on the concentration of drug in CSLAHNPs. Similar findings 
were reported for biphasic release of 5-fluorouracil loaded ANPs (319). Moreover, the 
Korsmeyer-Peppas release model showed high correlation for drug release from ETB-
CSLAHNPs at both pH values. The diffusion exponent, ?, was about 0.8, which 
confirmed that the anomalous diffusion or non-fickian diffusion was the controlling 
factor in drug release. Therefore, drug release from CSLAHNPs was governed by both 
diffusion and erosion of matrix as indicated by non-fickian diffusion mechanism (320). 
 
Stability of CSLAHNPs in serum is an important consideration for their 
usefulness of CSLAHNPs as the drug delivery system in vivo where dilution after 
intravenous administration could result in NPs aggregation, disassembly and/or drug 
leakage. CSLAHNPs were incubated in 50 % serum at 37oC with gentle stirring followed 
by determination of the absorbance at 560 nm. Absorption method was used since 
CSLAHNPs cannot be accurately detected in dense serum solution by dynamic light 
scattering technique due to the matrix protein interference from serum (321).Aggregation 
phenomena were characterized by increased absorbance to higher values. The interaction 
of CSLPHNPs with various serum proteins in the incubation media would cause 
neutralization of zeta potential of NPs. The process subsequently would reduce repulsion 
energy between particles and progressively facilitate agglomeration process and the 
formation of larger particles. As shown in Figure 3-12, ETB-CSLAHNPs were stable in 
serum retaining the integrity up to 6 h as indicated by no significant change in absorbance 
values at 560 nm similar to ETB-ANPs.  
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Table 3-2. In vitro release kinetics of ETB-CSLAHNPs 
 
Release model        r2/K    pH 7.4        pH 5.2 
Zero Order r2 
K0 
0.8874 
0.9127 
0.7156 
0.9789 
First Order r2 
K1 
0.9795 
-0.0099 
0.9214 
-0.0183 
Higuchi r2 
KH 
0.97 
9.9221 
0.8816 
11.298 
Hixon-Crowell r2 
KHC 
0.9619 
-0.0252 
0.857 
-0.0361 
Korsmeyer-
Peppas 
r2 
n 
0.9626 
0.7841 
0.9652 
0.8073 
 
r2 = Coefficient of determination. K0 = Zero-order release rate constant. K1 = First-order 
release rate constant. KH = Higuchi release rate constant. KHC = Hixon-Crowell release 
rate constant. n = diffusion exponent.  
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Figure 3-12. In vitro stability of ETB-CSLAHNPs and ETB-ANPs in 50% fetal 
bovine serum 
 
The data were presented as mean ± SD (n=3). Particles retained their physicochemical 
properties without aggregation for a prolonged period of time (6 h).  
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Summary and Conclusion 
 
The drug binding capacity of albumin in solution was studied and optimized at 
various pH conditions, durations of incubation, incubation temperatures, and drug-to-
albumin molar ratios. The maximum drug binding capacity of albumin was observed at 6 
h incubation in pH 7.4 at room temperature with drug-to-albumin molar ratio 10:1. ETB-
CSLAHNPs were successfully designed, prepared and optimized by the two step method 
as described in Chapter 2. Two strategies for drug loading in ANPs were studied; 
incorporation and sorption method. Sorption method provided better drug loading and 
entrapment efficiency in ETB-ANPs compared to incorporation method. Additional ETB 
was incorporated in the lipid bilayer to maximize the drug loading and entrapment 
efficiency of ETB-CSLAHNPs. ETB-CSLAHNPs were ~194 nm in size with PDI ~0.16, 
zeta potential -15.6 mV, yield 83.5 % w/w, DL 2.08 % w/w, and DEE 32.75 % w/w. 
SEM and TEM images showed smooth and spherical particles of ETB-CSLAHNPs. Drug 
release from ETB-CSLAHNPs occurred in a sustained manner up to 96 h with a biphasic 
release pattern in pH 7.4. Drug release was faster in acidic pH of 5.2. Drug release 
kinetics analysis showed a first order release kinetics with non-fickian diffusion 
mechanism. ETB-CSLAHNPs were stable in serum for up to 6 h. Therefore, the 
optimized ETB-CSLAHNPs would be utilized for the conjugation of monoclonal 
antibodies for the preparation of targeted ETB-CSLAHNPs as described in the following 
chapter. 
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 DEVELOPMENT OF HALF-ANTIBODY CONJUGATED CHAPTER 4.   
ERLOTINIB LOADED CORE SHELL TYPE LIPID ALBUMIN HYBRID 
NANOPARTICLES 
 
 
Introduction 
 
Conventional chemotherapy of cancer has often exhibited limited therapeutic 
efficacy along with severe systemic toxicities (322). As an alternative, small molecule 
EGFR tyrosine kinase inhibitors (TKI) such as ETB that target overexpressed EGFR 
present on the NSCLC tumor blood vessels endothelial membranes have been used 
clinically as the molecularly targeted therapy (323). However, EGFR TKI therapy can 
cause serious toxicities because they are not organ or tissue specific (324). After binding 
with growth factors such as EGF, EGFR elicits the internalization and intracellular 
sorting of receptor-ligand complexes and activates signaling pathways (325). The 
endocytosis of ligand-activated EGFR was found to be EGF concentration dependent. At 
low concentration of ligand (EGF), it involved clathrin-mediated endocytosis (326). At 
high EGF concentration, caveolae-mediated endocytosis was prevalent (327). The ligand-
EGFR complex undergoes intracellular trafficking and finally degrades in lysomes after 
ubiquitin-dependent sorting in early endosomes (325). The internalization and lysosomal 
trafficking phenomena can be utilized by directing TKI to specific tumor cells via passive 
targeting and/or active targeting strategies. Therefore, the efficacy of TKI could be 
improved by targeted delivery and release of small molecule EGFR TKI inside the tumor 
cells using anti-EGFR antibody conjugated NPs.  
 
In tumor pathogenesis, multiple factors such as increased metabolic function, 
decreased oxygen supply or hypoxia, and depletion of glucose triggers the formation of 
new blood vessels, a process also known as angiogenesis (328-330). Angiogenesis plays 
an important role in the proliferation, migration and maintenance of healthy tissues. 
Imbalance between pro-angiogenic and physiological anti-angiogenic signaling leads to 
the formation of the tumor vessels which are heterogeneous, immature and leakier than 
normal vessels (330-333). This leakiness is present because of the impaired recruitment 
of pericytes which are support cells of normal vessels (334). The intercellular openings 
between endothelial cells become larger than normal transcellular fenestrations. There is 
a significant heterogeneity in pore size within and between tumor types with nominal size 
range between 100 nm to 2 μm (51, 335, 336). The physical pressure arising from cancer 
cell proliferation causes compression of the intratumoral lymphatics which leads to poor 
lymphatic drainage or clearance. As a consequence, NPs which are smaller than the 
fenestrations can extravasate to the surrounding tumor tissues and entrapped in the tumor. 
This phenomenon is known as enhanced permeability and retention (EPR) effect. EPR 
effect is also known as passive targeting which has also been exploited by various drug 
delivery systems including NPs (50).Unlike passive targeting by EPR effect, active 
targeting utilizes peripherally conjugated targeting moieties such as monoclonal 
antibodies, proteins, peptides, vitamins or aptamers to direct drug loaded NPs to the 
specific tumor tissues (337). Targeting ligands can be attached to the surface of NPs by 
covalent and non-covalent conjugation chemistry techniques (152). Covalent coupling 
 80 
 
techniques employ various covalent linkages such as thioether (338), disulfide (339), 
carboxamide (340), amide (341), and hydrazine bonds (342) to bind ligands to NPs. Non-
covalent coupling method used to bind ligands to NPs include simple adsorption. 
However, the non-covalent method has limitations such as low ligand binding efficiency, 
incorrect orientation of ligands, difficulty in controlling amount of ligands, and 
detachment of ligands in vivo (343). 
 
Most NSCLC tumors (50-90%) overexpress EGFR or HER1 which are associated 
with tumor cell proliferation, metastasis, and angiogenesis. Small molecule EGFR 
tyrosine kinase inhibitors (e.g. erlotinib and gefitinib) inhibit autophosphorylation by 
binding to the ATP binding site of the intracellular tyrosine kinase domains of EGFR. 
Alternatively, therapeutic EGFR directed monoclonal antibodies such as Cetuximab 
(marketed as Erbitux®, Bristol-Myers Squibb company) were used to prevent ligand 
binding to the extracellular domain of the receptor(344-346). EGFR specific monoclonal 
antibodies (mAb) were investigated as the targeting ligand in nanoparticulate drug 
delivery systems in NSCLC (347-353). Whole mAbs (molecular weight 150 kDa) which 
are immunoglobulins (IgG) have two identical heavy (H) chains and two identical light 
(L) chains of amino acids held together by disulfide bridges between the cysteine 
residues (354). The mAbs conjugated onto NPs have several limitations such as shorter 
circulation half-life because of the large hydrodynamic size of mAbs increases non-
specific uptake by RES. Large hydrodynamic size of mAbs also limit both intratumoral 
uptake and homogeneous distribution in the tumor, thus adversely affecting 
pharmacokinetic properties of mAb-conjugated NPs (355). In addition, binding 
orientation is important for maximizing the functionality of mAbs for targeting (356). 
However, non-specific conjugation of nanoparticle to mAb via amide bond may hinder 
the binding sites of mAb (357). Antibody fragments can penetrate tissue more rapidly 
than whole mAbs due to their smaller size than mAbs (358, 359). Antibody fragments 
such as single chain variable fragments (scFv), diabodies, and nanobodies have been used 
to replace mAbs (360, 361). Peng et al reported a significant increase in intracellular 
cisplatin concentration and enhanced antitumor efficacy of the single-chain variable 
fragment (ScFv) EGFR conjugated heparin NPs (362). A ScFvEGFR functionalized 
quantum dots (QDs were reported to bind and internalize by EGFR-expressing cancer 
cells (363).  
 
Half-antibodies (hAb) or reduced IgG were synthesized by TCEP induced 
cleavage of the disulfide bridges in the hinge region between two heavy chains of mAb 
(94, 364). The hAbs possess intact binding site and retain their receptor binding affinity 
(364, 365). NPs can be conjugated through the readily available thiol functional groups 
that are present in the constant region of hAb (94, 365). The other advantages compared 
to mAbs include relatively smaller hydrodynamic size, longer circulation half-life, and 
rapid extravasation to tumor tissues. For the present study, ETB-CSLAHNPs were 
conjugated to anti-EGFR hAb via thioether bonds between maleimide terminated 
CSLAHNPs and thiol groups of hAb. The objective of this study was to prepare and 
characterize prototype anti-EGFR hAb-conjugated ETB-CSLAHNPs for the purpose of 
active targeting to NSCLC. 
 
 81 
 
Experimental Section 
 
 
Materials 
 
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000, 
purity 95-99 %), glutaraldehyde solution (25 % in water), 2-mercaptoethanesulfonic acid 
sodium salt (MESNA), sodium chloride, and Ellman's reagent (5,5'-dithiobis-(2-
nitrobenzoic acid) or DTNB) were obtained from Sigma-Aldrich (St. Louis, MO). 
Erlotinib hydrochloride (purity 99 %) was obtained from LC Laboratories (Woburn, 
MA). The lipids used in this work were all of research grade. 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-hoshoethanolamine-N 
(poly(ethylene glycol)2000) [DSPE-PEG(2000)], and 1,2-distearoyl-sn-glycero-3-
phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) [DSPE-PEG2000-
maleimide] were purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol was 
purchased from Sigma (St. Louis, MO). High performance liquid chromatography 
(HPLC) grade water, ethanol, and methanol were obtained from Fisher Scientific (Fair 
Lawn, NJ). HPLC grade chloroform and 1N sodium hydroxide solution were purchased 
from Acros Organics (Morris Plains, NJ). Mouse monoclonal EGFR antibody (D-8) was 
obtained from Santa Cruz (Dallas, TX). Tris(2-carboxyethyl)phosphine hydrochloride 
[TCEP] was supplied by Thermo Scientific (Rockford, IL). All other chemicals and 
reagents were of analytical grade and used without further purification or 
characterization. 
 
 
Preparation of maleimide terminated ETB-CSLAHNPs 
 
Maleimide terminated ETB-CSLAHNPs were prepared and purified using the 
method previously reported in Chapter 2 and 3 with the replacement of 1 mol % DSPE-
PEG2000 with DSPE-PEG2000-maleimide.  
 
 
Assay of maleimide 
 
Maleimide content of ETB-CSLAHNPs after incorporation of DSPE-PEG2000-
maleimide was quantified using the modified Ellman’s assay (366). Briefly, a standard 
curve was prepared by adding the Ellman’s reagents to different concentrations of a water 
soluble thiol MESNA in 100 mM PBS pH 8. The absorbance was read at 412 nm using a 
UV-visible spectrophotometer and thiol concentration was quantified from the standard 
curve. An aliquot of maleimide terminated ETB-CSLAHNPs in PBS was reacted with 
excess molar concentration of MESNA for 5 min at room temperature, followed by 
addition of Ellman’s reagent and absorbance was read at 412 nm. The concentration of 
maleimide was calculated by subtracting unreacted MESNA from initial concentration of 
MESNA added. 
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Synthesis of anti-EGFR half antibody 
 
For antibody conjugation, anti-EGFR half-antibody (hAb) were synthesized from 
anti-EGFR intact monoclonal antibody (mAb) by reducing the disulfide linkages between 
the heavy chains of mAb (94). Briefly, mAb in 1xPBS (50 μg/mL) was mixed with 50:1 
molar ratio of [tris(2-carboxyethyl)phosphine] (TCEP) to mAb and incubated for 1h at 
room temperature(364). The samples were passed through Amicon® Ultra-0.4 filters 
MWCO 100 kDa, followed by 50 kDa. The sample retained in 50 kDa was collected. 
Total cell proteins from each sample (25-50 μg) were added to Laemmli 5x loading 
buffer and incubated at 37oC for 10 min. The samples were loaded into the wells of 4-15 
% SDS-PAGE gels immersed in running buffer (tris-glycine/SDS) and resolved at 150V 
for 45 min using standard molecular weight ladder. Finally, the gel was stained with 
water soluble colloidal CoomassieTM blue stain for 12 h. A calibration curve was 
constructed using standard concentrations of BSA resolved by SDS-PAGE as described 
above. The Coomassie-stained gels were used for densitometric measurements using 
ImageJ 1.39u software (National Institutes of Health, Bethesda, MD). Using a calibration 
curve, the densitometric units of the samples were converted into concentrations. 
 
 
Preparation of half-antibody conjugated ETB-CSLAHNPs 
 
The molar ratio of hAb to DSPE-PEG2000-maleimide used was 8.6 nM/μM as 
reported by Meel et al (367). CSLAHNPs with maleimide moieties (1 mL) were 
incubated with selectively reduced anti-EGFR hAb (1mL) for 4h at 4oC. The samples 
were assayed for maleimide content by modified Ellman’s assay as reported previously. 
The unconjugated antibodies, TCEP and other small molecular weight species were 
removed by spinning the dispersion in Sepharose Cl-4B packed gel filtration column. To 
confirm the presence of hAb on targeted CSLAHNPs, the samples were resolved by 
SDS-PAGE and hAb concentration was determined by the method described above. 
 
 
Characterization of half-antibody conjugated ETB-CSLAHNPs  
 
The mean diameter, polydispersity index (PDI), zeta potential, morphology, drug 
loading, drug release, and in vitro serum stability of the targeted CSLAHNPs were 
determined using the methods reported in Chapter 2 and 3. 
 
 
Results and Discussion  
 
The schematic diagram of the preparation of targeted ETB-CSLAHNPs was 
shown in Figure 4-1.To prepare targeted ETB-CSLAHNPs, anti-EGFR half-antibody 
(hAb) was conjugated to maleimide-terminated ETB-CSLAHNPs. The preparation of 
hAb from monoclonal antibody (mAb) via disulfide bond reduction method was the 
critical step in the preparation of targeted hAb-ETB-CSLAHNPs. A number of protein 
disulfide reducing agents are available such as β-mercaptoethanol (BME) (368), cysteine,  
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Figure 4-1. Schematic diagram of the preparation of anti-EGFR half antibody 
(hAb) conjugated ETB-CSLAHNPs 
 
Anti-EGFR monoclonal antibody (mAb) was selectively reduced to half-antibody (hAb) 
with thiol groups. Maleimide-PEG-DSPE incorporated ETB-CSLAHNPs were 
conjugated with hAbs to produce hAb-ETB-CSLAHNPs. 
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dithiothreitol (DTT) (369), tris(2-carboxyethyl)phosphine (TCEP). In this study, TCEP 
was used as the reducing agent because it is stable, specific, and effective at wide range 
of pH (370). Anti-EGFR mAb was selectively reduced by using TCEP which breaks the 
disulfide bonds between the two heavy chains of the mAb to form hAb or reduced IgG. 
The extent of mAb reduction was controlled by TCEP concentration and duration of 
reaction (94, 364). Normally, the reduction products include half-antibody or hAb 
fragments (?75kDa), heavy chain fragments (? 50 kDa), light chain fragments (?25 
kDa) along with unreacted mAb (? 150 kDa) (371). Various molar ratios of mAb: TECP 
were incubated at room temperature for 1 h (364). The samples were resolved in SDS-
PAGE and visualized by staining with CoomasieTM blue (Figure 4-2). It was observed 
that 1:100 or higher molar ratio of mAb:TCEP completely cleaved to heavy-chain and 
light-chain fragments. The optimized molar ratio of 1:50 of mAb:TCEP maximized the 
yield of hAb and minimize the production of non-targeting fragments.  
 
Maleimide-terminated ETB-CSLAHNPs (Mal-ETB-CSLHANPs) were prepared 
by the previously described two-step method using 1 mole % DSPE-PEG2000-
maleimide. The final composition of the lipids used was DPPC, cholesterol, DSPE-
PEG2000, and DSPE-PEG2000-maleimide at a molar ratio of 60:30:9:1 respectively. 
Since the incorporation of lipids in the Mal-ETB-CSLAHNPs was not 100%, the molar 
concentration of maleimide groups on the particles were determined by modified 
Ellman’s assay (366). The Ellman’s assay showed actual amount of DSPE-PEG2000-
maleimide in CSLAHNPs was ~ 30-40% of the theoretical amount added. The ratio of 
hAb to DSPE-PEG2000-maleimide was kept at 8.6 nM/μM of DSPE-PEG 2000-
maleimide as reported previously (367). Based on the theoretical assumptions, it was 
estimated to be ~ 30 hAb molecules per CSLAHNPs (372).The anti-EGFR mAbs were 
reduced by TCEP at 1:50 molar ratio for 1 h to produce hAbs with readily available 
sulfahydryl groups (-SH). Mal-ETB-CSLAHNPs and hAbs were incubated together at 
4oC overnight to obtain hAb-conjugated ETB-CSLAHNPs or targeted CSLAHNPs (hAb-
ETB-CSLAHNPs). The conjugation of hAbs and CSLAHNPs were accomplished 
through the formation of thioether linkages between sulfahydryl groups and maleimide 
groups present on the distal end of PEG chains on the Mal-ETB-CSLAHNPs. To confirm 
that hAb was successfully conjugated to ETB-CSLAHNPs, samples were run through 
SDS-PAGE and visualized by staining in comparison with standard molecular weight 
ladder (Figure 4-2). The physicochemical properties of hAb-ETB-CSLAHNPs were 
reported in Table 4-1. Targeted hAb-ETB-CSLAHNPs were ~ 200 nm in mean 
hydrodynamic size with PDI ~ 0.13, zeta potential ~ -13mV, DL ~ 2 % w/w, and DEE ~ 
31% w/w.  
 
The TEM image of hAb-ETB-CSLAHNPs was shown in Figure 4-3. It showed 
that targeted CSLAHNPs were spherical in shape with moderate degree of polydispersity. 
The conjugation of hAb onto ETB-CSLAHNPs did not significantly change the 
morphology and shape of the particles compared to ETB-CSLAHNPs without hAb (as 
shown in Chapter 3). 
 
The drug release data expressed as percentage of drug released from hAb-ETB-
CSLAHNPs in two dissolution media (PBS pH 7.4 and acetate buffer pH 5.2) as a  
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Figure 4-2. Analysis of proteins by SDS/PAGE with coomassie staining 
 
Lane 1 represents ETB-CSLAHNP without targeting half-antibody (hAb) which did not 
show any protein band. Lane 2 represents ETB-CSLAHNPs conjugated with hAb which 
showed a distinct band at ~75 kDa. Lane 3 represents TCEP reduced mAb at 1:50 molar 
ratio of mAb: TCEP. It showed three distinct bands at~75 kDa, 45 kDa, and 25kDa. Lane 
4 represents anti-EGFR mAb which showed a sharp band at ~150 kDa. The rightmost 
lane represents a standard molecular weight proteins marker.  
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Table 4-1. Physicochemical properties of targeted CSLAHNPs 
 
Batch Mean 
Size 
(nm) 
PDI Zeta 
potential 
(mV) 
DL 
(% w/w) 
DEE 
(% w/w) 
Mal-ETB-CSLAHNPs 196 ±5 0.11±0.01 -19.1±5.1 2.12±0.3 31.95±3.34 
hAb-ETB-CSLAHNPs 199 ±7 0.13±0.02 -12.6±4.1 2.01±0.2 30.95±4.37 
 
The data were presented as mean ± SD (n=3). Mal-ETB-CSLAHNPs represent 5 mol % 
DSPE-PEG2000-maleimide incorporated ETB-CSLAHNPs. hAb-ETB-CSLAHNPs 
represent anti-EGFR half-antibody (hAb) conjugated ETB-CSLAHNPs. 
 
 
  
 87 
 
 
 
 
Figure 4-3. TEM images of targeted hAb-ETB-CSLAHNPs 
 
Scale bar represents 100 nm. The sample was stained with 1% sodium silicotungstate. 
The particles showed smooth and spherical shapes with moderate degree of polydisersity. 
The lipid shell appeared as a dark corona around each particle. 
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function of time (Figure 4-4). The hAb-conjugated CSLAHNPs showed similar release 
profiles in pH 7.4 and pH 5.2 compared to ETB-CSLAHNPs without targeting antibody 
(as shown in chapter 3). The encapsulated ETB was released from the hAb-ETB-
CSLAHNPs at a sustained rate over 96 h in PBS pH 7.4 with a biphasic release pattern.  
In acetate buffer pH 5.2, the drug release rate was faster compared to PBS pH 7.4, 
indicating pH sensitive release of hAb-ETB-CSLAHNPs (Figure 4-4). 
 
NP-serum protein interactions are related to the particular physicochemical 
characteristics of the particles, such as their colloidal stability, and this significantly 
influences the subsequent NP-cell interaction. The colloidal stability of hAb-ETB-
CSLAHNPs in 50 % fetal bovine serum showed by measuring absorbance at 560nm for 
various incubation time points (Figure 4-5).There was no perceptible change in 
absorbance values for up to 6 h. After prolonged incubation for 24 h, the absorbance 
value increased indicating aggregation due to the adsorption of serum proteins. Lipid 
coating around polymeric core particles also showed enhanced serum stability compared 
to bare PNPs (373). Surface charge was identified as the critical parameter which 
influenced the colloidal stability of NPs. It was reported that positively charged NPs 
displayed a significantly lower colloidal stability than neutral and negatively charged 
particles (374). The targeted CSLAHNPs possessed negative zeta potential which 
increased colloidal stability by electrostatic repulsive forces. In addition, the presence of 
PEG chains on the particle surface provided increased colloidal stability via steric 
repulsion by reducing serum protein adsorption (375). 
 
 
Summary and Conclusion 
 
Targeted hAb-ETB-CSLAHNPs were prepared by the maleimide-thiol 
conjugation reaction after incorporating 1 mol % DSPE-PEG2000-maleimide in ETB-
CSLAHNPs during preparation. Anti-EGFR mouse monoclonal antibody (mAb) was 
reduced to half-antibodies (hAb) using TCEP at 50:1 molar ratio of TCEP:mAb and 
coupled to maleimide-terminated ETB-CSLAHNPs. Targeted hAb-ETB-CSLAHNPs 
were ~ 200 nm in hydrodynamic mean size with PDI ~ 0.13, zeta potential ~ -13 mV, DL 
~ 2 % w/w, and DEE ~ 31 % w/w. TEM image showed smooth and spherical particles 
with moderate degree of polydispersity. Drug release from hAb-ETB-CSLAHNPs 
occurred in a sustained manner up to 72-96 h with a biphasic release pattern in pH 7.4. A 
faster rate of drug release was observed in acidic pH of 5.2. The hAb-ETB-CSLAHNPs 
were stable in 50% serum for up to 6 h. Therefore, the hAb-ETB-CSLAHNPs were used 
for the cell-based assays.  
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Figure 4-4. In vitro drug release profiles of targeted hAb-ETB-CSLAHNPs in pH 
7.4 and acetate buffer pH 5.2 at 37oC 
 
The data were presented as mean ± SD (n=3). Sustained release of drug from 
CSLAHNPs was observed for about 72-96h. Drug release rate was faster in pH 5.2 
compared to pH 7.4.  
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Figure 4-5. In vitro stability of targeted hAb-ETB-CSLAHNPs in 50% fetal 
bovine serum at 37oC 
 
The data were presented as mean ± SD (n=3). Particles retained their physicochemical 
properties without aggregation for a prolonged period of time.  
 
  
 91 
 
 IN VITRO UPTAKE, TRAFFICKING, AND EFFICACY OF CHAPTER 5.   
TARGETED AND UNTARGETED ERLOTINIB LOADED CORE SHELL TYPE 
LIPID ALBUMIN HYBRID NANOPARTICLES IN NSCLC CELLS 
 
 
Introduction 
 
A detailed understanding of the involved processes of NPs to cell interaction is an 
important aspect for developing NPs for anticancer drug delivery (376, 377). Cell 
membrane acts as a barrier impermeable to many large particles while allowing very 
small particles of size 10-30 nm (378, 379). One of the mechanisms to overcome the 
barrier for larger particles is known as endocytosis. It is a process utilized by viruses 
when they invade cells. Endocytosis has been described as the uptake of particulate 
matter such as proteins, nutrients, cell debris, and foreign cells via formation of 
invagination of the cell membranes (380). Phagocytosis is a type of endocytosis in which 
cells (e.g. macrophages, monocytes, and neutrophils) engulf larger particles (e.g. bacteria, 
cell debris) of diameter between 0.5 to 10 μm as a response of body’s immune defense. 
In addition to phagocytosis, cells also utilize the pinocytosis process for the uptake of 
soluble substances. There are two major pinocytic mechanisms currently known: 
micropinocytosis and receptor-mediated endocytosis (RME). Macropinocytosis is the 
process of uptake of particles via formation of larger vesicles (0.3 – 5 μm) mediated by 
membrane ruffling driven by actin cytoskeleton (381). There are different pathways 
observed in RME: clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
clathrin- and caveolin-independent endocytosis. Clathrin-mediated endocytosis is the 
uptake of particles through the formation of clathrin coated pit. The process involves five 
stages: nucleation, cargo selection, clathrin coat assembly, vesicle scission, and 
uncoating/clathrin component recycling. The size of the clathrin-coated pits varies from 
species to species in the range of 15 - 200 nm (382). Caveolae mediated endocytosis 
involves uptake of particles via the formation of invaginated, flask-shaped plasma 
membrane domains, known as caveolae. These vesicles are typically 50-80 nm in 
diameter and are enriched with cholesterol and sphingolipids. After internalization, 
caveolae- or lipid raft-derived vesicles travel to caveosomes. Caveosomes have neutral 
pH compared to endosomes which have an acidic pH. In caveosomes, internalized cargo 
could reside, sorted to the Golgi complex, or to the endoplasmic reticulum. In addition to 
active endocytotic processes, NPs may also enter the cells by non-endocytotic 
mechanisms such as diffusion or active transport.  
 
NPs interact with biomolecules including proteins, carbohydrates, and lipids 
present in the extracellular fluids prior to association with the cell membrane. A protein 
corona forms around the NPs and subsequently triggers activation of cell surface 
receptors (383). Plasma protein such as immunoglobulin binding caused opsonization and 
receptor-mediated phagocytosis of carboxyl-functionalized NPs (264). Cellular uptake 
and internalization of NPs are strongly influenced by physico-chemical properties of NPs 
including size (384, 385), shape (386, 387), surface charge (388, 389), surface functional 
groups (390) and hydrophilicity (391). 
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Apart from quality, the biological safety and efficacy of nanomedicines have to be 
fully investigated to comply with the rules and regulations set forth by regulatory 
agencies such as Food and Drug Administration. For the biological testing of 
nanomedicines, cell culture models have been widely used as an exceptionally powerful 
and economic tool before moving to expensive in vivo models (392). Cell based models 
offer unique platform to test the efficacy and safety of nanomedicines under controlled 
and reproducible conditions (393). In addition, a number of experimental variables can be 
easily manipulated to simulate the in vivo conditions (394).  
 
The objective of this work was to investigate the cellular binding, uptake and 
internalization of fluorescently labeled ETB-CSLAHNPs (untargeted) and hAb-ETB- 
CSLAHNPs (targeted) in two human lung adenocarcinoma cells (A549 and HCC827). In 
addition, in vitro efficacy of CSLAHNPs was determined by cell viability assay and 
clonogenic assay. Finally, the expression levels of biomarker (p-EGFR) with and without 
treatment of CSLAHNPs were assessed by western blot. 
 
 
Experimental Section 
 
 
Materials 
 
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000, 
purity 95-99%), and cholesterol were obtained from Sigma-Aldrich (St. Louis, MO). The 
lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-
glycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG2000], 1,2-
distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) 
[maleimide DSPE-PEG2000], and 1-palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino]hexanoyl]-sn- glycero-3-phosphocholine (NBD-PC) were purchased from 
Avanti Polar Lipids (Alabaster, AL). Mouse monoclonal EGFR antibody (D-8) was 
obtained from Santa Cruz (Dallas, TX). Tris(2-carboxyethyl)phosphine hydrochloride 
[TCEP] was supplied by Thermo Scientific (Rockford, IL). CellTiter-Glo® Luminescent 
cell viability assay substrate and buffer was purchased from Promega (Madison, WI). 
High performance liquid chromatography (HPLC) grade water, ethanol, and methanol 
were obtained from Fisher Scientific (Fair Lawn, NJ). All other chemicals and reagents 
were of analytical grade and used without further purification or characterization 
 
 
Preparation of fluorescently labeled CSLAHNPs for imaging 
 
For imaging cellular uptake and intracellular localization , fluorescently labeled 
ETB-CSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were prepared and 
purified using the methods reported in Chapter 3 and Chapter 4 respectively with the 
replacement of 1 mol % DPPC with NBD-PC, a fluorescent phospholipid (Ex/Em 
460/530 nm). 
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Preparation of CSLAHNPs 
 
For in vitro cellular viability, colony-forming assay, and western blots, ETB-
CSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were prepared and 
purified using the methods reported in Chapter 3 and Chapter 4 respectively. 
 
 
Culture of human lung cancer cell lines 
 
Two cell lines, A549 (human lung adenocarcinoma; ATCC® CCL-185TM, 
Manassas, VA, USA) and HCC827 (human lung adenocarcinoma; ATCC® CRL-2868TM, 
Manassas, VA, USA) were used for this project. HCC827 cells have an acquired 
mutation in the EGFR tyrosine kinase domain (E746 - A750 deletion).  
 
A549 cells were cultured in Ham’s F12K (Kaighn’s) medium containing 10% 
foetal bovine serum (FBS), 1% penicillin streptomycin (Penstrep) (all purchased from 
ATCC, VA, USA). HCC827 cells were cultured in RPMI 1640 medium containing 10% 
FBS, 1% Penstrep. Cells were grown under standard conditions (37oC and 5% CO2) to 
reach a confluency of 70% to 80% before being subjected to any further experimentation. 
 
 
In vitro cellular uptake of fluorescently labeled CSLAHNPs 
 
To study the cellular uptake of fluorescently labeled CSLAHNPs, two techniques 
were utilized as given below. 
 
Visualization and qualitative uptake of CSLAHNPs were studied by using 
confocal laser scanning microscopy (CLSM) technique (392). Cells were seeded in Lab-
Tek® II chamber slides (4 wells) at a density of 5 x 104 cells per well and incubated at 
37oC, 5 % CO2 in complete growth medium until 80-90 % confluence. Appropriate 
volume (50-100 μL) of fluorescent CSLAHNPs were added in each well and incubated 
for 0-4 h. Following the incubation, cells were washed with 1x PBS and fixed in 4% 
paraformaldehyde for 10 min at room temperature. Following fixation, cells were washed 
with 1X PBS thrice 3 min each time. The upper chamber was separated from the slide. 
The cells were counterstained with a drop of VECTASHIELD® mounting medium 
containing DAPI to visualize nuclei. A coverslip was placed over the slide containing 
fixed cells. The cover slip was immobilized by placing clear nail polish around the edges. 
Finally, the slides were examined on a Zeiss LSM 710 confocal laser scanning 
microscope (carl Zeiss SMT Inc., USA) by using a Plan-Apochromat 60×/1.4o na Oil 
DIC objective. Images were processed using the Zeiss LSM Zen software 2010. 
 
For quantitative estimation of cellular uptake, flow cytometry (FCM) was used 
(395). Cells were seeded into 6-well plates at a density of 5x104 cells per well in 2 mL of 
complete medium and cultured at 37oC in a 5 % CO2 humidified atmosphere until 80-90 
% confluence. The growth medium was replenished, followed by addition of appropriate 
volume of fluorescently labeled CSLAHNPs. The cells were incubated for 0-4 h at 37oC, 
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followed by rinsing with ice-cold 1x PBS three times. The cells were detached by 
trypsinized, centrifuged at 130 g for 7 min and washed with 1x PBS. The mean 
fluorescence intensity (MFI) was determined using a BD AccuriTM C6 flow cytometer 
(Becton Dickinson Inc., NJ, USA) with FITC channel. Generally 10,000 events were 
acquired per sample, and samples were run in triplicates. Data were analyzed using BD 
AccuriTM CFlow Plus analysis software. 
 
 
Cell association study of fluorescently labeled CSLAHNPs 
 
To determine the target binding specificity of hAb-ETB-CSLAHNPs on EGFR 
cell surface receptors, cell association studies at 4oC were performed as reported by 
Oliviera et al (396). Cells at a density of (1x105) were incubated with fluorescently 
labeled CSLAHNPs (untargeted and targeted) in the dark for 1h at 4oC at a final 
concentration of 0.05-10 μM. Thereafter, cells were washed three times with 1% BSA in 
1X PBS and the mean fluorescence intensity (MFI) was determined using a BD 
AccuriTM C6 flow cytometer (Becton Dickinson Inc., NJ, USA) with FITC channel. 
Generally 10,000 events were acquired per sample, and samples were run in triplicates. 
Data were analyzed using BD AccuriTM CFlow Plus analysis software. The cell 
association of targeted and untargeted CSLAHNPs was also conducted by CLSM as 
described under the section “In vitro cellular uptake of CSLAHNPs”. 
 
 
Cellular uptake mechanism of CSLAHNPs  
 
To elucidate potential cellular uptake pathways of CSLAHNPs, cells were pre-
treated with following endocytosis inhibitors at a concentration that were not toxic to 
cells. Genistein (200 μM) (397), chlorpromazine (10 μg/mL)(398), amiloride (10 mM) 
and methyl-β-cyclodextrin (10 mM)(399) were added to block caveola-mediated 
endocytosis, clathrin-mediated endocytosis, micropinocytosis, lipid rafts and lipid-raft-
mediated endocytosis respectively. Following pre-incubation with inhibitors for 1h, 
fluorescently labeled CSLAHNPs were added for further 1 h. Subsequently, the cells 
were washed thrice with 1xPBS and analyzed using a BD AccuriTM C6 flow cytometer 
(Becton Dickinson Inc., NJ, USA) with FITC channel. Generally 10,000 events were 
acquired per sample, and samples were run in triplicates. Data were analyzed using BD 
AccuriTM CFlow Plus analysis software. CSLAHNPs without any inhibitor treatment 
were used as control, and the mean fluorescence intensity (MFI) of controls was 
expressed as 100 %. 
 
 
Intracellular trafficking of CSLAHNPs  
 
Endolysosomal trafficking of CSLAHNPs was studied in cells using confocal 
laser scanning microscopy (CSLM) and transmission electron microscopy (TEM).  
For CLSM, cells were grown on Lab-Tek® II 4-chambered slides with complete growth 
medium until 70-80 % confluence. The cells were replenished with complete growth 
 95 
 
medium containing fluorescently labeled CSLAHNPs. LysoTracker® deep red (a specific 
marker for secondary endosome and lysosome) at a final concentration of 50nM was 
added into the medium 15 min prior to the experimental endpoint. Following the 
incubation, cells were washed with 1x PBS and fixed in 4% paraformaldehyde for 10 min 
at room temperature. Following fixation, cells were washed with 1X PBS thrice 3 min 
each time. The upper chamber was separated from the slide. The cells were 
counterstained with a drop of VECTASHIELD® mounting medium containing DAPI to 
visualize nuclei. A coverslip was placed over the slide containing fixed cells. The cover 
slip was immobilized by placing clear nail polish around the edges. Finally, the slides 
were examined using confocal microscopy (Zeiss LSM 710, Jena, Germany) by using a 
Plan-Apochromat 60×/1.4o na Oil DIC objective. Images were processed using the Zeiss 
LSM Zen software 2010. 
 
For TEM, CSLAHNPs loaded with 10% water soluble iron-oxide NPs with 
carboxyl group (IONPs, size 15 ± 2.5 nm, Ocean NanoTech, Springdale, AR) were 
prepared by the two-step method described in Chapter 4. Cells were seeded in BioFlex® 
Collagen type I 6-well plates at a density of 1 × 105 cells/mL. After 24 h incubation, cells 
were treated with 200 μg/mL IONP-loaded CSLAHNPs for 0-4h. The cells were washed 
with cold 1X PBS for 3 times and fixed in 4 % paraformaldehyde solution in 1x PBS 
overnight. The cells were rinsed with 0.1M cacodylate buffer, 3 x 20 min at RT on rotator 
and dehydrated with successive 50, 70, 80, 90, 95, 100 % ethanol for 30 min at RT on 
rotator. The cells were infiltrated with 1:1 ethanol:Spurr’s resin, overnight at RT on 
rotator, followed by 100 % Spurr’s resin for 2 h at RT on rotator. The cells were 
embedded in an epoxy resin molds with appropriate labels, the plastic was cured in oven 
for 48 h at 70° C, cut into ultra-thin sections with an ultramicrotome using a diamond 
knife, and mounted on 150 mesh copper grids. The cell ultrastructures were stained with 
uranyl acetate and lead citrate and then observed under TEM. 
 
 
In vitro efficacy of CSLAHNPs in NSCLC cells 
 
The CellTiter-Glo®Luminescent cell viability assay was used for the 
determination of the number of viable cells in culture based on the quantitation of ATP, 
an indicator of metabolically active cells. The cells were seeded in 96 well opaque 
(white) plates at a density of 5000 cells per well and incubated for 24 hours at 37oC, 5% 
CO2 in complete medium. Then, the culture medium was replenished with 100 μL of 
CSLAHNPs at different concentrations (0-15 μM) in complete medium and incubated for 
24-72 h. The CellTiter-Glo® buffer and lyophilized CellTiter-Glo®Substrate were 
equilibrated at room temperature. The substrate was reconstituted with the buffer to form 
the CellTiter-Glo® reagent. , The plate contents were equilibrated at room temperature for 
approximately 30 min. A 100 μL portion of CellTiter-Glo® reagent were added to each 
well and mixed for 2 min on an orbital shaker to induce cell lysis. Control wells 
containing complete growth medium without cells were prepared to measure the 
background luminescence. The plates were equilibrated at room temperature for 10 min 
to stabilize the luminescent signal. Finally, luminescence was recorded using 
SpectraMax® M2e microplate reader (Molecular devices, Sunnyvale, CA).  
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Colony-formation assay 
 
Colony formation assay, also known as clonogenic assay were performed by the 
previously reported method (400). The cells were plated at a density of 500 to 1000 cells 
on 6-well tissue culture treated plates and allowed to attach for 24 h. After that, cells were 
treated with CSLAHNPs or controls and allowed to grow for 10-14 days. The cell 
colonies were washed with 1x PBS thrice, followed by fixing with -20oC methanol in 
freezer for 5-15 min. The colonies were washed with 1x PBS thrice and stained with 
hematoxylin. The photographs were taken using GelDoc-it imaging system (UVP, 
Upland, CA). The efficacy of the CSLAHNPs was determined by counting the number of 
colonies and comparing with controls. 
 
 
Expression of phosphorylated EGFR  
 
Expression of phosphorylated EGFR was investigated by western blotting. Cells 
were seeded into 6-well plates at a concentration of 2 × 105 cells per well. When 90-95% 
confluency reached, cells were treated with ETB/ ETB-CSLAHNPs/hAb-ETB-
CSLAHNPs at the corresponding IC50 values and incubated for 6 h, followed by 
stimulation using 60 ng/mL EGF for 15 min. Cells were washed with ice cold 1X PBS 
thrice and lysed with 0.2% Triton X-100 in 1X PBS on the shaker at 4oC for 1 h. The 
lysates were scraped out, placed in Eppendorf tubes and centrifuged at 13000 rpm for 15 
min. Protein contents in the lysates were estimated by Pierce BCA protein assay kit by 
optical absorbance method using BSA as the standard. Total cell proteins from each 
sample (25-50 μg) were added to Laemmli 5x loading buffer and incubated at 37oC for 
10 min. The samples were loaded into the wells of 4-15% SDS-PAGE gels (Mini-
PROTEAN® TGX Gels, Bio-Rad, Hercules, CA) immersed in running buffer (tris-
glycine/SDS) and resolved at 150V for 45 min using standard molecular weight ladder. 
The transfer stacks were prepared with the order sponge-3 filter papers-PVDF 
membrane-gel-3 filter papers-sponge. The PVDF membrane was soaked with methanol 
before placing in the transfer stack. The gel bands were transferred to PVDF membrane 
at 4oC, 90 V for 1.5 h, followed by blocking in blocking buffer (5% non-fat milk in 
TBST) and probed using appropriate dilutions of primary monoclonal antibodies directed 
against phospho-specific EGFR (p-EGFR) and β-actin as control at 4oC overnight. The 
membrane was washed thrice with TBST 5 min each, followed by recommended dilution 
of labeled secondary antibody in 5 % blocking buffer in TBST at room temperature for 1 
h. The membrane was washed thrice with TBST 5 min each. Immunoreactive bands were 
detected by enhanced chemiluminescence reagents (Amersham Biosciences). 
 
 
Statistical analysis  
 
Student’s t-test (two tailed) was performed to compare the mean values of 
different groups; p values less than 0.05 were considered to be significant. All the results 
are represented as mean ± SD, with n equaling the number of experiments. 
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Results and Discussion  
 
EGFR is a tumor specific receptor overexpressed in various NSCLCs (401). Two 
representative human lung cell lines, A549 and HCC827, were used to test the cellular 
uptake and efficacy of targeted and untargeted CSLAHNPs. A549 is a lung carcinoma 
cell line which expresses wild type EGFR. Constitutive upregulation of 
autocrine/paracrine secretion of EGFR ligands, particularly ARG, results in an increase in 
active phosphorylated-EGFR in A549 cells (402). HCC827 is a human lung 
adenocarcinoma cell line that has an acquired mutation in the EGFR tyrosine kinase 
domain (exon 19 deletion or the del E746-A750 mutation) (403). Literature reports 
support that HCC827 and A549 cells overexpress EGFR (404, 405).  
 
To study the cellular uptake of CSLAHNPs, both confocal laser scanning 
microscopy (CLSM) and flow cytometry (FCM) techniques were utilized. CLSM 
visualized the localization of CSLAHNPs in the cellular compartments, while FCM gave 
quantitative analysis of the mean fluorescence intensity (MFI) of the treated cells. The 
application of these two techniques in parallel helped to visualize as well as quantify the 
uptake of CSLAHNPs in human lung adenocarcinoma cells. Both hAb-ETB-CSLAHNPs 
(targeted) and ETB-CSLAHNPs (untargeted) were labeled with 1 mol % of a 
fluorescently labeled phospholipid, NBD-PC for visualization and quantification. The 
physicochemical properties of fluorescent targeted and untargeted CSLAHNPs such as 
size, PDI and zeta potential were almost similar to the non-fluorescent targeted and 
untargeted CSLAHNPs (data not reported).  
 
CLSM images of the cellular uptake of CSLAHNPs at two time points were 
shown in Figure 5-1 for HCC827 cells and in Figure 5-2 for A549 cells. Upon excitation 
at 460 nm, the NBD-PC tagged CSLAHNPs appeared green under CLSM (emission 
wavelength of NBD-PC at 534 nm). DAPI (Ex/Em 358/461 nm) was used for nuclear 
staining (blue color). The appearance of green color surrounding the blue colored nucleus 
indicated that the CSLAHNPs were extensively present in the cytoplasm of the cells. In 
both cells, significantly higher uptake of targeted and untargeted CSLAHNPs was 
observed at 3.5 h compared to 0.5 h. Higher uptake was observed with hAb-ETB-
CSLAHNPs in HCC827 cells compared to untargeted ETB-CSLAHNPs.  
 
As shown by FCM, NSCLC tumor cells treated with 1 mol % fluorescent NBD-
PC lipid loaded CSLAHNPs exhibited a time dependent increase of their mean 
fluorescence intensity (MFI) which indicated enhanced intracellular uptake of 
CSLAHNPs. It was significantly different from the control only after 30 min of exposure 
in both the cells A549 and HCC827 (Figure 5-3). Overall, a higher cellular uptake was 
observed in HCC827 cells compared to A549 cells. Targeted NBD-hAb-ETB-
CSLAHNPs were taken up significantly higher in HCC cells after 4h compare to 
untargeted ETB-CSLAHNPs. As observed by CLSM, CSLAHNPs were found inside the 
cytoplasm of cells. Observation of treated cultures revealed that CSLAHNPs were almost 
entirely internalized after 4 h suggesting that the MFI measured by FCM mainly reflected 
internalized CSLAHNPs. Therefore, the results of both FCM and CLSM confirmed the 
uptake of CSLAHNPs.   
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Figure 5-1. Confocal microscopy images of CSLAHNPs uptake in HCC827 cells 
after 0.5 h (A) and 3.5 h (B) 
 
DAPI stained nucleus, NBD represents fluorescent NBD-PC loaded CSLAHNPs. 
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Figure 5-2. Confocal microscopy images of CSLAHNPs uptake in A549 cells  
 
(A) 0.5 h and (B) 3.5 h . DAPI stained nucleus, NBD represents fluorescent NBD-PC 
loaded CSLAHNPs. 
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Figure 5-3. Flow cytometric analysis of cellular uptake of CSLAHNPs in HCC827 
cells 
 
(A) and A549 cells (B). The data were presented as mean ± SD (n=3). * represents p-
value of <0.05. 
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Cell association studies at 4oC were performed to determine whether hAb-ETB-
CSLAHNPs could specifically interact with EGFR expressed on the cell surface. For 
comparison, control sets were run at 37oC. After 1h incubation at 4oC, cell associations of 
fluorescent CSLAHNPs were determined by measuring MFI using FCM (Figure 5-4). 
A549 cells showed no significant difference in MFI between targeted and untargeted 
CSLAHNPs. As expected, HCC827 cells incubated with targeted CSLAHNPs presented 
4 fold higher MFI than untargeted CSLAHNPs. CLSM images confirmed the observed 
anti-EGFR hAb medicated cell association of targeted CSLAHNPs compared to 
untargeted particles (Figure 5-5). A higher degree of association was observed for both 
targeted and untargeted in HCC827 cells compared to A549 cells. This could be 
explained by a higher level of EGFR expression in HCC827 compared to A549. The 
presence of anti-EGFR hAb on the surface of CSLAHNPs resulted in a specific cell 
association, and enhanced signal compared to control groups. At 37oC, targeted and 
untargeted CSLAHNPs were taken up by both the cells. 
 
The process of cellular uptake of NPs via endocytosis pathway can involve 
clathrin mediated endocytosis, caveolae mediated endocytosis, micropinocytosis, and 
clathrin/caveolae independent endocytosis (377). The flow cytometry results of the effect 
of endocytosis inhibitors on the uptake of fluorescently labeled CSLAHNPs in both A549 
and HCC827 cells were shown in Figure 5-6. Macropinocytosis is a non-specific, ligand 
independent mechanism which involves formation of large irregular vesicles known as 
macropinosomes (406). Amiloride is an inhibitor of micropinocytosis by inhibiting 
Na+/H+ exchange (407). It had no significant inhibitory effect on the CSLAHNPs uptake 
compared to control in both A549 and HCC827 cells. Chlorpromazine is known to block 
assembly of clathrin-coated pit formation at the plasma membrane and causes clathrin 
lattices to assemble on endosomal membranes (408). The treatment with chlorpromazine 
did not decrease cellular uptake of CSLAHNPs compared to control group in both A549 
and HCC827 cells. Caveolae mediated endocytosis involves the formation of 50-100 nm 
invaginated plasma membranes known as caveolae (409). Caveolae are rich in caveolin, 
glycolipids, and cholesterol. Genistein is a specific inhibitor of caveolae-mediated 
endocytosis (410). It showed a significant inhibition of cellular uptake of CSLHANPs in 
both cells. Methyl-β-cyclodextrin was used to block cholesterol depletion and lipid-raft 
mediated endocytosis (399). It did not inhibit the cellular uptake of CSLAHNPs. 
Therefore, the results showed that the caveolae-mediated endocytosis played a major role 
in the cellular uptake of CSLAHNPs in human lung adenocarcinoma cells. One of the 
major components of CSLAHNPs was the albumin NPs. Albumin NPs were reported to 
bind to protein on the endothelial cell surface localized on caveolae and activate 
gp60/caveolae receptor medicated endocystosis (411). Therefore, the literature report 
confirmed the present finding. 
 
In vitro cellular internalization, localization and intracellular trafficking were 
investigated by TEM. Figure 5-7 showed the TEM image of the cells incubated with 
IONPs-loaded CSLAHNPs for 4h. IONPs were loaded into CSLAHNPs to track them 
inside the cells. IONPs were observed at or near cell membranes, inside the cytoplasm 
and also into the endolysomal vesicles. Figure 5-8 showed the confocal microscopy 
images of cells incubated with fluorescently labeled CSLAHNPs for various time 
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Figure 5-4. Cell association study using flow cytometric analysis of cellular 
uptake of CSLAHNPs in HCC827 cells and A549 cells at 4oC and 37oC 
 
The data were presented as mean ± SD (n=3). * represents p-value of <0.05. 
 
  
4oC 
37oC 
[Type a quote from the 
document or the summary 
of an interesting point. 
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Figure 5-5. Confocal microscopy images of the cell association of CSLAHNPs 
after 1 h incubation at 4oC 
 
DAPI stained nucleus, NBD represents fluorescent NBD-PC loaded CSLAHNPs. 
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Figure 5-6. Effect of endocytosis inhibitors on the cellular uptake of CSLAHNPs 
using flow cytometric analysis 
 
The data were presented as mean ± SD (n=3). * represents p-value of <0.05. Inhibitors 
were treated with cells for 1 h, followed by CSLAHNPs incubation for 1 h. 
 
HCC827 
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Figure 5-7. TEM image of a single HCC827 cell after incubation of IONPs-loaded 
targeted CSLAHNPs 
 
The image revealed intracellular localization of 15 nm iron-oxide nanoparticles (IONPs) 
loaded targeted hAb-ETB-CSLAHNPs after 4h incubation at 37oC. 
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Figure 5-8. Confocal microscopy image of a single HCC827 cell after 1 h 
incubation with fluorescent hAb-ETB-CSLAHNPs 
 
The images showed the endolysosomal localization using colocalization of NBD (green) 
and lyosotracker (red) signals in the merged image. The nucleus was stained with blue 
color. 
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intervals. The confocal microscopy revealed that the CSLAHNPs were co-localized with 
endosomes and lysosomes, which were marked by LysoTracker Deep Red.  
 
After confirmation of the binding and internalization of the hAb-ETB-
CSLAHNPs and ETB-CSLAHNPs to deliver ETB to target cells, in vitro cellular 
viability of ETB solution, ETB-CSLAHNPs, and hAb-ETB-CSLAHNPs were tested 
against both A549 and HCC827 cells using CellTitre Glo®Luminescent cell viability 
assay. Cells were treated with CSLAHNPs or ETB solution for 72h, followed by the 
determination of cell viability. The plots of ETB concentration versus in vitro cellular 
viability were shown in Figure 5-9 for HCC827 cells and in Figure 5-10 for A549 cells. 
Overall the dose-response curves showed higher sensitivity to ETB, hAb-ETB- 
CSLAHNPs, and ETB-CSLAHNPs treatments in HCC827 cells compared to A549 cells. 
The ETB concentrations were in nanomolar (nM) range for HCC cells where high 
micromolar (μM) ETB concentrations were required for A549 cells. This could be 
explained by EGFR expression in both the cells. HCC827 cells express EGFR at a much 
higher level due to the presence of acquired mutation in the EGFR tyrosine kinase 
domain (403). A549 cells express a lower level of total and phosphorylated EGFR 
compared to HCC827 cells (412). In HCC827 cells, hAb-ETB-CSLAHNPs were more 
effective compared to ETB-CALSHNPs and ETB-solution . The IC50 values (the 
concentration required to kill 50 % of the cells) were ~ 20 nM for hAb-ETB-CSLAHNPs, 
~45 nM for ETB-CSLAHNPs and ~51 nM for ETB-solution. The comparison of IC50 
values demonstrated that anti-EGFR hAb conjugated CSLAHNPs were about 2.5 folds 
more efficacious in reducing viability of HCC cells after 72 h compared to ETB-solution. 
This could be explained by higher cellular uptake of hAb-CSLAHNPs via receptor 
mediated endocytosis pathways compared to free ETB in solution form. The untargeted 
particles showed no significant difference in viability of HCC827 cells compared to ETB-
solution form due to the absence of targeting ligands in ETB-CSLAHNPs. In contrast, the 
A549 cells were less sensitive to ETB, hAb-ETB-CSLAHNPs, and ETB-CSLAHNPs 
treatments as concentrations of ETB to 1 did not result in a significant decrease in 
proliferation 
 
The clonogenic assay or colony formation assay is an in vitro long-term cell 
survival assay based on the ability of a single cell to grow into a colony consisting of at 
least 50 cells (400) . The assay has been essentially used to test the efficacy and toxicity 
of anticancer drugs, drug delivery systems and radiation therapies (413). The colony 
formation assay results are shown in Figure 5-11.  In HCC827 cells, treatment of ETB-
CSLAHNPs and hAb-ETB-CSLAHNPs at a concentration close to IC50 (10 nM) 
significantly decreased the formation of colonies compared to control groups. The ETB 
solution form also showed decreased number of colonies at 10 nM concentration but not 
to the same extent as CSLAHNPs. Control and blank CSLAHNPs showed very high 
colony counts as expected. In A549 cell, reduced number of colonies was observed after 
treatment of ETB-CSLAHNPs and hAb-ETB-CSLAHNPs at 5 mM compared to control 
group and blank CSLAHNPs. The ETB-solution form had significantly higher number of 
colonies compared to hAb-ETB-CSLAHNPs and ETB-CSLAHNPs groups. Therefore, 
overall increased efficacy was observed in both untargeted and targeted CSLAHNPs 
compared to ETB solution and controls.  
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Figure 5-9. Plot of the in vitro HCC827 cell viability as a function of ETB (drug) 
concentration after 72 h 
 
CellTiter-Glo®Luminescent cell viability assay was used. The data were presented as 
mean ± SD (n=3). * represents p-value of <0.05. IC50 targeted CSLAHNPs was ~20 nM 
which was lower than the IC50 of untargeted CSLAHNPs (~45 nM) and ETB-solution 
(~51 nM). 
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Figure 5-10. Plot of the in vitro A549 cell viability as a function of ETB (drug) 
concentration after 72 h 
 
CellTiter-Glo®Luminescent cell viability assay was used. The data were presented as 
mean ± SD (n=3). * represents p-value of < 0.05. IC50 of targeted and untargeted 
CSLAHNPs ~5μM which was lower than the IC50 of ETB-solution > 20μM. 
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Figure 5-11. Colony formation assay results after in (A) HCC827 cells and (B) 
A549 cells 
 
ETB dose was 50nM for HCC cells and 5μM for A549 cells. 
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The phosphorylated EGFR (active form) expression by western blotting was 
showed in Figure 5-12. The drug (ETB) binds with the ATP binding site in the 
intracellular tyrosine kinase domain of EGFR. Thus, it inhibits phosphorylation of EGFR 
to its active form, thereby preventing downstream signaling cascade leading to cell 
proliferation and angiogenesis. In HCC827 cells, the treatment of ETB-CSLAHNPs at 50 
nM showed significant down regulation of p-EGFR expression compared to control. 
Treatment with only ETB-solution did not show significant downregulation of p-EGFR 
compared to control. Blank CSLAHNPs had no effect on p-EGFR expression in HCC827 
cells. A549 showed lesser sensitivity to ETB or ETB-CSLAHNPs treatments. At 5 μM 
ETB-CSLAHNPs, slight reduction in p-EGFR expression was observed compared to 
control.  
 
 
Summary and Conclusion 
 
In summary, cellular uptake, intracellular trafficking, and cellular viability of 
ETH-CSLAHNPs and targeted hAb-ETB-CSLAHNPs were investigated in A549 and 
HCC827 cells. For intracellular imaging, 1 mol % of NBD-PC was incorporated into 
CSLAHNPs. The targeting ability of hAb-ETB-CSLAHNPs was confirmed by cell 
association study. Confocal microscopy and flow cytometry results showed higher uptake 
of hAb-ETB-CSLAHNPs and ETB-CSLAHNPs in HCC827 cells compared to A549 
cells up to 4 h. Endocytosis inhibitor assay showed major mechanism of particle uptake 
was via caveolae-mediated endocytosis. Significantly higher reduction in cell viability 
was observed for both targeted and untargeted ETB-CSLAHNPs compared to ETB-
solution form in HCC827 compared to A549 cells. Similar results were observed for 
colony formation assay. Western blot results showed significant downregulation of 
phosphorylated EGFR after ETB-CSLAHNPs treatment compared to control. The results 
suggest the potential therapeutic advantages of targeted and untargeted ETB-CSLAHNPs 
over ETB in solution in EGFR-overexpressing NSCLC. 
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Figure 5-12. Expression of phosphorylated-EGFR by western blot 
 
(1) ETB-solution, (2) control, (3) hAb-ETB-CSLAHNPs, and (4) blank hAb-
CSLAHNPs. ETB dose was 50 nM for HCC cells and 5 μM for A549 cells. All 
treatments were incubated with the cells for 6 h. The blots showed higher downregulation 
of phosphorylated EGFR (active form) after ETB-CSLAHNPs treatment in HCC827 
cells.  
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 LYOPHILIZATION OF TARGETED AND UNTARGETED CHAPTER 6.   
ERLOTINIB LOADED CORE SHELL TYPE LIPID ALBUMIN HYBRID 
NANOPARTICLES 
 
 
Introduction 
 
Physical and chemical stability of the colloidal drug delivery systems including 
CSLAHNPs in aqueous dispersion is a major concern in the development of a drug 
product with acceptable shelf-life (344). Phospholipids which constitute the shell of the 
CSLAHNPs can undergo hydrolysis and/or oxidation and lead to degradation when 
stored as aqueous dispersions (414). As a result, the encapsulated drug tends to leak from 
the bilayer which surrounds the core of CSLAHNPs (415). Apart from drug leakage, the 
CSLAHNPs may aggregate or fuse together resulting in an increase in particle size 
distribution. The albumin core and the targeting antibody conjugated to the CSLAHNPs 
are also susceptible to chemical and physical degradation pathways, such as oxidation, 
deamidation, aspartate isomerization, peptide bond hydrolysis and aggregation (416-419). 
The long-term stability of colloidal drug delivery systems including CSLAHNPs can be 
improved by various techniques such as freezing-drying, lyophilization, spray drying, and 
supercritical fluid technology. Lyophilization is one of the preferred methods to improve 
long-term stability of NPs containing thermosensitive drugs and proteins (170). It can 
prevent a number of physical and chemical degradation pathways during storage (170). 
By removing water by lyophilization process, the physicochemical characteristics of 
CSLAHNPs can be retained with improved storage stability.  
 
Lyophilization is the process of removing water from a frozen sample by 
sublimation and desorption to increase the shelf-life of materials (420-422). It combines 
three separate and interdependent processes; freezing, primary drying (sublimation), and 
secondary drying (desorption). The first step is the freezing which is initiated by cooling 
the shelves to the desired freezing temperature and holding the temperature to equilibrate 
and create a solid matrix. The key process parameters for freezing step include freezing 
temperature, freezing rate and hold time at the freezing temperature. The freezing 
temperature should be below the glass transition temperature (Tg´) of the formulation. A 
slow cooling rate results in relatively homogenous ice crystal formation. The majority of 
water is removed in the primary drying by the process of sublimation. There are two 
critical process parameters; shelf temperature and chamber pressure. The shelf 
temperature is maintained 2-5oC below Tg´ of the frozen product to maintain structural 
integrity of the maximally frozen amorphous phase and prevent collapse. For crystalline 
materials, product temperature must be kept below the eutectic melting temperature (Te) 
of the crystalline component in the formulation to prevent meltback. The chamber 
pressure is kept below the saturated vapor pressure of the ice at frozen product 
temperature to provide driving force for sublimation process to occur. The final stage is 
the secondary drying, the bound unfrozen water is removed via desorption by raising the 
shelf temperature at ambient or higher values while maintaining low chamber pressure. 
To characterize the frozen samples, subambient analytical techniques are utilized such as 
differential scanning calorimetry (DSC) and freeze-drying microscopy (170).  
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Lyophilization may generate various stresses such as cryo/freezing and 
lyo(sublimation) stresses which could destabilize NPs. In order to minimize the stresses 
and subsequent destabilization, excipients are added before the lyophilization process. 
The excipients include cryoprotectant, lyoprotectant, bulking agents, buffers, tonicity 
adjusters, and collapse temperature modifiers. Cryoprotectants are used to protect the 
product from freezing stress while lyoprotectants are added to protect the product from 
sublimation stress (423). Cryoprotectants stabilize NPs by preferential “exclusion” 
mechanism (424). The examples of cryoprotectants include polyethylene glycol, glycerol, 
and dimethylsulfoxide (425). A number of excipients are available as lyoprotectants such 
as glucose, sucrose, trehalose, mannitol, lactose, sorbitol, glycine, dextran, fructose, 
maltose, glycerol, polyvinyl alcohol (426). They stabilize the NPs by either “water 
substitution” or “vitrification” mechanism (427). In vitrification mechanism, the glassy 
sugar matrix below Tg´ immobilizes NPs and prevents aggregation. 
 
The specific aim of this study was to develop lyophilized hAb-ETB-CSLAHNPs 
(targeted) and ETB-CSLAHNPs (untargeted) CSLAHNPs of ETB to improve the shelf-
life of the CSLAHNPs during storage. The cryo/lyoprotective ability of sucrose and 
trehalose at various concentrations during the process of lyophilization was investigated 
to optimize the better protectant and it’s concentration. Finally, the stability of liquid 
dispersion and lyophilized dry powder were evaluated after stored at different storage 
conditions for various lengths of time.  
 
 
Experimental Section 
 
 
Materials 
 
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000, 
purity 95-99%), glutaraldehyde solution (25% in water), sucrose, and trehalose were 
obtained from Sigma-Aldrich (St. Louis, MO). Erlotinib hydrochloride (purity 99%) was 
obtained from LC Laboratories (Woburn, MA). The lipids used in this work were all of 
research grade. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-
sn-glycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG(2000)], and 
1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene 
glycol)2000) [maleimide DSPE-PEG(2000)] were purchased from Avanti Polar Lipids 
(Alabaster, AL). Cholesterol was purchased from Sigma (St. Louis, MO). High 
performance liquid chromatography (HPLC) grade water, ethanol, and methanol were 
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform and 1N sodium 
hydroxide solution were purchased from Acros Organics (Morris Plains, NJ). Mouse 
monoclonal EGFR antibody (D-8) was obtained from Santa Cruz (Dallas, TX). Tris(2-
carboxyethyl)phosphine hydrochloride [TCEP] was supplied by Thermo Scientific 
(Rockford, IL). All other chemicals and reagents were of analytical grade and used 
without further purification or characterization. 
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Preparation of ETB-CSLAHNPs and hAb-ETB-CSLAHNPs 
 
ETB-CSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were 
prepared by the methods as described in Chapter 3 and Chapter 4. 
 
 
Determination of Tg 
 
Two lyoprotectants were used; sucrose and trehalose. The effect of lyoprotectant 
on glass transition temperature (Tg´) was monitored by DSC using a Q2000 differential 
scanning calorimeter equipped with refrigerated cooling system (TA Instruments, New 
Castle, DE). About 10-20 μL of the CSLAHNPs and lyoprotectant mixture was placed 
into T-Zero aluminum pans and hermetically sealed. An empty pan prepared in a similar 
manner was used as reference. The samples were equilibrated at 25°C and then cooled at 
5°C/min to -70°C. After equilibration, the samples were heated at the rate of 10°C/min to 
30°C. The Tg′ was also determined from these thermograms. 
 
 
Lyophilization of CSLAHNPs  
 
ETB-CSLAHNPs and hAb-ETB-CSLAHNPs dispersions were mixed with 
sucrose or trehalose solution. Different weight ratios of CSLAHNPs to lyoprotectant 
were used (1:1, 1:4, 1:8, and 1:16). The samples (1 mL) were filled into 5cc glass lyo 
vials. Rubber lyo stoppers placed in the vials with partial opening to allow water vapor 
escape. The vials containing stoppers were placed into the tray and loaded into the 
benchtop lyophilizer (VirTis adVantage Plus, SP Scientific, Gardiner, NY). The 
lyophilization cycle was designed based on the Tg′ of maximally freeze-concentrated 
amorphous phase as determined by DSC. The following parameters were selected: 
freezing shelf temperature -45oC (duration 6h), primary drying shelf temperature -35oC 
(duration 12 h), and secondary drying shelf temperature 15oC (duration 6 h), primary 
drying chamber pressure 100 mTorr, secondary drying chamber pressure 50mTorr. The 
product temperature, shelf temperature, and condenser temperature were controlled and 
monitored using Wizard 2.0 software. On completion of the drying cycle, the vials were 
sealed after filling nitrogen in the headspace of the vials at atmospheric pressure.  
 
 
Characterization of lyophilized CSLAHNPs  
 
The lyophilized powders were inspected for cake volume and cake appearance 
including collapse or meltback and skin formation. 
 
The moisture content of the lyophilized cake was determined using Mettler 
Toledo DL31 Karl Fischer Titrator (Mettler Toledo Inc., Boston, MA). The titrator was  
calibrated on each day of analysis with a known quantity of water. About 10-20 mg of the  
lyophilized powder was weighed accurately and added to the titration vessel. The titration 
was started after allowing one minute for extraction. Triplicate measurements were 
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recorded. The residual moisture content in the lyophilized cake was expressed in % w/w. 
 
The lyophilized powders were reconstituted with HPLC grade water. The 
hydrodynamic mean size (Z-avg) of the reconstituted CSLAHNPs was determined using 
dynamic light scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, 
MA) equipped with 4.5 mW diode laser as a source of light operating at 670 nm. The 
samples were suitably diluted with HPLC grade water. Three independent measurements 
were performed for each sample. Zeta potential was determined from electrophoretic 
mobility using samples suitably diluted with HPLC grade water.  
 
 
Stability evaluation of liquid and lyophilized CSLAHNPs  
 
Short-term stability was assessed for 3 months by after storage of ETB-
CSLAHNPs and hAb-ETB-CSLAHNPs (targeted). The different batches of targeted and 
untargeted CSLAHNPs (aqueous dispersion and lyophilized powder) were stored at two 
temperatures 2-8oC and 25oC in glass vials for up to 3 months. After predetermined time 
intervals, liquid samples were characterized for the physicochemical properties including 
mean size, PDI, zeta potential. For lyophilized batches, powders were reconstituted with 
water and evaluated for physicochemical properties. The total and free ETB in the 
CSLAHNPs before and after lyophilization were determined using an HPLC method. 
Briefly, a centrifugal ultrafiltration device (Amicon® Ultra-4, MWCO 100 KD, Millipore, 
Bedford, MA) was used to separate free drug from the ETB-CSLAHNPs. Drug 
entrapment efficiency (DEE) and drug loading (DL) of ETB-CSLAHNPs and hAb-ETB-
CSLAHNPs were quantified by HPLC method previously described in chapter 3. Finally, 
the characteristics of CSLAHNPs were compared with that of the initial values. 
 
 
Results and Discussion 
 
Lyophilization was used to remove water from CSLAHNPs to obtain lyophilized 
powders for storage stability. The determination of the glass transition temperature (Tgʹ) 
of the maximally frozen concentrated mixture of the formulation components is a critical 
parameter which helps to set the freezing and the primary drying temperatures of the 
lyophilization cycle. To dry the product with retention of the structure of materials, the 
product is maintained in the solid state below the collapse temperature. The collapse 
temperature is also known as Tgʹ for amorphous materials. To determine Tgʹ, DSC was 
performed using four different weight ratios of CSLAHNPs and lyoprotectant (1:1, 1:4, 
1:8, and 1:16). The DSC thermograms were shown in Figure 6-1. The Tgʹ values 
decreased with an increase in sucrose weight ratio in the mixture (428). The Tgʹ value 
was around -33oC. Therefore, primary drying temperature was set 2-5oC below the Tgʹ to 
prevent collapse. For the lyophilization cycle, freezing step was performed at -45oC. The 
cooling rate was ~ 0.4oC/minute, followed by holding at -45oC for 4 h. The primary 
drying was performed at -35oC to prevent collapse. The end of primary drying process 
was determined by the rise in product temperature which matched with the shelf 
temperature. The total hold time was found to be around 12 h at around -35oC. The  
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Figure 6-1. DSC thermograms of CSLAHNPs and sucrose mixture 
 
CSLAHNPs to sucrose weight ratio used were (A) 1:0, (B) 1:1, (C) 1:4, (D) 1:8, and (E) 
1:16. The Tg´ was determined using Universal Analysis 2000 software (TA instruments, 
New Castle, DE). Blank CSLAHNPs without drug and targeting ligand were used for the 
DSC studies. Tg´ was found to be around -33oC. 
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chamber pressure was set at 100 mTorr which was below the vapor pressure of ice at sub-
zero temperature (423, 429). The difference between the ice vapor pressure at -35oC and 
the chamber pressure was the driving force for the sublimation process at primary drying 
phase. For the secondary drying, the temperature was slowly ramped to 15ºC and hold for 
4 h with maximum vacuum of 50 mTorr. The end of secondary drying was monitored by 
measuring the moisture content of the lyophilized cake.  
 
Two disaccharides, sucrose and trehalose were used as lyoprotectants in the 
lyophilization of CSLAHNPs. Four different weight ratios of CSLAHNPs to  
lyoprotectant (sucrose or trehalose) were lyophilized. The effect of lyoprotectant sucrose 
on the mean size and PDI of reconstituted CSLAHNPs dispersions were compared to 
their mean size and PDI before lyophilization (Figure 6-2). Sucrose was able to retain the 
physicochemical characteristics of CSLAHNPs at the selected ratios of CSLAHNPs to 
lyoprotectant. Trehalose showed slight increase in mean size at 1:1, 1:4 but maintained 
the mean size at 1:8 and 1:16 (Figure 6-3). The possible explanation could be the 
presence of core albumin which acted a support to prevent the lipid bilayer shell collapse 
during lyophilization. Albumin NPs were shown to be stable for 6 months in liquid form 
without affecting physical stability (305, 430). Therefore, the structural integrity of the 
CSLAHNPs at lower lyoprotectant ratios could be justified. In addition, the presence of 
PEG chains on the surface of CSLAHNPs provided additional protection during the 
freezing phase. PEG has been widely used as a cryoprotectant which prevents the NPs 
aggregation during the freezing phase. Evaluation of the cake properties of the 
lyophilized powders with trehalose and sucrose revealed that sucrose was better as 
lyoprotectant than trehalose (Figure 6-4). The major limitation of trehalose is it’s 
tendency to crystallize during lyophilization (431-433). Crystallization of the 
lyoprotectant trehalose could alter the structural integrity of CSLAHNPs during 
lyophilization or after the storage. Therefore, sucrose was selected as the lyoprotectant 
for further studies. At 1:16 weight ratio of CSLAHNPs to sucrose, the cake volume was 
equal to the initial fill volume. In addition, the cake was immediately reconstituted with 
gentle shaking. The mean size, PDI and zeta potential of CSLAHNPs were retained after 
lyophilization at 1:16 weight ratio of CSLAHNPs to sucrose. At lower ratios, although 
physicochemical properties of CSLAHNPs were retained, shrinkage of the cake volume 
was observed. One of the quality control parameters for any lyophilized product is the 
measurement of the residual water content of the lyophilized cake. Higher moisture 
content might lead to poor stability and loss of biological activity (434). The low residual 
moisture content of 0.5-3% w/w was recommended for lyophilized powders containing 
both small molecular weight drugs and monoclonal antibodies (435). The moisture 
content of the lyophilized powders of CSLAHNPs containing 16 times higher sucrose 
content was in the range of 1.85 ± 0.25% w/w which is acceptable for storage stability. 
Therefore, 1:16 weight ratio of CSLAHNPs to sucrose was the optimum ratio used to 
prepare lyophilized CSLAHNPs. 
 
To further evaluate short-term stability, liquid dispersion and lyophilized ETB-
CSLAHNPs and hAb-ETB-CSLAHNPs (containing 1:16 weight ratio of CSLAHNPs to 
sucrose) were stored at 2–8oC (refrigerated conditions) as well as 25oC (accelerated 
condition) for up to 60 days. Physicochemical properties including mean size, PDI, and  
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Figure 6-2. Influence of CSLAHNPs to sucrose weight ratio on mean size(A) and 
polydispersity index (B) of CSLAHNPs before and after lyophilization 
 
The data were presented as mean ± SD (n=3). Blank CSLAHNPs without drug and 
targeting ligand were used and indicated as HNPs.  
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Figure 6-3. Influence of CSLAHNPs to trehalose weight ratio on mean size (A) 
and polydispersity index (B) of CSLAHNPs before and after lyophilization 
 
The data were presented as mean ± SD (n=3). Blank CSLAHNPs without drug and 
targeting ligand were used and indicated as HNPs. 
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Figure 6-4. Physical appearance of the lyophilized cakes at various weight ratios 
of CSLAHNPs to lyoprotectant (A) sucrose and (B) trehalose 
 
At 1:16 weight ratio of CSLAHNPs to sucrose, the cake volume was equal to the initial 
liquid fill volume and the cake appeared uniform. 
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zeta potential were analyzed immediately after lyophilization and at various time points  
up to 60 days. Residual moisture content of the formulations was determined directly 
after freeze drying and after a storage time of 60 days. Directly after the freeze-drying 
process, the CSLAHNPs showed residual water content 1.85 ± 0.25%. After a storage 
period of 60 days, the samples stored at 2–8oC showed no significant increase in the 
residual water content. Samples stored at 25oC showed shrinkage and change in 
appearance of cake after storage for 1-2 weeks. The determination of residual moisture 
content using Karl Fisher titration method showed an increase in moisture level to 4-5 % 
w/w after 1-2 weeks. This may be caused by ingress of moisture in the vials from 
stoppers or inappropriate container-closure integrity (436). The lyophilized samples 
stored at 25oC showed shrinkage and change in appearance of cake. Therefore, it can be 
concluded that storage at 25oC showed significant instability of CSLAHNPs. The 
lyophilized targeted and untargeted CSLAHNPs showed acceptable long-term storage 
stability at 2-8oC with regard to mean size and PDI after reconstitution (Figure 6-5). For 
comparison, liquid CSLAHNPs dispersions were also analyzed for their physicochemical 
properties at two conditions. At 2-8oC storage of the liquid dispersion, the mean size and 
PDI changed gradually over storage time of 30 days (Figure 6-6). The liquid samples 
stored at 25oC showed aggregation and formation of sediments within 3-5 days of 
storage. Therefore, the stability study at 25oC was discontinued.  
 
In the case of drug loaded CSLAHNPs a further aspect, which needs 
consideration, is the drug loading stability after freeze drying. Freeze-drying process may 
influence the drug loading efficiency of CSLAHNPs since the process might result in 
drug loss due to change or loss of the particle structures. Therefore, the samples were also  
investigated for potentially released or leaked drug after reconstitution. After redispersion 
the resulting particle suspensions were centrifuged through Amicon® ultrafiltration 
device with MWCO 100 kDa, followed by HPLC analysis of both filtrate and retained 
particles. Figure 6-7 showed the influence of storage time on retention of ETB in 
lyophilized CSLAHNPs. Immediately after lyophilization, the amount of free drug was 
low and the percent drug retained in the CSLAHNPs was approximately 90 %. The 
lyophilized CSLAHNPs were able to retain about 80 % of the drug for up to 60 days at 2-
8oC. However, the liquid dispersion stored at 2-8oC showed much higher leakage and 
lower drug retention about 60 % in CSLAHNPs for up to 30 days (Figure 6-8). 
Therefore, it has to be concluded that the freeze-drying process exerted no significant 
influence on drug loading stability of CSLAHNPs.?
?
?
Summary and Conclusion 
 
The present study showed that targeted and untargeted ETB-CSLAHNPs can be 
stabilized both during the lyophilization process as well as for long-term storage using 
adequate concentrations of suitable excipients. Among the two disaccharides (sucrose 
and trehalose) used as lyoprotectants, sucrose was the best in preserving the acceptable 
physicochemical characteristics at 1:16 weight ratio of CSLAHNPs to sucrose. Storage at 
room temperature (25oC) had a negative influence on both physical and chemical stability 
of both lyophilized cake and liquid dispersion form of CSLAHNPs. The study also  
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Figure 6-5. Effect of storage time on the mean size (A) and polydispersity index 
(B) of the lyophilized CSLAHNPs at 2-8oC 
 
The data were presented as mean ± SD (n=3). 
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Figure 6-6. Effect of storage time on the mean size and polydispersity index of the 
liquid dispersion of CSLAHNPs at 2-8oC 
 
The data were presented as mean ± SD (n=3). 
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Figure 6-7. Influence of storage time on the % drug retention in CSLAHNPs at 2-
8oC 
 
The data were presented as mean ± SD (n=3). 
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Figure 6-8. Influence of storage time on the % drug retention in liquid dispersion 
of CSLAHNPs at 2-8oC 
 
The data were presented as mean ± SD (n=3). 
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showed that the lyophilized form retained the physicochemical properties CSLAHNPs 
compared to the liquid dispersion after 2-8oC storage condition for 60 days. 
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 SUMMARY AND CONCLUSION CHAPTER 7.   
 
 
Lung cancer is the leading cause of cancer related death worldwide. Among 
various histological subtypes, NSCLC is the most prevalent type accounting for 85 to 90 
% of all lung cancer cases. One of the main reasons for the poor survival rates among 
patients with advanced stages of NSCLC is the limited efficacy of traditional 
chemotherapy along with severe adverse effects of the high doses of cytotoxic anticancer 
drugs. To over the limitations of conventional chemotherapy, molecularly targeted agents 
were developed to target specific receptors or pathways of tumor cells with higher 
specificity. For instance, erlotinib was approved for the treatment of locally advanced or 
metastatic NSCLC after failure of at least one chemotherapy regimen. ETB is a highly 
selective inhibitor of HER1/ EGFR-TK. However, limitations of oral administration of 
ETB tablet include several adverse effects/toxicities in cancer patients and development 
of drug resistance by P-glycoprotein mediated efflux pump or other pathways by NSCLC 
tumors. Nanoparticulate carriers are attractive for cancer chemotherapy due to their 
ability to enhance accumulation of anticancer agents at the tumor site, resulting in an 
increased tumor cell kill efficacy, reduction in total dose and dose-related adverse effects 
to healthy cells. In addition, NPs often overcome drug resistance to tumors by evading 
the normal pathways of drug resistance. Recently, core–shell-type lipid–polymer hybrid 
nanoparticles have emerged as a promising drug delivery platform. This unique platform 
combines the mechanical advantages of biodegradable polymeric nanoparticles and 
biomimetic advantages of liposomes. The system provides advantages such as 
controllable particle size, surface functionality, high drug loading, potential for 
entrapment of multiple therapeutic agents, tunable drug release profile, and good serum 
stability. The overall goal of this project was to develop untargeted and anti-EGFR half-
antibody conjugated core-shell type lipid-albumin hybrid nanoparticles (CSLAHNPs) for 
the targeted delivery of ETB in NSCLC cells. The central hypothesis of the project was 
that CSLAHNPs will improve therapeutic efficacy and thereby reduce toxicities of ETB 
in NSCLC therapy.  
 
The first aim was to design, prepare and optimize blank CSLAHNPs without drug 
and targeting antibody as described in Chapter 2. Blank CSLAHNPs were designed and 
prepared with albumin core and phospholipid bilayer shell by the two step method using 
bovine serum albumin, DPPC, cholesterol, and DSPE-PEG2000 as the formulation 
ingredients. All the ingredients used were biodegradable, biocompatible, non-
immunogenic or mildly immunogenic and approved by FDA for human use. The 
formulation and process variables were identified and optimized for the preparation of 
blank CSLAHNPs. Various factors influenced the physicochemical properties including 
mean size, polydispersity index, and zeta potential of both ANPs (core) and CSLAHNPs. 
For the preparation of ANPs (core) by the desolvation method, the optimized variables 
include albumin concentration of 20 mg/mL, pH of the albumin solution at 8, ethanol 
addition rate 1 mL/min, volume ratio of water to ethanol 1:2, and gluteraldehyde-to-
albumin ratio 0.47% w/w. For the lipid shell, DPPC, cholesterol, and DSPE-PEG2000 
were used at a molar ratio of 60:30:10. The critical parameter of the lipid-film hydration 
method was identified as the weight ratio of lipid-to-ANPs (WLipid/WANPs) during the 
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optimization of CSLAHNPs. The experimental WLipid/WANPs was found around 15% w/w 
(equivalent WDPPC/WANPs ~ 8% w/w) which was close to the calculated value (~10% 
w/w) based on the theoretical assumptions. TEM images showed smooth and spherical 
particles of both ANPs (core) and CSLAHNPs with some degree of polydispersity. A 
distinct electron dense corona around periphery of the CSLAHNPs was visible which was 
absent in ANPs. 
 
Following the preparation of blank CSLAHNPs, the aim of Chapter 3 was to load 
the drug erlotinib in the CSLAHNPs to prepare ETB loaded CSLAHNPs. The drug 
binding capacity of albumin in solution was studied and optimized at various pH 
conditions, durations of incubation, incubation temperatures, and drug-to-albumin molar 
ratios. The maximum drug binding capacity of albumin was observed at 12h incubation 
in pH 7.4 at room temperature with drug-to-albumin molar ratio 10:1. ETB-CSLAHNPs 
were successfully designed, prepared and optimized by the two step method as described 
in Chapter 2. Two strategies for drug loading in ANPs were studied; incorporation and 
sorption method. Sorption method provided better drug loading and entrapment 
efficiency in ETB-ANPs compared to incorporation method. Additional ETB was 
incorporated in the lipid bilayer to maximize the drug loading and entrapment efficiency 
of ETB-CSLAHNPs. ETB-CSLAHNPs were 194nm in size with PDI 0.16, zeta potential 
-15.6mV, yield 83.5% w/w, DL 2.08% w/w, and DEE 32.75% w/w. SEM and TEM 
images showed smooth and spherical particles of ETB-CSLAHNPs. Drug release from 
ETB-CSLAHNPs occurred in a sustained manner up to 96h with a biphasic release 
pattern in pH 7.4. Drug release was faster in acidic pH of 5.2. Drug release kinetics 
analysis showed a first order release kinetics with non-fickian diffusion mechanism. 
ETB-CSLAHNPs were stable in serum for up to 6h.  
 
The specific aim of chapter 4 was to prepare and characterize targeted anti-EGFR 
half-antibody conjugated ETB loaded CSLAHNPs (hAb-ETB-CSLAHNPs). Targeted 
hAb-conjugated ETB-CSLAHNPs were prepared by maleimide-thiol conjugation 
reaction after incorporating 1 mol % DSPE-PEG2000-maleimide in ETB-CSLAHNPs 
during preparation. Anti-EGFR mouse monoclonal antibody (mAb) was reduced to half-
antibodies (hAb) using TCEP at 50:1 molar ratio of TCEP: mAb and coupled to 
maleimide-terminated ETB-CSLAHNPs. Targeted hAb-ETB-CSLAHNPs were ~ 200 
nm in mean hydrodynamic size with PDI ~ 0.13, zeta potential ~ -13mV, DL ~ 2 % w/w, 
and DEE ~ 31% w/w. TEM image showed smooth and spherical particles with moderate 
degree of polydispersity. Drug release from hAb-ETB-CSLAHNPs occurred in a 
sustained manner up to 96h with a biphasic release pattern in pH 7.4. A faster rate of drug 
release was observed in acidic pH of 5.2. The hAb-ETB-CSLAHNPs were stable in 50% 
serum for up to 12h.  
 
The specific aim of Chapter 5 was to evaluate the cellular uptake, intracellular 
trafficking, and cellular viability of ETH-CSLAHNPs and targeted hAb-ETB-
CSLAHNPs in two human lung adenocarcinoma cells, A549 and HCC827 cells. A549 
cells express low levels of wild-type EGFR whereas HCC827 cells express higher levels 
of EGFR due to the acquired mutation in the EGFR tyrosine kinase domains. For 
intracellular imaging, 1 mol % of NBD-PC was incorporated into CSLAHNPs. The 
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targeting ability of hAb-ETB-CSLAHNPs was confirmed by cell association study. 
Confocal microscopy and flow cytometry results showed higher uptake of hAb-ETB-
CSLAHNPs and ETB-CSLAHNPs in HCC827 cells compared to A549 cells up to 4 h. 
Endocytosis inhibitor assay showed major mechanism of particle uptake was via 
caveolae-mediated endocytosis. Significantly higher reduction in cell viability was 
observed for both targeted and untargeted ETB-CSLAHNPs compared to ETB-solution 
form in HCC827 compared to A549 cells. Similar results were observed for colony 
formation assay. Western blot results showed significant downregulation of 
phosphorylated EGFR after ETB-CSLAHNPs treatment compared to control. The results 
suggest the potential therapeutic advantages of targeted and untargeted ETB-CSLAHNPs 
over ETB in solution in EGFR-overexpressing NSCLC. 
 
The final aim of the project was to prepare lyophilized CSLAHNPs and also to 
perform the storage stability for both liquid dispersion and lyophilized solid powder. The 
present study also showed that CSLAHNPs can be stabilized both during the 
lyophilization process as well as for long-term storage using adequate concentrations of 
suitable lyoprotectants. Among two disaccharides (sucrose and trehalose) used as 
lyoprotectants, sucrose was the best in preserving the cake properties and 
physicochemical characteristics at 1:16 weight ratio of CSLAHNPs to sucrose. 
Accelerated temperature storage at 25oC had a negative influence on both lyophilized 
and liquid form stability. The study also showed that the lyophilized form retained the 
physicochemical properties CSLAHNPs compared to the liquid dispersion form at 2-8oC 
storage condition for 60 days of storage. 
 
Overall, the results suggest successful design and development of targeted hAb-
ETB-CSLAHNPs and untargeted ETB-CSLAHNPs. Various formulation and process 
variables were optimized to obtain prototype formulation with acceptable 
physicochemical properties including mean size, polydispersity index, zeta potential, 
drug loading efficiency and drug release profiles. The study also showed the potential 
therapeutic advantages of targeted and untargeted ETB-CSLAHNPs over ETB in solution 
in EGFR-expressing NSCLC cells. Lyophilzed power of CSLAHNPs containing sucrose 
exhibited refrigerated storage stability for 2 months retaining acceptable physicochemical 
properties. Therefore, the overall experimental data supported the central hypothesis of 
improved therapeutic efficacy of anti-EGFR half-antibody conjugated erlotinib loaded 
CSLAHNPs as a potential targeted drug delivery system for the therapy of non-small cell 
lung cancer. 
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